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ABSTRACT 
Polyunsaturated fatty acids (PUFA) have been shown to modulate immune 
responses and have therapeutic effects in inflammatory disorders. The specific 
mechanisms of their actions have yet to be defined. The objective of this work 
was to elucidate such mechanisms. Macrophages are a key component of the 
innate response, which express toll-like receptors (TLRs). Ligation of TLR4, by 
its ligand lipopolysaccharide (LPS), results in macrophage activation. This study 
demonstrates that the n-6 derivative, conjugated linoleic acid (CLA) and n-3 
PUFA, DHA and EPA differentially modulate the response of macrophages to 
LPS. Specifically, phagocytosis was enhanced by CLA and suppressed by n-3 
PUFA and these PUFA suppressed TNFα, IL-6 and enhanced IL-10 production, 
rendering the macrophage less inflammatory. PUFA also suppressed macrophage 
migration in response to LPS and inhibited production of chemokines. 
Furthermore, CLA inhibited activation of the TLR4 downstream transcription 
factors NF-κB and IRF3, while n-3 PUFA, DHA and EPA solely inhibited NF-
κB.  
 
Further investigation revealed that PUFA selectively regulate the expression of 
TLR4 and its associated molecule CD14 in response to LPS, but had no effect on 
LPS binding to TLR4. The exact mechanism of the effects of PUFA on CD14 
was elucidated by examining lipid raft ‘microdomains’, the location where the 
receptor complex clusters upon activation. We found that treatment of 
macrophages with CLA reduced the incorporation of CD14 into lipid rafts 
following activation with LPS. We then examined endocytosis of TLR4 given 
the role of CD14 in this process, and we found that it was suppressed by CLA. 
This study therefore reveals a novel mechanism whereby CLA exerts its anti-
inflammatory effects. This involves suppression of CD14, the subsequent 
suppression of TLR4 endocytosis culminating in decreased IRF3 activation. 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 2 
1 THE IMMUNE SYSTEM 
The immune system is a complex network of lymphoid organs, cells and humoral 
factors. Collectively, they provide defences of increasing specificity by means of 
innate ‘early’ and adaptive ‘delayed’ immunity. Although considered separate, both 
responses work closely to initiate and maintain protection within the body. 
 
1.1 OVERVIEW OF INNATE IMMUNITY 
Innate immunity represents a non-specific first line of defence to the body. 
Metazoans have survived millions of years with innate defence alone. Only 
vertebrates have developed alternative modes of protection and pathogen 
elimination, collectively known as ‘adaptive immunity’ [see section 1.2]. Primary 
components of innate defence include physical and chemical barriers to infection. 
Upon breach of these barriers a combination of cellular and humoral elements are at 
the face of innate immunity (Beutler 2004). These elements are involved in both the 
sensing or ‘activation’ and action or ‘effector mechanisms’ of fighting infection. 
Present since birth, the innate network operates non-specifically and immediately 
against practically any pathogen/molecule to threaten the body.  
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1.1.1 CELLULAR AND HUMORAL ACTIVATION 
Cellular activation is mainly dependant on myeloid cells that engulf and destroy 
pathogens, including macrophage (MØ) and neutrophils. Additionally, mast cells 
and polymorphonuclear phagocytes such as eosinophils and basophils are crucial to 
the containment of infection as reviewed by (Beutler 2004).  Pathogens that 
overcome the epithelial barrier are first encountered by MØ in residing tissues and 
secondly by neutrophils and monocytes recruited to the site of infection. As 
specialised phagocytes, macrophage and neutrophils are equipped with pathogen 
recognition receptors (PRRs) that bind recognisable structures or components of the 
invading microbe [see sections 1.6 – 1.8] (Janeway et al. 2008). Such components 
are shared by many types of prokaryotic organisms and are not found on eukaryotic 
cells allowing for discrimination between self and non-self [see section 1.10] 
(Janeway et al. 2008). They also express surface receptors that recognize the Fc 
portion of antibodies. Binding of these receptors induces the engulfing of microbes 
into a membrane-bound vesicle or ‘phagosome’ (Beutler 2004). Concurrently, 
binding of PRRs triggers cell signaling, producing soluble mediators such as 
cytokines, chemokines, acute phase proteins and complement initiating an 
inflammatory response.  
 
Neutrophils are released daily into the blood stream in high numbers and recruited 
to sites of infection in response to cytokines and complement activation. They 
express some but not all PRRs and have a half-life of several hours. Importantly, 
they express other cell associated molecules that have been recognised as microbial 
sensors. For example, f-methionyl-leucyl-phenylalanyl (fMLP) receptor is an 
important inducer of chemotaxis during infection (Gao, Lee and Murphy 1999).  
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The innate system also has ‘humoral’ means of detecting microbial pathogens and 
activating a response. Extracellular proteins such as mannose binding lectin (MBL) 
of the collectin family (Super and Ezekowitz 1992) recognise terminal mannosyl 
residues on the surface of microbes and activate the complement (C') cascade 
(Janeway et al. 2008). Similarly, CD14 in its shed form (a co-receptor for 
lipopolysaccharide (LPS)), [see section 1.9.1] aids the cellular activation of innate 
cells in response to gram-negative bacteria (Frey et al. 1992).  Collectively, cellular 
and humoral activation initiate the inflammatory response leading to an influx of 
effector cells and an accumulation of plasma proteins at the site of infection.   
 
1.1.2 CELLULAR AND HUMORAL EFFECTOR MECHANISMS 
Effector cells include macrophage, dendritic cells (DC), neutrophils and natural 
killer (NK) cells.  Monocytes and neutrophils migrate to the site of infection, engulf 
and destroy invading pathogens. Monocytes, which mature to macrophage at the 
site of infection, are long lived and play a broad role in the clearance of invading 
pathogens, apoptotic cells and necrotic cells by phagocytosis [see section 1.3] 
(Gordon and Taylor 2005).  Within the phagosomes of neutrophils and macrophage, 
reactive oxygen species (ROS) act as powerful microbicidal molecules destroying 
and often eliminating infection. ROS are produced in a series of enzymatic 
reactions initiated by NADPH oxidase (HIRSCH and COHN 1960) and are 
reviewed by (Hampton, Kettle and Winterbourn 1998).  
 
DC, like macrophage, reside in connective tissues and are antigen presenting cells 
(APC), meaning they have the ability to present antigen and up-regulate cell surface 
markers required for the activation and co-stimulation of T-cells in adaptive 
immunity. This includes up-regulation of major histocompatability complex II 
(MHCII) (antigen presentation) and CD40, CD86 (co-stimulation). (Janeway et al. 
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2008). Up-regulation of such molecules is highly efficacious and was described as 
accounting for the adjuvant effects of microbial endotoxin or LPS 50 years ago 
(CONDIE, ZAK and GOOD 1955).  
 
Influx of effector cells is critical to immune function and accomplished in three 
stages that include adhesion, diapedesis and chemotaxis [see figure 1.1.2]. Cell-
adhesion molecules and soluble mediators in the immediate inflammatory milieu 
control interactions between leukocytes and endothelial cells allowing this process 
to occur (Janeway et al. 2008). Homeostatically, leukocytes flow in the centre of the 
blood vessel and some roll slowly along the vascular endothelium making contact 
via intergrin receptors on their surface and selectins expressed on the endothelium. 
However, under inflammatory conditions autocoid substances (i.e histamine, 
bradykinin) cause local vasodilation, slowing blood flow and allowing many 
leukocytes to interact with the vascular endothelium (Beutler 2004). Secretion of 
the cytokine TNFα by macrophage activates the endothelium increasing expression 
of selectin molecules (i.e P-selectin (minutes), E-selectin (~2 h)).  Selectins interact 
with sulfated-sialyl-Lewisx (s-Lex) on leukocytes. This interaction increases the 
percentage of leukocytes rolling slowly and adhering to the endothelium. 
Concurently, TNFα upregulates intracellular adhesion molecules (i.e ICAM-1) on 
the inflamed endothelium. ICAMs in turn bind to integrin LFA-1 on leukocytes in 
the later and stronger stages of adhesion (Beutler 2004). Chemokines such as IL-8 
stimulate leukocyte diapedesis, the process by which leukocytes cross the 
vasculature. They convert leukocyte-endothelium adhesion into stable binding by 
inducing conformational changes to integrins (i.e. LFA-1). In turn, leukocytes cross 
the blood vessel walls squeezing between endothelial cells. In the final step 
chemokines direct the migration or ‘chemotaxis’ of leukocytes along a 
concentration gradient increasing towards the site of infection (Janeway et al. 
 6 
2008). The entire process is reversible, facilitating the trafficking of antigen to and 
from local lymph nodes [see section 1.2].  
 
Figure 1.1.2: Diagrammatic representation of leukocyte adhesion, diapedesis and 
chemotaxis at the inflammed endothelium. Taken from (Janeway et al. 2008). 
 
 
Humoral effector mechanisms include the actions of enzymes and proteins 
particularly those of the acute phase response (APR) and complement system (C') 
(Beutler 2004, Janeway et al. 2008, Wood 2006). Continued stimulation of MØ in 
the presence of infection leads to increased production of the pro-inflammatory 
cytokines TNFα, IL-1 and IL-6, (common nomenclature, interleukin, IL). These 
cytokines affect other organs such as the brain and liver which are far removed from 
the site of infection. IL-1 acts on the brain inducing fever, lethargy and loss of 
appetite (Wood 2006). While IL-6 potently activates hepatocytes to secrete a group 
of proteins termed ‘acute phase proteins’ (APPs) (Janeway et al. 2008). Like 
antibodies, APPs have the ability to bind and opsonize bacterium (the process by 
which pathogens are targeted for phagocytosis). However, unlike antibodies APPs 
have a broad specificity and depend solely on the presence of cytokines for their 
production (Wood 2006).  
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Acute phase proteins include fibrinogen, mannose binding lectin (MBL), C-reactive 
protein (CRP), serum amyloid A (SAA) and pulmonary surfactants A and D 
(Janeway et al. 2008, Wood 2006)  to name a few. APPs play a direct role in the 
killing of microbes by activating the complement system/cascade (C'). C' is 
involved in the destruction of microbes and consists of a group of inactive precursor 
proteins that upon activation are converted to their proteolytic form. Activation of 
one is followed by the sequential activation of the next protein in the cascade 
(Janeway et al. 2008). C' can be activated in one of three ways: 1. The Classical 
Pathway, 2. The Lectin Binding Pathway and 3. The Alternative Pathway. All three 
pathways culminate in the activation of the enzymatic cascade commonly referred 
to as the complement cascade, C' (Beutler 2004, Janeway et al. 2008, Castellano et 
al. 2004). 
 
Enzymes such as lysozyme and lactoferrin also destroy bacteria. Lysozyme destroys 
the cell walls of gram-negative and gram-positive bacteria (Beutler 2004). 
Lactoferrin alters bacterial motility and was particularly found to inhibit biofilm 
formation in certain bacteria (Singh et al. 2002).  
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1.2 OVERVIEW OF ADAPTIVE IMMUNITY 
Infectious agents must overcome the innate host defenses to establish a focus of 
infection. In such circumstances the innate system sets the scene for the induction of 
an adaptive response. Adaptive immunity utilizes antigen-specific receptors found 
on T and B lymphocytes to direct effector responses.  T and B lymphocytes 
originate in the bone marrow from progenitor cells.  T cells migrate and mature in 
the thymus whereas B cells remain in the bone marrow undergoing further 
development (Janeway et al. 2008). Antigen specificity is attributed to membrane-
bound antibody (Ab) and a T cell receptor (TCR) found on B cells and T cells, 
respectively. In both cases specificity is due to the random rearrangements of the 
genes encoding Ab and TCR. This results in the expression of a huge repertoire of 
receptors (Nemazee 2006). Naïve lymphocytes enter peripheral lymphoid organs 
where the majority of immune responses occur. Each lymphocyte cell bears surface 
receptors for a single antigen. However, high specificity combined with the huge 
repertoire of lymphocytes means only a small number of lymphocytes are able to 
recognise a given antigen (Janeway et al. 2008). 
 
Naïve lymphocytes are activated in the presence of three signals: 1) TCR 
stimulation 2) co-stimulatory molecule ligation and 3) stimulation by polarising 
cytokines. This results in the activation and clonal expansion of specific 
lymphocytes over several days. Naïve T cells proliferate and differentiate into 
effector T cells (Bono et al. 2007). An effective immune response upon re-exposure 
to antigen or ‘immunological memory’ is achieved by means of a number of 
antigen-specific B and T lymphocytes that persist for some time after removal of 
the initiating antigen (Janeway et al. 2008).  
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Signal 1 is the antigen-specific signal via TCR ligation with MHC class-II-peptide 
complexes found on APCs. APCs include DC, MØ and B cells, however, DC are 
viewed as the most potent APC. DC act by ingesting antigen at sites of infection 
and then travelling to local lymph nodes where they mature to present antigen and 
activate T cells (Janeway et al. 2008). Conversely, to enhance opportunities of 
encountering antigen, lymphocytes continually circulate between the blood and 
peripheral lymph nodes. This migration is aided by the production of chemokines 
during an inflammatory response (Ebert, Schaerli and Moser 2005), as discussed 
[see section 1.1.2]. Signal 2 is the co-stimulatory molecule ligation mainly mediated 
by the triggering of CD28 on naïve T cells by CD80 and CD86 on an APC. Finally, 
signal 3 is a polarizing signal mediated by various soluble or membrane-bound 
factors, such as cytokines. This last signal will depend on the response of APCs to a 
particular pathogen via their PRRs (Janeway et al. 2008).  
 
Naïve T cells are divided into CD4+ and CD8+ populations. CD8+ T cells, also 
known as cytotoxic lymphocytes (CTL), kill their target cells and are important in 
defence against intracellular pathogens such as viruses. Viral antigens are displayed 
to CD8+ T cells complexed with MHCI molecules on the surface of APCs. CD4+ T 
cells have the ability to differentiate into subsets of effector cells mainly T helper 
types (TH), TH1, TH2, TH17 and regulatory T cells (Treg). TH1 differentiation is 
regulated by IL-12, IL-27, type I IFNs, and IFN-γ; TH2 differentiation is influenced 
by IL-4 (Agnello et al. 2003) and TH17 are induced by TGFβ and IL-6 (Janeway et 
al. 2008). TH subtypes are regulated by a heterogenous group of effector cells, Treg. 
Treg are characterised by an ability to suppress adaptive T cell responses in order to 
prevent autoimmunity. In general, Treg can target effector T cells, compete with 
pathogenic T cells for access to APCs, or directly target APCs, reviewed by (Mills 
2004).  
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T helper cells also vary in terms of their cytokine profiles and the type of pathogen 
they target. TH1 cells produce IL-2, TNF-β, and IFN-γ, which activate macrophage, 
NK cells, and CTL, primarily targeting intracellular pathogens (Trinchieri 2003a). 
TH2 cells produce IL-4, which stimulates IgE production, IL-5, an eosinophil 
activating factor, and IL-10 and IL-13, which in combination with IL-4 can 
suppress cell-mediated immunity and inflammation (Gouwy et al. 2005).  
Extracellular pathogens tend to induce differentiation towards a TH2 subtype. 
Additionally, IL-27 secreted by APCs inhibits various immune responses and 
negatively regulates TH1 and TH2 cells (Stumhofer and Hunter 2008).  TH17 cells 
produce a distinct set of cytokines, including IL-17 and IL-6. This subtype are 
believed to target pathogens distinct from those targeted by TH1 and TH2 cells 
(Weaver et al. 2006).  
 
Cellular communication is of paramount importance during an immune response, 
particularly between T lymphocytes and APCs.  MHCII is found mainly on MØ and 
DC and it is long established that MØ are required for an adaptive immune response 
(Beutler 2004). Expression of this marker and other co-stimulatory molecules is 
pivotal in supporting bidirectional stimulatory signals between MØ and T cells. In 
fact, such signals not only make T cell activation possible but also act in the 
regulation and activation of MØ. For example, MØ-T cell contact via T cell-
associated CD40 ligand (CD40L) with CD40 on monocytes is required for the 
production of IFNγ and IL-12 by MØ (Shu et al. 1995). Indeed, CD4+ T cells can 
activate MØ and therefore have a critical role in defence against pathogens that 
resist killing after being engulfed by MØ (Janeway et al. 2008). 
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Interferon-γ (IFNγ) produced by TH1 cells or CTLs, along with TNFα from APCs 
gives rise to classically activated macrophages, [see section 1.3.2.1]. These MØ 
secrete cytokines IL-1, IL-6 and IL-23 which give rise to TH17 cells. In addition, 
classically activated MØ produce IL-12 promoting a TH1 phenotype. IL-10 
produced by Treg cells can give rise to a population of regulatory MØ. Regulatory 
MØ produce IL-10 and can induce TH2 phenotype (Mosser and Edwards 2008). 
Recent evidence also indicates that alternatively activated MØ [see section 1.3.2.2] 
actively induce Treg in the periphery of the body indicating that Treg development is 
not solely dependent on the thymus. Conversely, groups have shown that Treg are 
able to gain influence on the innate immune system by interacting with MØ 
(Mahnke et al. 2008). The relationship between cytokine production and signaling 
between T cells and MØ is represented in figure 1.2.1. 
 
 
Figure 1.2.1: Taken from (Mosser 2003). Diagrammatic representation of the 
interaction between macrophage and T cells. 
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1.2.1 LINKING INNATE AND ADAPTIVE IMMUNITY 
 
Co-ordination of innate and adaptive responses is supported by signalling between 
different PRRs [see section 1.5]. Without vital actions of innate ‘effector’ cells such 
as antigen presentation and cytokine production, adaptive responses are ineffectual. 
At best, innate mechanisms can prevent infection being established. While crucially 
important in this role, innate mechanisms do not lead to immunological memory 
(Janeway et al. 2008). It is only the adaptive response that provides specifically 
enhanced and lasting protection against pathogens. In essence the innate system can 
more often play a delaying function, holding an infection at bay while a more 
specific adaptive response is mounted. 
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1.2 MACROPHAGE 
MØ are immune effector cells with well established roles in host defence, wound 
healing and immune regulation. First recognised by Elie Metchnikoff in 1905 as 
important phagocytes (Metchnikoff 1905), MØ have since been a constant source of 
investigation for immunologists. MØ develop from common myeloid progenitor 
cells (hematopoietic stem cells) in the bone marrow, precursors for many different 
cell types, for example the closely related DC (Janeway et al. 2008). These 
precursor cells undergo differentiation until committing to the monocyte lineage 
upon which they are released from the bone marrow into the blood stream (Gordon 
and Taylor 2005). These monocytes add integrity to endothelial-cell lining of blood 
vessels (Auffray et al. 2007). Furthermore, under steady state conditions they 
migrate and mature to become tissue resident MØ and during infection and injury 
are the main source of inflammatory MØ (Gordon and Taylor 2005).  
 
MØ are distributed widely throughout body tissue (Janeway et al. 2008). Monocytes 
mature and replenish tissue resident MØ continually to make up MØ of the bone 
(osteoclasts), central nervous system (migroglial cells), alveoli, liver (Kupffer 
cells), spleen, peritoneum, connective tissue (histocytes) and gastrointestinal tract 
(Gordon and Taylor 2005). As a cell type they are also morphologically diverse 
including, the ‘spindle-shaped’ tissue histocyte, the flattened Kuppfer cell and the 
stellate microglial cell (Beutler 2004). 
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1.3.1 MACROPHAGE FUNCTION 
MØ have important roles within immunity and homeostasis. As specialised 
phagocytes they have the ability to recognise, engulf and destroy invading 
pathogens. Their involvement in the immune response can be divided into innate 
and adaptive components. Recognition of invading microbes is performed by means 
of PRRs they express such as toll-like receptors (TLRs) recognising specific 
pathogen associated molecular patterns or PAMPs. Recognition of PAMPs by MØ 
initiates signalling pathways culminating in the production of immune and 
inflammatory genes (Janeway et al. 2008). As previously discussed, MØ are 
capable of initiating an adaptive immune response by presenting antigen to CD4+ T 
cells via MHC II molecules (Janeway et al. 2008) [see section 1.2]. Indeed, this is 
accompanied by the production of soluble mediators such as cytokines and 
chemokines [see section 1.4 – 1.5] that act by recruiting immune cells to the site of 
injury or infection thereby amplifying the immune response (Beutler 2004). 
 
As exceptional phagocytic cells they are involved in the clearance of debris from 
wound healing and apoptosis. Receptors that mediate this homeostatic clearance 
include phosphatidyl serine receptors, thrombospondin receptor, integrins, 
complement receptors and scavenger receptors (Erwig and Henson 2007b). This is a 
vital role without which the host would not survive. Importantly, the removal of 
apoptotic debris does not induce the production of inflammatory mediators in 
unstimulated MØ (Erwig and Henson 2007a). However, phagocytosis of necrotic 
debris initiates a striking change in their physiology. Necrosis is a form of cell death 
resulting from states of hypoxia, stress or toxic injury (Mosser and Edwards 2008). 
Often the self antigens released in this form of cell death such as heat shock 
proteins (hsp), histones and deoxyribonucleic acids (DNA) are immunogenic 
(Zhang and Mosser 2008). The profound physiological change that occurs within 
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any MØ population includes the up-regulation of various surface markers and the 
production of inflammatory cytokines (Erwig and Henson 2007b).  
 
1.3.2 MACROPHAGE ACTIVATION 
A variety of stimuli can trigger MØ activation. Thus far categories of MØ activation 
have included classically and alternatively activated populations (Lewis 1999, Ma 
et al. 2003). However, due to the remarkable plasticity displayed by macrophage 
these categories are under constant review and investigation. Currently, 
classification has shifted to incorporate not only immune functions but the crucial 
homeostatic roles of macrophage. Subsets include classically activated, alternatively 
activated (wound healing) and regulatory MØ (Mosser and Edwards 2008). The 
work within this study has focused on the functional status of classically activated 
macrophage. 
 
1.3.2.1 Classical Activation 
MØ activated during cell-mediated immune responses are commonly referred to as 
‘classically activated’. Classical activation involves two signals. Firstly, MØ are 
primed by cytokine IFNγ, produced by cells of the adaptive response and acting as 
the most important priming stimulus. IFNγ is produced by both T helper (TH1) cells 
or CD8+ T cells (Mosser and Edwards 2008). The second is the pro-inflammatory 
cytokine TNFα (Lewis 1999, Ma et al. 2003). Typically TNFα is induced by the 
ligation of a TLR to its respective ligand, activating the MyD88-dependant 
signalling pathway [see sections 1.9.4]. MØ are also classically activated by innate 
stimuli but in a transient manner (Mosser and Edwards 2008). Natural Killer (NK) 
cells respond to stress and infection by producing IFNγ and prime the population 
see figure 1.3.1. Crucially, the combination of these signals enhances the overall 
microbicidal and tumoricidal activity of the MØ (O'Shea and Murray 2008). IFNγ 
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primes MØ to secrete the pro-inflammatory cytokine IL-12 (Trinchieri 2003b) and 
nitrogen radicals (MacMicking, Xie and Nathan 1997) enhancing their ability to kill 
microbes. These cells also produce moderate amounts of the anti-inflammatory 
cytokine, IL-10 (Mosser and Edwards 2008). IL-10 inhibits TH1 cell responses by 
reducing the capacity of macrophage to produce IL-12. Classical activation is also 
associated with increased MHC II (antigen presentation) and CD86 (co-stimulatory 
molecule) expression along with enhanced production of chemokines, MIP-
1α/CCL3, IP-10/CXCL10 and MCP-1 (Mosser 2003). IFNγ induces several 
transcription factors such as interferon regulatory factors (IRF1 to IRF 9) (Ma et al. 
2003). Particularly, certain TLR agonists activate the MyD88-independent pathway 
leading to production of IFNβ (Yamamoto et al. 2003). Therefore, in response to 
certain TLR ligands, endogenously produced IFNβ can replace IFNγ produced by 
NK and T cells to classically activate MØ. The role of classically activated 
macrophages in the defence of intracellular pathogens is reviewed extensively by 
(Gordon 2007). However, classically activated MØ must be tightly regulated. 
Exacerbation of their actions can lead to extensive tissue damage associated with 
autoimmune diseases such as rheumatoid arthritis (Szekanecz and Koch 2007) and 
inflammatory bowel disease (Zhang and Mosser 2008). 
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Figure 1.3.1: Taken from (Mosser 2003). Diagrammatic representation of cytokines 
produced by immune cells and their effect on macrophage physiology.  
 
 
 
1.3.2.2 Alternative Activation 
 MØ are said to undergo ‘alternative activation’ in the presence of TH2 cytokines, 
IL-4 and IL-13 (Martinez, Helming and Gordon 2008). The original classification 
of ‘alternative’ was assigned as IL-4 stimulated MØ displayed up-regulation of 
mannose receptor (Stein et al. 1992) compared to classically activated MØ (Kreider 
et al. 2007). However, alternatively activated MØ are now commonly referred to as 
wound healing MØ. Similar to classically activated MØ they can develop in 
response to innate and adaptive signals. Basophils, mast cells and other 
granulocytes provide an early source of innate IL-4 (Brandt et al. 2000), see figure 
1.1.1. Granulocytes are activated in response to injury and also chitin, a structural 
component of fungi and parasites (Reese et al. 2007). Adaptive responses to 
disturbances in mucosal surfaces induces a TH2 cell phenotype (Reese et al. 2007). 
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This phenotype is also found in non-mucosal tissues in response to helminth 
infections (Wilson et al. 2007). IL-4 secreted by these cells rapidly converts MØ to 
wound healing populations by stimulating arginase. Arginase activity leads to cell 
growth, division and collagen formation. In this way MØ are directed to contribute 
to repair and production of the extracellular matrix (Kreider et al. 2007) and thus 
the term wound healing MØ. Additionally, several groups have shown this MØ 
population aids clearance of helminth and nematodes (Anthony et al. 2006, Zhao et 
al. 2008). However, this is overwhelmed by the evidence pointing towards their 
main function as wound healers. The polyamines and chitinase molecules produced 
by arginase are vital to matrix reorganisation and wound healing (Kzhyshkowska et 
al. 2006, Zhu et al. 2004). Similar to classically activated MØ, dysregulated 
activation of this population can have deleterious effects. For example, uncontrolled 
activation of wound healing MØ has been attributed with tissue fibrosis that occurs 
in schistosmiasis (Hesse et al. 2001).  
 
1.3.2.3 Regulatory Macrophage 
Regulatory MØ are activated by innate and adaptive responses and other varied 
stimuli. These include prostaglandins (Strassmann et al. 1994), ligands of G-protein 
coupled receptors (GPCR) (Hasko et al. 2002), glucocorticoids (Sternberg 2006), 
apoptotic cells (Erwig and Henson 2007b), immune complexes (Gerber and Mosser 
2001) or IL-10 (Mosser and Edwards 2008) [see figure 1.3.1]. This population also 
requires two stimuli to induce their anti-inflammatory phenotype. The first signal is 
provided by stimuli mentioned above and the second signal from the ligation of a 
TLR ligand. Both signals direct the MØ to produce IL-10, the most potent 
characteristic of regulatory MØ (Edwards et al. 2006). Regulatory MØ also down-
regulate IL-12 (Gerber and Mosser 2001), express high levels of CD80 and CD86 
(required for co-stimulation) and have the ability to present antigen to T cells 
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(Edwards et al. 2006). They do not produce any soluble mediators involved in 
production of extracellular matrix and they secrete high levels of the chemokine, 
CCL1/TCA3 (Mosser and Edwards 2008). Significantly, phagocytosis is a 
fundamental role of all MØ populations. Stimulation by pathogens, particularly 
through TLRs enhances the phagocytic activity of MØ and promotes phagosome 
maturation, allowing sufficient capture and destruction of microbes. (Blander and 
Medzhitov 2004). As iterated, MØ activation must be tightly regulated to avoid 
deleterious effects. While all phenotypes have important roles required for host 
defence and repair the right balance must be maintained between populations for 
adequate healing and resolution. 
 
Macrophage execute many roles including, yet not limited to, those within innate 
immunity. As described, they exhibit remarkable plasticity allowing them to change 
phenotype in response to various stimuli, a topic reviewed extensively by (Mosser 
and Edwards 2008, Mosser 2003, Martinez, Helming and Gordon 2008). The 
immense plasticity of  MØ makes it difficult to assign specific biochemical markers 
to each population. It also remains elusive as to whether discrete monocyte 
populations give rise to specific MØ in tissues and whether this may be used in 
disease diagnosis (Mosser and Edwards 2008). A basic understanding of the 
molecular mechanisms involved in MØ activation should provide a foundation for 
novel drug development aimed at modulating MØ activity. Also, the potential of 
utilising MØ subsets as biomarkers for disease is immense and it remains for further 
studies to be carried out. 
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1.3 CYTOKINES 
Cellular communication within the immune system is largely mediated by a group 
of low molecular weight polypeptides or glycoproteins known as cytokines (Parkin 
and Cohen 2001). Cytokines act by binding their respective receptors and are 
grouped on the basis of their structural features (Pugh-Humphreys and Thompson 
1998). Signalling is dependant on families of tyrosine kinases and the signalling 
mechanism of many cytokines is mediated through Jak (Janus-kinase)-STAT 
(signal transducer and activator of transcription) pathways (O'Shea, Ma and Lipsky 
2002, Fujii 2007). 
 
Unlike hormones, cytokines are produced by virtually all immune cells and act in an 
autocrine and paracrine manner (Zidek, Anzenbacher and Kmonickova 2009). They 
have multiple regulatory functions (pleiotropy) and often the effects of different 
cytokines overlap. In general terms they influence cellular division, apoptosis, 
activation or recruitment (Parkin and Cohen 2001). Modes of action depend on the 
cytokine itself and cell types in the local environment. In addition, cytokine 
functions are tightly regulated by feedback mechanisms that influence their 
production both synergistically and antagonistically (Zidek, Anzenbacher and 
Kmonickova 2009). Cytokines are separated according to their biological function, 
generally those promoting inflammation are said to be pro-inflammatory such as 
IFN-γ, TNF-α, IL-17, IL-12, and IL-1β (Gay and Gangloff 2008, Vilcek 2003). 
These cytokines are commonly produced during TH1/TH17 responses. On the other 
hand those generated during a TH2 or regulatory response such as IL-4, IL-10, and 
TGF-β are considered anti-inflammatory (Hill and Sarvetnick 2002). Representative 
cytokines, their modes of action and the cells that produce them are listed in table 
1.2. 
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1.4.1 CHEMOKINES 
Immune cells are recruited to sites of infection by a class of cytokines with 
chemoattractant properties known as chemokines (Zidek, Anzenbacher and 
Kmonickova 2009). Chemokines are produced by and act on the majority of cells. 
They are the only members of the cytokine family not to signal through cytokine 
receptors and signal through the G-protein coupled receptor (GPCR) superfamily 
(Lodowski and Palczewski 2009, Goncharova and Tarakanov 2008). Chemokines 
are classified into four subfamilies based on the position of the first N-terminal 
cysteine residue in a conserved cysteine motif. In the CC family (β-chemokines) the 
first two cysteines are adjacent, in the CXC family (α-chemokines), cysteines are 
intervened by one amino acid. For the third group the CX3C family (δ-chemokines) 
the first two cysteines are separated by three amino acids. Finally, the fourth group 
the C family (γ-chemokines) have only two of the four conserved cysteines (Zlotnik 
and Yoshie 2000). Chemokines are secreted in response to TH1 cytokines IFNγ and 
IL-2 and other pro-inflammatory cytokines such as IL-1 and TNFα. In contrast, the 
TH2 cytokine IL-4 and Treg cytokines, IL-10 and TGFβ are known to down-regulate 
secretion of chemokines (Adams and Lloyd 1997). Interestingly, imidazoquinoline 
derivatives, inducers of interferons, also activates secretion of IL-1β, IL-6, TNFα 
and IL-12p40 along with chemokines IL-8/CXCL8, MIP-1α/CCL3 and MCP-
1/CCL2 (Gupta, Cherman and Tyring 2004, Thomsen et al. 2004). Representative 
chemokines, their modes of action and the cells that produce them are listed in table 
1.2.  
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1.4.2 CYTOKINES AND CHEMOKINES IN DISEASE 
As with many components of the immune system, ()dysregulation among cytokines 
and their receptors can have direct implications in the development of disease. 
Tissue destruction in autoimmune disease is associated with elevated levels of 
cytokines IFNγ, TNFα and IL-1 (Rabinovitch 1994, La Cava and Sarvetnick 1999). 
Particularly, high levels of TNFα are evident in the pathophysiology of rheumatoid 
arthritis (RA) (Furst 2008). The recruitment of leukocytes in response to 
chemokines is paramount in aiding clearance of infection, however elevated levels 
of chemokines are also implicated in inflammatory disease. Depleted levels of MIP-
2 and MCP-1 are associated with impaired clearance of Klebsiella pneumon and 
Cryptococcus neoforms (Strieter et al. 1996), respectively.  Similarly, a role for 
MIP-1α and RANTES in eosinophil recruitment during the pathogenesis of allergic 
airway inflammation has been established (Lukacs et al. 1996). Additionally, 
studies have shown a role for MCP-1 in macrophage rich areas of atherosclerotic 
plaques (Nelken et al. 1991).  
 
As a result considerable effort has been placed on developing therapeutic targets 
that can modulate the activities of chemokines and cytokines. Development of an 
anti-TNFα therapy has been the most successful therapy in treatment of RA to date 
(Furst 2008). Also of particular interest is the development of genetically modified 
chemokines to abborogate excessive chemokine expression in disease. A 
recombinant MIP-1α has been developed that retains its receptor binding properties 
yet looses its functional activity and ability to recruit monocytes (Graham et al. 
1994). Chemokine receptors are also implicated in several disease states including 
psoriasis, atherosclerosis, and malaria (Patel, McInnes and Graham 2009, Plant et 
al. 2006, de Groot et al. 2007, Kershaw et al. 2009). However, comprehensive 
experimental and clinical evidence remains inconclusive as to whether possible 
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treatments targeting chemokines and cytokines can lead to resolution of established 
inflammation. As such further studies are warranted in this area.  
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Cytokine Source Mode of Action Inflammatory Status 
IL-1β Monocytes, MØ, B 
cells, DC 
Co-stimulates T cells, enhances 
NK cell activity, chemoattractant Pro-inflammatory 
IL-4 TH2 cells, NK cells, Basophils 
TH2 polarising cytokine, MØ 
activation 
Anti-inflammatory    
(TH2) 
IL-6 Monocytes, MØ, DC, TH17 cells 
Activates T and B cells, 
TH17 cell differentiation 
Pro-inflammatory        
IL-10 Treg, DC, Monocytes, MØ, B cells  
Immunosuppressive, inhibits TH1 
response and cytokine production 
Anti-inflammatory   
(Treg) 
IL-12 MØ, monocytes, DC, 
neutrophils 
Directs TH1 cell development, 
stimulates APC, NK cells, and 
CD8+ T cells 
Pro-inflammatory 
IL-13 TH2 cells, NK cells, Basophils 
MØ activation, induces B cell 
isotype switching 
Anti-inflammatory    
(TH2) 
IL-17 
TH17 cells, 
Neutrophils, CD8+ T 
cells 
Induces cytokine and chemokine 
production, DC maturation  
Pro-inflammatory   
(TH17) 
IL-23 Monocytes, MØ & DC 
Expansion and survival of TH17 
cells, induces pro-inflammatory 
cytokine production 
Pro-inflammatory 
IFN-γ 
TH2, CD8+ T cells, 
NK cells, MØ, B 
cells 
TH1 expansion, induces cytokine 
& chemokine secretion, enhances 
NK cell function 
Pro-inflammatory     
(TH1) 
TNF-α MØ, DC, T cells,     NK cells 
Amplifies inflammation & induces 
cytokine release Pro-inflammatory 
TGF-β 
TH3, MØ, 
Neutrophils, many 
non-lymphoid cells 
Immunosuppressive but involved 
in TH17 cell differentiation 
Anti-inflammatory 
but multi-faceted         
(mainly Treg) 
Chemokines Source Mode of Action Inflammatory Status 
MIP-1 α MØ, DC, T cells, NK 
cells, stem cells 
T cell proliferation, enhanced 
CD8+ cytotoxity, cell recruitment, 
Wound Healing 
Pro-inflammatory 
MIP-2 MØ, Monocytes, 
neutophils 
Recruitment of effector cells, 
mucosal lymphocyte migration Pro-inflammatory 
MCP-1 Monocytes, T cells, Basophils, stem cells Inflammatory, Wound Healing Pro-Inflammatory 
MCP-2 
Monocytes, T cells, 
Eosinophils, Mast 
cells 
Recruitment of pro-inflammatory 
cells Pro-inflammatory 
 TABLE 1.2 Representative cytokines produced by different cells and their mode of action. Main reference 
sources (Janeway et al. 2008, Zidek, Anzenbacher and Kmonickova 2009 and, Adams and Lloyd 1997). 
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1.6 INNATE IMMUNE RECEPTORS 
The general strategy of innate immune detection relies on the recognition of 
microbial molecules with conserved molecular patterns known as ‘pathogen 
associated molecular patterns’ (PAMPs). As highly conserved components of 
microbes, PAMPs are not readily altered by mutation or selection and provide ideal 
targets for innate recognition. PAMPs are sensed by a limited number of specialised 
receptors commonly referred to as ‘pattern recognition receptors’ (PRRs). PRRs 
within innate immunity are reviewed by (Beutler 2004) .  
 
1.6.1 PATTERN RECOGNITION RECEPTORS (PRRs) 
PRRs include TLRs, Scavenger receptors (SRs), NOD-like receptors (NLRs) and 
RIG-I-like proteins, named the RIG-like receptors (RLRs) [see sections 1.9]. All 
play critical roles in early defence against invading pathogens. PRRs can recognise 
and respond to molecules derived from bacterial, fungal and viral pathogens. The 
response involves the maturation of immune cells and activation of intracellular 
pathways leading to the influx of inflammatory cytokines and other soluble factors 
(Creagh and O'Neill 2006, Ishii et al. 2008, Kumagai, Takeuchi and Akira 2008). 
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1.7 TOLL-LIKE RECEPTORS 
TLRs were discovered with the identification of Toll, a receptor expressed by 
Drosophilia melanogaster. Originally, Toll was found to be essential for 
development of dorsoventral polarity during embryogenesis (Hashimoto, Hudson 
and Anderson 1988). Further studies identified a role for Toll in the innate response 
of Drosophilia to fungal infection (Lemaitre et al. 1996). Subsequently, it was 
found that the cytoplasmic region of Toll was analogous to that of the type I 
receptor (IL-1RI) in mammals and several homologues were identified in humans. 
This resulted in the classification of 10 human TLRs (Takeda and Akira 2005) and 
the designation of the Toll/Interleukin-1 (TIR) superfamily of receptors. 
Importantly, the first human Toll, TLR4 was classified in 1998 (Poltorak et al. 
1998). TLR structure, activation and signalling are discussed further below. 
 
Activation of the innate system is prerequisite for induction of an adaptive response. 
TLRs play a pivotal role in this process. TLRs are expressed on many cells of the 
innate system including; MØ, DC, fibroblasts, neutrophils, mast cells, endothelial 
and mucosal epithelial cells (Andreakos, Foxwell and Feldmann 2004, Medzhitov 
2001). TLRs are type I transmembrane receptors and form part of the 
Toll/interleukin-1 (TIR) superfamily that includes the IL-1 receptors (IL-1Rs) 
because of the shared homology of their cytoplasmic regions (Gay and Keith 1991). 
In contrast, their extracellular regions (ectodomains) are considerably different. 
TLR ectodomains contain tandem repeats of leucine rich regions referred to as 
leucine rich repeats (LRRs), while IL-1Rs have three immunoglobulin (Ig)-like 
domains see figure 1.7.1. The TIR family of receptors is reviewed by (Martin and 
Wesche 2002).  
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Each TLR has the ability to recognise a particular ligand or discrete set of ligands, 
as summarised in table 1.7.2. The arrangement of LRR side chains confers a unique 
combinatorial code to each TLR enabling it to bind a specific ligand. This was first 
found in the LRR detection of follicle stimulating hormone (FSH) through its G-
protein-coupled receptor, FSHR(HB) (Fan and Hendrickson 2005). The particular 
ligand any TLR detects is dependant on the cellular location of the TLR and the 
unique code conferred to it by the arrangement of its LRRs (Brikos and O'Neill 
2008, Gay, Gangloff and Weber 2006). In this way individual TLRs have the ability 
to interact with structurally unrelated ligands of endogenous and exogenous origin. 
The structure of TLRs and their respective ligand complexes are reviewed 
extensively (by Jin and Lee 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7.1: Schematic of TLR versus IL-1 receptor structure taken from (Akira and 
Takeda 2004). 
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1.7.2 TLR EXPRESSION AND LOCALISATION 
TLRs are distinguished by ligand specificity, signal transduction, expression 
patterns and cellular localisation, all of which are discussed here. As mentioned, 
TLRs are expressed in cells at the front line of defence. However, innate immunity 
is not antigen specific and varied expression of TLRs between cell types facilitates 
the direction of an immune response to a particular pathogen (Andreakos, Foxwell 
and Feldmann 2004, Medzhitov 2001). TLR1 is found ubiquitously while TLR2-10 
display more limited expression patterns see table 1.7.1 (McGettrick and O'Neill 
2004). The exact expression of TLRs in cell types remains conflicting as studies 
demonstrate differences between mRNA levels and the responsiveness of a given 
cell to TLR agonists (Iwasaki and Medzhitov 2004). For example, highly purified 
human peripheral blood mononuclear cells (PBMCs) express TLR1, TLR2 and 
TLR4 and low levels of TLR9 yet they do not respond to unmethylated CpG 
(Hornung et al. 2002). Similarly, eosinophils express TLR1, TLR4, TLR7, TLR9 
and TLR10 mRNA and only respond to stimulation with a TLR7 agonist (Nagase et 
al. 2003). Ultimately, the diversity of an immune response lies greatly on the set of 
TLRs expressed by cells and the locations those cells reside in (Iwasaki and 
Medzhitov 2004). The location of any given TLR is related to the origin of ligand it 
recognises. TLR1, TLR2, TLR4, TLR5 and TLR6 are expressed on the plasma 
membrane and are largely involved in the detection of bacterial products in the 
extracellular space. On the other hand TLR3, TLR7, TLR8, and TLR9 are located 
within endocytic compartments that present nucleic acids of viral origin to these 
TLRs (Akira and Takeda 2004, Boehme and Compton 2004).  
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Table 1.7.1: Differential expression patterns of TLRs taken from (McGettrick and O'Neill 
2004) 
 
Toll-Like Receptor (TLR) Expression 
TLR1 Ubiquitous 
TLR2 Monocytes, DC 
TLR3 DC and NK cells 
TLR4 MØ, DC, Endothelial cells 
TLR5 Monocytes, NK cells, immature DC 
TLR6 Monocytes, B and NK cells 
TLR7 Plasmacytoid precursor DC, B cells 
TLR8 Monocytes, NK and T cells 
TLR9 
Plasmacytoid precursor DC, MØ, microglial 
cells, B and NK cells 
TLR10 Plasmacytoid precursor DC and B cells 
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TLR4 recognises lipopolysaccharide (LPS) from gram-negative bacteria [see 
section 1.6.1] (Poltorak et al. 1998, Hoshino et al. 1999). Recognition of LPS by 
TLR4 leads to the activation of transcription factors NF-κB and IRF3 [see section 
1.9.4]. Signalling by all TLRs culminates in NF-κB activation and up-regulation of 
pro-inflammatory cytokines (see figure 1.7.2) (McGettrick and O'Neill 2004, 
Boehme and Compton 2004). TLR signalling, relevant adaptor molecules and 
inducible genes are listed in table 1.7.2. TLR2 recognises peptidoglycan (PG) from 
gram-positive bacteria (Takeuchi et al. 1999). In certain cases TLRs form dimers 
broadening the range of ligands they can detect. TLR2/1 and TLR2/6 dimers 
recognise triacylated and diacylated bacterial lipoproteins (BLP), respectively 
(Takeuchi et al. 2002, Takeuchi et al. 2001, Shimazu et al. 1999). TLR5 recognises 
bacterial flagellin, a principal component of bacterial flagella, from both gram-
positive and gram-negative bacteria (Hayashi et al. 2001). TLR3 is activated by 
double-stranded RNA (dsRNA), a molecular pattern associated with viral infection 
(Alexopoulou et al. 2001).  TLR7 and TLR8 both detect viral single-stranded RNA 
(ssRNA) (Diebold et al. 2004, Heil et al. 2004). In addition TLR7 and to a lesser 
extent TLR8 are activated by small synthetic molecules, the imidazoquinolines 
(Hemmi et al. 2002). TLR9 recognises unmethylated CpG (CpG) motifs from 
bacterial and viral DNA (Wagner 2002). 
 
TLR location is also important for the discrimination between ‘self’ and ‘non-self’. 
In contrast to most TLR ligands nucleic acids can be of self and foreign origin. A 
study by (Barton, Kagan and Medzhitov 2006) demonstrates that a chimeric TLR9 
consisting of a transmembrane and cytoplasmic domain of other TLRs is localised 
to the plasma membrane. Here it is able to detect and respond to mammalian DNA 
yet remain unresponsive to viral nucleic acids, highlighting the importance of TLR 
location. Expression of the chimeric TLR9 on the cell surface exposes the receptor 
 31 
to mammalian DNA. Endogenous TLR9 is not exposed to mammalian DNA and 
can only be activated by viral DNA ingested and acidified within endosomes. 
Additionally, (Barton, Kagan and Medzhitov 2006) demonstrate the ability of 
transmembrane and cytoplasmic regions to dictate TLR localisation.  
 
 
 
 
Figure 1.7.2: Schematic of TLR localisation and signalling pathways taken from (Boehme 
and Compton 2004). TLR1, TLR2, TLR4, TLR5 and TLR6 are expressed on the plasma 
membrane while TLR3, TLR7, TLR8 and TLR9 typically localize within endocytic 
compartments. TLRs make use of adaptor molecules Mal, MyD88, Trif and TRAM to 
activate signaling pathways. Like TLR4, TLR2 in combination with TLR1 or TLR6 utilizes 
MyD88 and Mal as primary adaptors to activate NF-κB and inflammatory cytokine 
secretion. TLR4 can also make use of Trif and TRAM to activate IRF3 and the IFN 
pathway. TLR3 utilizes Trif but not TRAM to activate IRF, while TLR7, TLR8 and TLR9 
trigger inflammatory cytokine secretion and the IFN pathway through MyD88. Other than 
MyD88, the signalling components used by TLR7, TLR8 and TLR9 to activate IFN 
responses remain undefined. 
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1.7.2 TLR ACTIVATION AND SIGNALLING 
Recognition of PAMPs by TLRs results in the activation of signalling pathways that 
induce the up-regulation of cytokines, chemokines and co-stimulatory molecules. 
The initial step in signal transduction of class I transmembrane receptors involves 
the binding of ligand resulting in dimerization of two receptor chains. In the case of 
TLR4 this homodimer is induced by the binding of MD-2 to the lipid A moiety of 
LPS (Saitoh et al. 2004). Conformational changes in the receptor then leads to the 
association of two receptor TIR domains (Gay, Gangloff and Weber 2006, Gay, 
Gangloff and Weber 2006, Gangloff, Weber and Gay 2005). It is believed the 
overall structure of the TLR ectodomain, transmembrane and cytoplasmic regions 
in turn constitute a molecular switch ‘turned-on’ by a sequence of stimulus (ligand 
binding) induced conformational changes. To date several crystal structures of TLR 
dimers have been elucidated and dimers of TLR3, TLR2/1 and TLR4 taken from 
(Jin and Lee 2008) are shown in figure 1.8.2. Ultimately, association of TIR 
domains provides a new scaffold for the recruitment of specific adaptor molecules 
which also contain a TIR domain. The result is a post-receptor signalling complex 
associating relevant adaptor molecules to active TIR domains of TLR dimers.  
 
 
 
 
 
 
 
Figure 1.7.3: The crystal structures of ‘m’ shaped TLR dimers induced by ligand binding 
are shown taken from (Jin and Lee 2008) (A) TLR1-TLR2-Pam3CSK4, (B) TLR3-dsRNA 
and (C) a model of TLR4-MD-2-Eritorian complex. Double apostrophes mark the second 
TLR or associated molecule (MD-2) in the receptor complex. 
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Alternatively, it is also considered that TIR dimers may exist in an ‘inactive’ form 
within the cell and upon ligand binding reorientation of TIR domains may occur to 
facilitate adaptor recruitment. This has recently been demonstrated by (Latz et al. 
2007) who show that an ‘inactive’ TLR9 dimer exists in a steady state prior to 
ligand binding. Binding of CpG resulted in close apposition of the cytoplasmic TIR-
domains required for the recruitment of adaptor molecules. TLRs, relative adaptor 
molecules, signalling pathways and inducible genes are listed in table 1.7.2. 
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Table 1.7.2: Toll-like receptors 1-11 and their corresponding ligands, adaptor molecules and inducible genes. Main reference sources listed in 
text.  * All TLRs activate NF-κB. +Orphan: denotes a receptor of similar structure to other identified receptors but no endogenous ligand has been 
identified. 
 
Toll-like receptor 
 
Ligand 
 
Origin of Ligand 
 
Adaptor/Pathway 
Transcription Factor/ 
Inducible genes 
TLR1/2 Lipopeptide (BLP) Bacteria and mycobacteria Mal, MyD88  NF-κB* 
TLR2/6 Peptidoglycan (PG), BLP Gram +/-bacteria Mal, MyD88 NF-κB 
TLR3 dsRNA Viruses Trif IRF3/Type I IFN α/β,  NF-κB 
TLR4 
Lipopolysaccharide (LPS), 
hsp60, F protein 
Gram +bacteria 
Mal, MyD88 
Trif, TRAM 
NF-κB 
IRF3 
TLR5 Flagellin Gram +/-bacteria MyD88 NF-κB, TNFα, IL-6 
TLR6 Triacylated BLP, Zymosan Bacteria, Yeast MyD88 NF-κB 
TLR7 ssDNA Viruses MyD88 NF-κB 
TLR8 ssDNA Viruses MyD88 NF-κB 
TLR9 CpG DNA, Hemazoin Bacteria and Viruses MyD88 NF-κB, IRF-3, IRF-7/IFN-α 
TLR10 Orphan + - - NF-κB 
TLR11 Uropathogenic bacteria Toxoplasma gondii - NF-κB 
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There are five adaptor molecules known to transduce signals through TLRs via their 
TIR-domain and include; myeloid differentiating protein 88 (MyD88) (Lord, 
Hoffman-Liebermann and Liebermann 1990), MyD88 adaptor like/TIR domain-
containing adaptor protein (Mal/TIRAP) (Fitzgerald et al. 2001), TIR-domain-
containing adaptor inducing interferon-β/TIR-containing adaptor molecule-1 
(Trif/TICAM-1) (Yamamoto et al. 2002b), Trif-related adaptor molecule/TIR-
containing adaptor molecule-2 (TRAM/TICAM-2) (Bin, Xu and Shu 2003), and 
sterile alpha (SAM), HEAT/Armidillo motif and TIR-containing adaptor protein 
(SARM) (Carty et al. 2006). The proximal events of ligand binding and adaptor 
recruitment to the active TIR-domains of TLRs can result in the activation of two 
major signalling cascades, namely the MyD88-dependant and MyD88-independent 
pathways (Sharma et al. 2003, Kaisho and Akira 2006).  
 
The MyD88 pathway leads to the activation of transcription factor NFκB and the 
expression of pro-inflammatory cytokines [see section 1.10.1]. As the name implies 
this pathway involves the recruitment of MyD88. The death domain of MyD88 
interacts with the IL-1 receptor associated kinase (IRAK) family. Firstly, 
phosphorylation of IRAK-1 leads to the association of TNF-receptor associated 
factor 6 (TRAF6). TRAF6 is subsequently ubiquitinated via a TAK1-TAB-1-TAB2 
kinase complex. This activates inhibitor of NFκB protein (IκB) kinase (IKK), IKKα 
and IKKβ. IKKs in turn phosphorylate IκB leading to its degradation. Degradation 
of IκB means NFκB is then free to translocate to the nucleus and initiate 
transcription of genes with a κB promoter element. In addition to NFκB, MyD88-
dependant signalling also gives rise to the activation of mitogen activated protein 
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kinases (MAPK) such as p38 and JNK, which also result in the expression of 
inflammatory cytokines (Kaisho and Akira 2006, Dunne and O'Neill 2005).  
 
MyD88-independent signalling activates the transcription factor interferon (IFN) 
regulatory factor 3, (IRF3). IRF3 activation leads to the expression of type I 
interferons, IFNα and IFNβ and other IFN-inducible genes. The MyD88-
independent pathway requires the recruitment of adaptor Trif. The N-terminus of 
Trif has a binding site for tank binding kinase-1 (TBK-1) and IKKi. These kinases 
phosphorylate IRF3 resulting in its dimerisation and translocation to the nucleus. 
Upon translocation IRF3 binds to interferon stimulated response element (ISRE) in 
the promoters of IFN-inducible genes (Fitzgerald et al. 2003). As an example, 
schematic representation of TLR4 activation of MyD88 dependant and independent 
pathways is outlined in figure 1.7.4. 
 
All TLRs with the exception of TLR3 are known to recruit MyD88 and activate the 
MyD88-dependent pathway activating MAPK and NFκB [see section 1.8.1] 
(Boehme and Compton 2004). In addition to MyD88, TLR2 and TLR4 require 
Mal/TIRAP to activate the MyD88-dependant pathway (Yamamoto et al. 2002a). 
TLR3 typically activates IRF and expression of interferons (IFN) from its endocytic 
compartments via Trif (Takeda and Akira 2004). TLR4 is unique in that it utilises 
both MyD88 and Mal to activate NFκB and Trif and TRAM to activate IRF3 [see 
section 1.9.4]. Of particular interest is that TLR4 signalling via Trif and TRAM also 
induces a late phase of NFκB activation (Kawai et al. 1999). TLR7, TLR8 and TLR9 
act through MyD88 to induce pro-inflammatory cytokine secretion and the IFNs. 
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Other than MyD88, the signalling proteins employed by TLR7-9 to activate IFN 
remain unidentified.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7.4: TLR activation of MyD88 dependant and independent pathways. Adapted 
from (Kawai and Akira 2006).  
 
TLRs have the ability to harness great immunostimulatory signals and are therefore 
tightly regulated and activated. Incorrect and/or over activation of these pathways 
can lead to autoimmune disease (Reindl et al. 2003) and fatal sepsis (Karima et al. 
1999). While many questions surround the exact interaction of TLRs and their 
 
TLR4 
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ligands, the complexities remain under constant investigation. TLR signalling and 
the responses they control continue to challenge thinking regarding the pathogenesis 
and treatment of cancers (O'Neill 2003), immune and infectious diseases as 
discussed in section 1.7.3. 
1.7.3 TOLL-LIKE RECEPTORS: DISEASE AND THERAPEUTIC 
TARGETS 
Over the past 30 years a great deal has been learned about innate immune activation 
on a molecular level. The TLR family represents just one of four important 
signalling systems involved in this activation. As such, the role of TLRs in the 
pathogenesis of infection and inflammatory disease is under constant investigation. 
Roles for TLRs have emerged in sepsis (Karima et al. 1999, BRAUDE, JONES and 
DOUGLAS 1963, Lorenz et al. 2002), rheumatoid arthritis (RA) (Seibl et al. 2003, 
Lee et al. 2006), inflammatory bowel disease (IBD) (Himmel et al. 2008), cancer 
(Eder et al. 2004, Smit et al. 2009), atherosclerosis (Kiechl et al. 2002, Liu et al. 
2008, Schoneveld et al. 2008), asthma (Eder et al. 2004, Smit et al. 2009) and 
multiple sclerosis (Reindl et al. 2003) to name a few. Also a role for TLRs has been 
implicated in autoimmune disease with TLR4 (Ohashi et al. 2000, Okamura et al. 
2001) and TLR9 (Leadbetter et al. 2002) responding to endogenous ligands. As a 
result, specific TLRs and their downstream signalling components present important 
targets for drug development in a wide range of inflammatory diseases and cancer.  
 
The potential for TLRs and their signalling components in this regard lies in the 
ability of TLRs to ‘tailor’ signalling events in response to specific ligands. For 
example, while all TLRs are known to induce a common set of genes, individual 
TLRs use combinations of adaptor molecules to activate different signalling 
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pathways, inducing specific ‘sets’ of genes optimising host responses to a particular 
infection. Consequently, several approaches are taken to the development of 
therapies. Limiting TLR function may limit disease pathogenesis whilst in contrast 
stimulating TLRs may have adjuvant effects. Table 1.7.3 summarises the links 
between specific TLRs and disease. 
 
 
 
Table 1.7.3: Taken from (O'Neill 2003). 
 
 
 
As pointed out, TLR signalling can be inhibited in an attempt to limit exacerbated 
inflammation in inflammatory and autoimmune disease. Blocking of TLR signalling 
by means of neutralising antibodies is a popular and effective approach. TLR4, the 
receptor for LPS implicated in gram-negative sepsis, is by far the most studied. 
TLR4 is notably activated in response to endogenous factors such as heat shock 
TLR Target Disease 
TLR1/2 Bacterial/Fungal Diseases, Gram-positive sepsis 
TLR3 Viral Diseases 
TLR4 
Bacterial diseases, Gram-negative sepsis, Chronic inflammation, 
Autoimmune diseases, Vaccines, Cancer, Atherosclerosis 
TLR5 Bacterial diseases 
TLR6/2 Mycobacterial diseases 
TLR7 Viral diseases 
TLR8 Viral diseases 
TLR9 
Bacterial and viral diseases, Autoimmune diseases, Vaccines, 
Cancer 
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protein 60 (hsp60) (Ohashi et al. 2000) and fibronectin (Okamura et al. 2001) 
released during tissue injury.  This and other work suggests an involvement of TLR4 
in ‘sterile’ or non-infectious inflammation of autoimmune disease (Kerfoot et al. 
2004, Racke, Hu and Lovett-Racke 2005).  
 
Most recently TLR4 antibodies have been generated that have been shown to 
protecting mice from lethal endotoxic shock and E. coli sepsis (Roger et al. 2009, 
Daubeuf et al. 2007), demonstrating the potential of TLR4 targeted therapy in the 
treatment of gram-negative sepsis. Also a model employing Malassezia furfur, 
implicated in the development of scalp lesions of psoriasis, was used to demonstrate 
that a TLR2 antibody could successfully inhibit M. furfur-induced IL-8 in human 
keratinocytes (Baroni et al. 2006). Uniquely, in attempts to evade the immune 
system, vaccinia virus expresses the proteins A46R and A52R that limit host defence 
(Bowie et al. 2000). Importantly, A52R specifically inhibits TLR3 activation (Harte 
et al. 2003) and it is envisaged that inhibitors of TLR signalling may be developed 
based on viral proteins such as those found in vaccinia. 
 
TLR antagonists have also been widely investigated and several attempts have been 
made to develop a TLR4 antagonist. The latest of which includes a phosphatidyl 
ethanolamine which blocks LPS activation of TLR4 by binding its co-receptor CD14 
(Lee et al. 2009) and a chemically developed inhibitory peptide (Slivka et al. 2009). 
Plant sterol and phytochemical glugglsterone is a potent antagonist of TLR4 and 
TLR3 (Youn, Ahn and Lee 2009) while oligonucleotides with unmethlyated motifs 
antagonise TLR7 and TLR9 (Robbins et al. 2007). Another approach is to inhibit 
common signalling components or specific adaptors of TLR pathways leading to 
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decreased inflammatory gene expression. Glugglsterone suppresses NFκB activation 
by inhibiting the activity of inhibitor-κB kinase (IκB) (Youn, Ahn and Lee 2009).  In 
terms of targeting specific adaptors the exact function of several of them remains to 
be elucidated.  
 
Activation of TLRs can have adjuvant effects, particularly in relation to anti-tumor 
and anti-viral immunotherapies. Currently, aluminium hydroxide (alum) is the only 
approved human adjuvant in many countries. While extremely effective at boosting 
antibody responses, repeated administration is necessary and responses tend to be 
anti-parasitic T helper 2 (TH2) rather than anti-viral and anti-bacterial T helper 
1(TH1), as reviewed by (Petrovsky and Aguilar 2004). Two clinically relevant TLR 
ligands have been investigated in this regard, CpG oligonucleotides (Lubaroff and 
Karan 2009) and a low toxicity derivative of LPS, monophosphoryl lipid A (MPLA) 
(Mata-Haro et al. 2007). CpG oligonucleotides induce type I interferon in a MyD88-
dependent manner (Honda et al. 2005) while MPLA has been shown to induce type I 
interferon in a TRIF-dependant manner (Mata-Haro et al. 2007). This demonstrates 
the ability of different TLR ligands to reach the same endpoint using different 
adaptor molecules. With this understanding improvements can be made to possible 
TLR-dependent adjuvants. In addition, TLRs detecting viral components such as 
TLR3, 7 and 8 are potent activators of anti-viral responses. It is predicted that 
stimulating TLR3, 7 and 8 would have adjuvant effects in immunotherapies (O'Neill 
2003). TLR7 and TLR8 are important inducers of type-I interferon’s in response to 
viral infection. A group of small molecules such as the imiquimods are potent 
ligands for TLR7 and TLR8 and are currently in trial for treatment of genital herpes 
(Jurk et al. 2002, Syed et al. 1998). Adjuvant effects of TLR ligands is reviewed 
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extensively by (Warshakoon et al. 2009). Similarly, enhancing TLR activity is 
favoured in developing cancer treatment. However, this is suggested to have the 
most effect when used in combination with anti-cancer agents. This is reviewed 
extensively in the Oncogene issue comprising ten reviews on the topic (Journal Issue 
2008). 
 
Importantly, blocking TLR-mediated responses can lead to inappropriate allergic 
TH2 responses or tolerance (Ishii, Uematsu and Akira 2006). It is also strongly 
desired that TLR antagonists present minimal toxicity in vivo. Furthermore, blocking 
TLR responses may also inhibit the inherent anti-inflammatory signalling of 
pathways essential in resolution (Serhan et al. 2007). It is crucial that mechanisms 
by which these anti-inflammatory pathways can be enhanced are investigated in 
order to promote resolution of inflammation. Current thinking has begun to focus on 
this aspect of TLR signalling in the development of therapies (Serhan et al. 2007). It 
is in no doubt that the risks and advantages involved in altering TLR signalling need 
to be balanced and investigated further. 
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1.8 SCAVENGER RECEPTORS 
Scavenger receptors (SRs), as the name implies were first described for their ability 
to bind, internalize or ‘scavange’ modified low-density lipoproteins (mLDL) 
(Goldstein et al. 1979, Brown and Goldstein 1983). SRs are expressed by 
macrophage, dendritic cells and certain endothelial cells. By binding and 
internalising mLDL, they contribute to the onset of atherogenesis (Kunjathoor et al. 
2002, Manning-Tobin et al. 2009). As PRRs they facilitate the receptor mediated 
endocytosis of microbes, and components of gram-negative (Amiel et al. 2007) and 
gram-positive bacteria (Peiser, Mukhopadhyay and Gordon 2002) including LPS and 
lipotechnoic acid (LTA), respectively. Additional functions include the clearance of 
apoptotic debris (Todt, Hu and Curtis 2008) and tissue homeostasis. The eight 
classes of the SR family (A-H) are structurally different with varying combinations 
of collagenous, cysteine-rich and/or C-type-lectin domains. Yet as a family of 
receptors they recognise and bind a range of common lipid and lipo-protein based 
ligands along with mLDL (Murphy et al. 2005). Although initial research focused on 
the role of SRs in atherogenesis, their role in defence is increasingly under 
examination. Scavenger receptor signalling has implications for cell morphology as 
well as cytokine and survival responses.  Several in vivo studies demonstrate mice 
lacking SR-A have altered responses to LPS (Kobayashi et al. 2000, Fulton et al. 
2006). Overexpression of class E scavenger receptor (LOX-1) has been 
demonstrated in rat zymosan-induced arthritis models (Nakagawa et al. 2002).  The 
gene for human LOX-1 is located on a cluster within chromosome 12 linked to NK 
cell function and transcription of lectin proteins implicated in immune function 
(Sobanov et al. 2001). Furthermore, mice deficient in the scavenger receptor, 
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MARCO, display reduced bacterial clearance from lung tissue indicating an 
important role in host defence against airborne pathogens (Arredouani et al. 2004). 
The biological function and structure of the SR family is reviewed extensively (by 
Murphy et al. 2005, Adachi and Tsujimoto 2006). 
 
1.8.1 SCAVENGER RECEPTOR A (SR-A) 
Class A scavenger receptors (SR-A) were first among eight classes of the SR family 
(A-H) to be cloned (Kodama et al. 1990, Rohrer et al. 1990). They are type II 
trimeric transmembrane glycoproteins initially described for their ability to bind 
(mLDL) (Goldstein et al. 1979) although they are now known to bind many 
polyanionic ligands (Platt and Gordon 2001). The group is comprised of five 
polypeptides encoded by three related genes and includes: macrophage receptor with 
collagenous structure (MARCO), scavenger receptor with C-type lectin (SRCL), 
SR-AI, SRAII and SR-AIII (Kangas et al. 1999, Nakamura et al. 2001, and Freeman 
et al. 1990). The later three of the group are naturally occurring isoforms and 
alternative splice variants of the same gene (Gough, Greaves and Gordon 1998). 
Both SRA-I and SRA-II isoforms bind mLDL, bacterial components, polynucleic 
acids and some carbohydrate based ligands (Dhaliwal and Steinbrecher 1999). SR-
AIII has no known ligand binding activity and is trapped in the endoplasmic 
reticulum (Gough, Greaves and Gordon 1998). These SR-A isoforms are largely 
expressed on macrophage but can also be found in smooth muscle and endothelial 
tissues (Murphy et al. 2005). All three isoforms are collectively referred to as SR-A 
(Mukhopadhyay and Gordon 2004). SR-A is structurally made of six domains: a 
transmembrane domain, α-helical coiled-coil domain, N-terminal cytoplasmic region, 
a spacer, a collagenous domain and a C-terminal domain see figure 1.8.1 (Kodama et 
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al. 1990, Rohrer et al. 1990). Several point mutation studies have indicated that the 
characteristic collagenous domain of each isoform confers ligand binding properties 
to the receptors (Doi et al. 1993). 
 
 
 
 
 
 
 
 
 
 
Figure 1.8.1:  Domain organization of SRAI and SRAII adapted from (Murphy et al. 2005).   
Each structure is made up of domains 1-6. 1. N-terminal cytoplasmic region, 2. 
transmembrane domain, 3. a spacer 4. α-helical coiled-coil domain, 5. collagenous domain 
and 6. a C-terminal domain. 
 
Research has focused on the ability of SR-A to bind mLDL contributing to 
atherogenesis by foam cell formation (Dhaliwal and Steinbrecher 1999, de Winther 
et al. 2000). However, their biological complexity and ability to bind a range of 
ligands corresponds to a much broader role for the receptors. Indeed, SR-A is known 
to be multifunctional having definitive roles in innate immunity, apoptotic cell 
clearance, tissue homeostasis and the pathogenesis of other inflammatory diseases 
such as Alzheimers, reviewed extensively by (Murphy et al. 2005, Mukhopadhyay 
and Gordon 2004, Peiser and Gordon 2001). 
 
 
SR-AI SR-AII 
6 
5 
4 
3 
2 
1 
 46 
Studies involving SR-A-/- mice indicate a clear role for SR-A in innate immunity. 
SR-A-/- mice are more susceptible to gram-positive bacteria (Listeria monocytogenes 
and Staphylococcus aureus) compared to wild-type mice (Kodama et al. 1990, 
Suzuki et al. 1997, Thomas et al. 2000). SR-A mediated phagocytosis of gram-
negative and gram-positive bacteria has also been demonstrated (Thomas et al. 2000, 
Peiser et al. 2000). In addition, SR-A is a critical phagocytic receptor in bone 
marrow derived dendritic cells (BMDCs) for internalisation of gram-negative 
bacteria (Amiel et al. 2007) all of which indicate a vital role of SR-A in the 
clearance of bacteria. Importantly, SR-A mediated phagocytosis does not activate 
macrophage or induce pro-inflammatory cytokines such as TNFα, crucial to 
maintaining homeostasis (Platt and Gordon 2001, Peiser and Gordon 2001) .  
 
Particularly, in vitro studies have demonstrated the ability of SR-A to bind LPS 
suggesting a possible role for SR-A in LPS clearance (Hampton et al. 1991). 
(Haworth et al. 1997) demonstrate that SR-A-/- mice (Haworth et al. 1997)are more 
susceptible to septic shock than wild type mice. The exact mechanism by which SR-
A confers protection remains unclear. However, it is believed it is involved in the 
removal of excess LPS from the site of inflammation making it less available for 
CD14 (another LPS receptor) [see section 1.9.2]. SR-As are a prime example of how 
PRRs play critical roles within innate immunity and may also contribute to disease 
processes under certain pathological conditions.  
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1.9 OTHER PATHOGEN RECOGNITION RECEPTORS 
TLRs occupy both the membrane and endosomes, giving them the ability to detect 
pathogens at the cell surface and within the cytosol. Together with TLRs, NLRs and 
RLRs exist as cytosolic sensors and facilitate the detection of intracellular PAMPs. 
TLRs recognize bacteria, fungi, protozoa and viruses; NLRs have been found to 
recognize bacteria and RLRs detect viral components. Nods are key regulators of 
apoptosis and NFκB activation in mammals in response to invading pathogens. 
Nod1 and Nod2 play important roles in innate and acquired immunity as sensors of 
bacterial components and their activation induce the production of pro-inflammatory 
mediators. Specifically, Nod1 confers recognition of bacterial lipopolysaccharide 
(LPS) and NFκB activation in a TLR4-independent manner (Inohara et al. 2001). 
Mutations within the Nod2 gene, primarily expressed in monocytes have been 
widely implicated in susceptibility to Crohn’s disease (Ogura et al. 2001) and linked 
to several immune diseases including psoriatic arthritis (Rahman et al. 2003) and 
allergic diseases (Kabesch et al. 2003). 
 
The RLR family of receptors detect viral DNA are widely expressed and are 
encoded by 3 genes in the human and mouse genomes (Yoneyama et al. 2005). Like 
anti-viral TLRs (TLR3, 7 and 9) [see section 1.7.1 – 1.7.2], RLR activation leads to 
NFκB and IRF3 induction and expression of type I IFNs. In contrast, recent studies 
indicate RLRs protect all virally infected cells unlike TLRs, known to mainly detect 
viral infections in plasmacytoid dendritic cells (pDC). The activation and roles of 
NLRs and RLRs within immunity are extensively reviewed by (Creagh and O'Neill 
2006, Yoneyama et al. 2005 and Inohara et al. 2005). 
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In certain cases it has been established that different PRRs co-operate. TLRs and 
certain NLRs are known to interact and mediate the induction of pro-inflammatory 
cytokine IL-1β. TLRs induce pro-IL-1β production and prime ‘inflammasomes’ or 
NLR-containing multi-protein complexes which respond to bacterial products and 
products of damaged cells activating caspase-1, which leads to the processing of 
pro-IL-1β to its active form (Netea et al. 2008). Similar interactions are believed to 
occur between TLRs and RLRs and further studies have to be carried out. 
Importantly, the interactions of various PRRs act synergistically or co-operatively to 
direct the overall innate response and provide ubiquitous protection. 
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1.10 TLR4 RECEPTOR COMPLEX 
By far, the most widely recognised and characterised microbial activator of an innate 
immune response is lipopolysaccharide (LPS), also referred to as bacterial endotoxin 
(Janeway et al. 2008). The potent role of LPS in the pathogenesis of sepsis was first 
recognised in the 1960s (BRAUDE, JONES and DOUGLAS 1963). LPS is an 
important component of the membrane of gram-negative bacteria.  LPS activates 
monocytes, MØ and other leukocytes promoting secretion of pro-inflammatory 
cytokines, TNFα, IL-12, IL-1, IL-6 and IL-8 (Cohen 2002) causing fever, 
hypotension, inadequate tissue perfusion, metabolic acidosis and organ failure 
(Beutler 2001). Due to the intensity with which LPS can induce inflammation and 
the pathogenesis of sepsis, many efforts were made to identify its receptor. In 1998 a 
group using the C3H/HeJ mice strain known to be hypo-responsive to LPS, 
demonstrated that TLR4 was the receptor for LPS (Poltorak et al. 1998). To date, 
TLR4 has been the most studied TLR in terms of it biological complexity, 
functioning in association with two accessory proteins, cluster of differentiation 14 
(CD14) and myeloid differentiation-2 (MD-2) (Shimazu et al. 1999, Kirkland et al. 
1993).  
 
In its most effective form a receptor complex of TLR4, CD14 and MD-2 is activated 
by LPS. However, LPS can induce minimal signalling through TLR4 and MD-2 
alone (Shimazu et al. 1999, Visintin et al. 2001). TLR4 is the signalling subunit 
directing signals intracellularly via the recruitment of adaptor molecules [see section 
1.7.2]. CD14 is a glycosylphosphatidylinositol (GPI) anchored protein devoid of 
signalling capacity acting as the major recognition receptor of LPS (Kirkland et al. 
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1993). A lipid binding protein, (LBP) acts as a lipid transferase aiding LPS 
recognition by CD14 (Schumann et al. 1990). While MD-2, a secreted protein 
retained at the cell surface by TLR4, is indispensable in the cellular recognition and 
signalling of LPS (Shimazu et al. 1999). A schematic of the TLR4 receptor complex 
is represented in figure 1.10.1. Activation of TLR4 is mediated by the ligation of 
LPS and results in signalling via the MyD88-dependent (principal adaptor – Mal) 
and independent (principal adaptor TRAM) pathways activating NFκB and IRF, 
respectively (Kaisho and Akira 2006, Takeda and Akira 2004).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10.1: Illustration of TLR4 receptor complex comprising the four cellular adaptor 
proteins known to participate in LPS recognition: Toll-like receptor 4 (TLR4), cluster of 
differentiation 14 (CD14), myeloid differentiation protein 2 (MD-2) and lipid binding 
protein (LBP). 
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1.10.1 TLR4 
TLR4 is an atypical TLR with extracellular leucine rich repeat (LRR), 
transmembrane and toll/interleukin-1 receptor (TIR) like cytoplasmic domains [see 
section 1.6.11]. (Espevik et al. 2003) reports two major localisation sites of TLR4; 
namely the plasma membrane and the Golgi apparatus. Furthermore, this group 
report localisation of TLR4 on the membrane of early endosomes. The exact 
mechanisms regulating TLR4 localisation remain controversial. (Visintin et al. 
2006) report accessory molecule MD-2 is not required for surface expression of 
TLR4, while other reports conflict with this (Nagai et al. 2002, Ohnishi, Muroi and 
Tanamoto 2003). However, it is recognised that TLR4 rapidly traffics between the 
Golgi and plasma membrane, suggesting it is a highly mobile protein (Espevik et al. 
2003, Latz et al. 2002).  While TLR4 recognises a wide range of molecules 
including heat shock proteins, fibrinogen and taxol, LPS remains its most potent 
ligand (Gay and Gangloff 2007).  
 
1.10.2 CD14 
CD14 is a 56kDa, GPI-anchored protein lacking a transmembrane and intracellular 
domain. CD14 acts as an accessory molecule for both TLR4 and TLR2 signalling 
(Wright et al. 1990, Jiang et al. 2005). TLR2 employs CD14 for the recognition of 
lipopeptide, lipoteichoic acid and zymosan as studies indicate that CD14 mutant 
mice display impaired responses to these TLR2 ligands (Jiang et al. 2005). LPS has 
poor immuno-stimulating activity while it is part of the bacterial membrane. To 
become potent, it must be extracted and presented to the TLR4-MD-2 receptor. LBP, 
a serum glycoprotein and lipid transferase, catalyzes the transfer of LPS from the 
bacterial outer membrane to membrane-bound (mCD14) or soluble CD14 (sCD14) 
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(Schumann et al. 1990, Miyake 2006a). In turn, CD14 facilitates physical proximity 
and binding of LPS completing the TLR4 ‘activation cluster’. Indeed, CD14 plays a 
crucial role in LPS signalling as CD14-deficient mice are highly resistant to LPS 
induced septic shock (Haziot et al. 1996).  
 
1.10.3 MD-2  
MD-2 is a small glycosylated protein, physically associated with TLR4 on the 
surface of cells and confers LPS responsiveness to the receptor (Shimazu et al. 1999, 
Gangloff and Gay 2004, Nu-A et al. 2009). Indeed, the absolute requirement of MD-
2 for maximal responsiveness of TLR4 signalling was demonstrated when disruption 
of the MD-2 gene in mice completely abrogated their responses to LPS (Schromm et 
al. 2001).  Furthermore, (Visintin et al. 2001) show that soluble MD-2 alone had 
great capacity to restore LPS responsiveness to reporter cells that expressed TLR4 
but not MD-2, demonstrating the high affinity interaction between the two. In 
contrast to TLR4, MD-2 binds LPS directly and does not require LBP or CD14 (da 
Silva Correia and Ulevitch 2002). A hydrophobic core and cationic lipid binding 
motif are structural features of the protein that make this binding possible (Gangloff 
and Gay 2004). A schematic of the crystal structure of TLR4-MD-2 binding LPS is 
depicted in section 1.7.2, figure 1.7.3. 
 
The exclusive interactions of the accessory molecules CD14 and MD-2 with LPS 
have been studied and reviewed extensively (Kirkland et al. 1993, Miyake 2006a, 
Gangloff and Gay 2004and, Nu-A et al. 2009, Kim et al. 2005, Visintin et al. 2003). 
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1.10.4 TLR4 SIGNALLING  
As discussed, the specific bacterial product, LPS from gram-negative bacteria 
predominantly drives TLR4 signalling. As this can mediate an overactivation of the 
immune response leading to chronic sepsis and organ failure, TLR4 signalling is 
finely tuned. Binding of agonistic ligand, LPS, to the TLR4 receptor complex causes 
dimerisation of the extracellular domain of two TLR4 receptors constituting a 
molecular ‘switch’. This induces conformational changes to the cytoplasmic domain 
of the TLR dimer producing two symmetrically related adaptor binding sites (Nunez 
Miguel et al. 2007). Subsequently, signalling cascades are activated via recruitment 
of adaptors MyD88, Mal, Trif and TRAM (Brikos and O'Neill 2008, Akira, 
Yamamoto and Takeda 2003, Lu, Yeh and Ohashi 2008). Signalling via TLR4 is 
unique in that it activates both the MyD88-dependant pathway via MyD88 and Mal 
and the MyD88-independent pathway via TRAM and Trif. It remains unknown as to 
whether an activated TLR4 dimer can stimulate Mal and TRAM directed pathways 
simultaneously or whether the engagement of each adaptor is mutually exclusive 
(Nunez Miguel et al. 2007). The MyD88-dependent pathway results in nuclear 
translocation of NFκB and induction of pro-inflammatory cytokines, while the 
MyD88-independent pathway mediates induction of Type I interferons and IFN-
inducible genes (e.g. IRF3) (Lu, Yeh and Ohashi 2008).  
 
It is well accepted that cellular activation of the MyD88-dependent pathway via 
TLR4 is an event occurring at the plasma membrane. Indeed, (Latz et al. 2002) 
demonstrate recruitment of MyD88 to the cell surface upon LPS exposure and 
antibody-induced signalling and aggregation of surface TLR4. Mal acts as a sorting 
adaptor and recruits MyD88 to TLR4 through its ability to interact with 
 54 
phosphatidylinositol 4, 5-bisphosphate (PIP2) (Kagan and Medzhitov 2006). 
Furthermore, by analogy the same group postulated that TRAM may also function as 
a sorting adaptor recruiting Trif to TLR4. Indeed, (Kagan et al. 2008) demonstrate 
that TRAM does act in this context. Surprisingly however, the group demonstrate 
that TRAM couples the endocytosis of TLR4 to the induction of MyD88-
independent signalling (Kagan et al. 2008). This was further supported by a study at 
the time showing that TLR4 activates Trif-signalling via endosomes after its 
relocation from the cell surface (Tanimura et al. 2008). In addition, prior to the 
above (Jiang et al. 2005) demonstrate the absolute requirement of CD14 for LPS 
induced activation of the MyD88-independent pathway, while (Shuto et al. 2005) 
elucidate the requirement facilitates LPS-induced endocytosis and down-regulation 
of surface TLR4 expression in CHO cells.(Lee et al. 2001, Lee and Hwang 2006 and 
Lee et al. 2003) As a result CD14 plays a fundamental role in the regulation of 
TLR4 signalling. An outline of TLR4 activation via the MyD88 dependant and 
independent pathways is illustrated in figure 1.10.2. 
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Figure 1.10.2: Illustration of TLR4 activation of MyD88 dependant and independent 
pathways. TLR4 activation of MyD88 signalling occurs at the membrane. Activation of the 
MyD88-independent pathway is mediated by endocytosis of TLR4 and TRAM in the 
presence of CD14 and subsequent interaction with Trif in early endosomes. 
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1.11 INTRACELLULAR SIGNALLING 
 
Intracellular signalling is the ultimate mechanism by which cellular activation 
occurs. PAMPS, cytokines and other mediators act through distinct signalling 
pathways to activate protein kinases, initiating phosphorylation and ubiqitination 
events. At the level of signalling kinases a data compression occurs, channelling all 
signals towards activation of specific transcription factors controlling gene 
expression. The complexity of cellular networks means they commonly overlap and 
cross regulate each other.  
 
1.11.1 NUCLEAR FACTOR  (NF-) κB 
Transcription factors such as NFκB play a vital role in inflammation, controlling 
genes that encode pro-inflammatory cytokines, chemokines, immune receptors and 
cell surface adhesion molecules (Li and Stark 2002). NFκB transcription factors 
include proteins with a highly conserved DNA-binding and dimerisation region 
known as the Rel homology (RH) domain (Hoffmann et al. 1999). Proteins of this 
family are divided into two groups based on their function, structure and mode of 
synthesis. Class I includes NFκB1 (p50), NFκB2 (p52) and class II includes RelA 
(p65), RelB and c-Rel. Members of both groups have the ability to form 
homodimers or heterodimers. Importantly, NFκB1 (p50) and NFκB2 (p52) function 
as transcription factors only upon forming dimers with a member of the second 
group (Baeuerle and Baltimore 1996).  
 
NFκB proteins exist in resting cells as homo/heterodimers sequestered in the 
cytoplasm due to their association with an IκB inhibitory protein. IκB disguises the 
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sequence of the NFκB protein important for nuclear localization and DNA-binding 
(Chen et al. 1998, Ghosh et al. 1995). Multiple innate stimuli can lead to the 
activation of NFκB (i.e. LPS via the MyD88 dependent pathway via TLR4 
activation). Ultimately, these stimuli lead to the activation of IκB kinase, IKK and 
subsequent phosphorylation of IκB proteins. Phosphorylated IκB proteins are 
targeted for degradation in the proteosome by ubiquitination. Degradation of IκB 
uncovers the nuclear localization sequence on NFκB. Translocation of NFκB to the 
nucleus facilitates the induction of pro-inflammatory genes that contain a κB-
binding motif in their promoter regions (Hanada and Yoshimura 2002). NFκB 
signalling can occur through either the classical (canonical) or alternative (non-
canonical) pathway.  The classical pathway is activated by members of IL-1R/TLR 
superfamily and utilises IKKβ and IKKγ. The alternative pathway is initiated by 
members of the TNF superfamily (i.e. CD40L) and is IKKα dependent (Bonizzi and 
Karin 2004). More than 150 extracellular signals can lead to the activation of NFκB 
and many of the possible signalling pathways involved in the induction of this 
transcription factor are reviewed extensively by (Li and Stark 2002).  
 
NFκB plays a critical role in both innate and adaptive immunity. It is associated with 
the transcription of many genes essential for lymphocyte survival and activation and 
is heavily involved in the induction of pro-inflammatory cytokines and chemokines 
(i.e TNF, IL-1, IL-6) (Li and Verma 2002). Constitutive activation of NFκB is 
commonly associated with inflammatory diseases including; RA, IBD and MS (Sun 
and Zhang 2007). Interestingly, NFκB activation is also involved in resolution of 
inflammation and is associated with the expression of anti-inflammatory genes. 
Indeed, inhibiting NFκB during resolution stages was found to prolong the 
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inflammatory response and prevent apoptosis (Hanada and Yoshimura 2002). While 
various stimuli lead to the induction of NFκB, many are largely unknown. Currently 
research in the field supports identifying these stimuli in order to elucidate the 
signalling pathways they induce. Hopefully this will aid the development of small 
molecule drugs for the treatment of inflammatory disease.  
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1.11.2 INTERFERON REGULATORY FACTOR 3 (IRF3) 
Transcription factors such as the family of interferon regulatory factors (IRF) play 
critical roles in anti-viral responses and are responsible for the induction of Type I 
Interferons (IFN) (Paun and Pitha 2007). Type I interferons include IFNα and IFNβ, 
two important anti-viral cytokines involved in preventing the replication and spread 
of invading viral pathogens (Janeway et al. 2008). The expression of IFNα/β genes is 
tightly regulated and the search for an IRF that could activate both, led to the 
discovery of IRF3 and IRF7 (Au et al. 1995, Marie, Durbin and Levy 1998). 
Particularly, the discovery of IRF3 had a major impact on understanding the 
molecular mechanisms in anti-viral innate responses. IRF3 is ubiquitously expressed 
and typically activated by viral double stranded RNA (dsRNA) through TLR3 (Au et 
al. 1995). Recognition of bacterial components such as LPS also activate IRF3 
(Navarro and David 1999, Sakaguchi et al. 2003). TLR3 initiates this activation 
from early endosomes within the cell, while recognition of LPS by TLR4 induces 
endocytosis of TLR4 and TRAM which also traffic to early endosomes to activate 
IRF3 (Kagan et al. 2008). Indeed, in response to these stimuli, IRF3 becomes 
phosphorylated by two non-canonical IκB kinases; TBK-1 and IKKε (Fitzgerald et 
al. 2003). This leads to a conformational change in IRF3, facilitating subsequent 
homodimerization or heterodimerization with IRF7 and translocation to the nucleus 
(Lin et al. 1998). Here dimers associate with co-factor cAMP-response binding 
protein, CREB. Furthermore, entry of IRF3 into the nucleus facilitates binding to a 
consensus DNA sequence known as the interferon-stimulated-response-element 
(ISRE) and the induction of IFN-inducible genes including; IFNα, IFNβ, and 
RANTES (Paun and Pitha 2007, Schafer et al. 1998, Lin et al. 1999).  
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There are well established links emphasising the importance of IRF3 induction and 
anti-viral responses. Indeed, many viruses target IRF3 functionally to inhibit Type I 
IFN genes (Weber, Kochs and Haller 2004). Furthermore, ubiquitous expression of 
IRF3 facilitates induction of IFNβ in the majority of virally infected cells (Sato et al. 
2000). Conversely, a distinct role for the transcription factor in anti-bacterial innate 
immune responses continues to emerge (Honda and Taniguchi 2006).  Indeed, IFNβ 
is required for the induced expression of co-stimulatory molecules CD80 and CD86 
on dendritic cells (Hoebe et al. 2003). In addition, the production of IFNβ is 
essential for induction of endotoxic shock and IRF3 deficient mice are resistant to 
endotoxin shock (Sakaguchi et al. 2003). Furthermore, the absence of IRF3 affects 
the expression profile of other cytokines as even small amounts of paracrine or 
autocrine IFNβ stimulates IRF7 activation and amplifies the response (Sato et al. 
1998). Overwhelmingly, studies point towards the global effects of IRF3 in the 
immune response. Future investigations will prove useful in the development of 
possible immunomodulators and anti-viral drugs. 
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1.12 LIPID RAFTS 
In general terms, lipid rafts are tightly packed, liquid ordered plasma membrane 
microdomains enriched in cholesterol, sphingolmyelin and glycolipids (Dykstra et 
al. 2003). These cellular domains are considered evolutionary structures that play a 
role in a number of cell signalling processes and have received widespread interest 
and investigation regarding their possible biological functions. Indeed, their very 
discovery has turned on its head the historic fluid-mosaic model of the plasma 
membrane described by Singer and Nicolson in 1972 (Singer and Nicolson 1972). 
(Schnitzer et al. 1995) were first to indicate the existence of structurally distinct 
subsets of rafts. This is now a broadly accepted concept and two types of rafts, 
caveolae and flat lipid rafts are considered common features of the plasma 
membrane. Caveolae exist as small invaginations of the plasma membrane 
containing caveolin. This protein is responsible for the flask-shaped structure of 
these lipid rafts and lines the invagination (Anderson 1998).  Furthermore, flat lipid 
rafts do not contain caveolin and therefore are level or ‘flat’ on the membrane and 
hence the name. Typically during subcellullar fractionation of rafts these two subsets 
are isolated together. As such, the term lipid raft is used generically to refer to both.  
 
1.12.1 LIPID RAFT STRUCTURE  
The outer leaflet of lipid rafts is composed of organised interactions between 
sphingolipids and cholesterol. The highly saturated acyl chains of sphingolipids pack 
tightly into microdomains. Any voids between sphingolipids are filled with 
cholesterol which acts as a spacer. Binding of sphingolipids and cholesterol 
promotes formation of a tight liquid ‘ordered’ phase. The remainder of the 
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membrane exists as a liquid ‘disordered’ phase due to the unsaturated, kinked acyl 
chains of the glycerophospholipid bilayer (Dykstra et al. 2003). Proteins are also 
associated with the outer leaflet of lipid rafts, particularly, through 
glycosyphoshatidylinositol, GPI-linkage. In this case, the saturated lipid tail of the 
GPI-anchored protein preferentially partitions into lipid rafts. Examples include, raft 
associated immune receptor, CD14, an Fc receptor, CD16 and adhesion and 
costimulatory molecules CD48 and CD58 (Dykstra et al. 2003). While a schematic 
of lipid raft structure is presented in figure 1.12.1, the biochemistry of lipid rafts is 
extensively reviewed by (Pike 2003, Pike 2003, Brown and London 2000, van der 
Goot and Harder 2001).  
 
 
 
 
 
Figure 1.12.1: Schematic representation of lipid raft microdomains comprising packed 
cholesterol, sphingolipids, GPI-anchored proteins and signalling proteins. Adapted from 
(Karp and van der Geer 2005).  
Cholesterol Sphingolipids 
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1.12.2 LIPID RAFT SIGNALLING 
A central feature of lipid rafts owed to their biochemistry and physical structure is 
their ability to allow lateral segregation of proteins within the plasma membrane, 
e.g. GPI-anchored proteins, as described (Simons and Toomre 2000). Furthermore, 
rafts have been largely implicated in signal transduction, inducing close proximity of 
signalling receptors by specifically recruiting complexes to raft domains upon 
activation (Webb, Hermida-Matsumoto and Resh 2000, Liang et al. 2001).    
 
Indeed, certain integral proteins reside constitutively at the border of lipid rafts and 
translocate to rafts following activation. This is particularly the case for multichain 
immune recognition receptors including, TCR and BCR, T cell and B cell receptors, 
respectively. In resting T cells, TCR is excluded from lipid rafts that actually contain 
several signalling components of the TCR signalling pathway including, LAT 
(linker for activation in T cells). Furthermore, upon engagement of TCR with 
antigen presenting cells, TCR associates with rafts (Montixi et al. 1998, Xavier et al. 
1998). Similarly, BCR is found to be excluded from rafts in resting cells, however, 
following cross linking with Ig-specific antibodies or antigen, BCR and a number of 
components of the BCR signalling pathway are recruited to rafts (Petrie et al. 2000). 
Studies are limited with regard to additional immune receptors and lipid raft 
involvement. Most significantly, (Triantafilou et al. 2004) demonstrate recruitment 
of TLR4 to raft domains following stimulation with LPS. Characteristics that allow 
the translocation of proteins to raft domains are not understood, however evidence 
suggests transmembrane domains are critical (Scheiffele, Roth and Simons 1997, 
Field, Holowka and Baird 1999).  
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The exact biological activities and functions of lipid rafts remains unclear and under 
constant investigation. However, what is clear; is the mounting evidence to suggest a 
role of lipid rafts and their modulation in health and disease. Roles for lipid rafts are 
emerging in cancer (Li et al. 2006), insulin resistance (Fruhbeck, Lopez and Dieguez 
2007) and microbial pathogenesis (van der Goot and Harder 2001). Until recently 
the biological features of the plasma membrane with regard to lipid rafts has been 
under-appreciated. While there is particular challenges to be faced in raft research 
with regard their isolation and exact structure, their mounting biological importance 
warrants further investigation. 
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1.13 POLYUNSATURATED FATTY ACIDS 
It has long been accepted that nutrition has a predominant role in health. However, 
only at the beginning of the 20th century were fatty acids linoleic acid and α-
linolenic acid recognised as essential components of the diet. Furthermore, the anti-
inflammatory potential of elongated and desaturated derivatives of both these 
molecules became evident only thirty years ago (Wan, Haw and Blackburn 1989). 
The presence of more than one double bond denotes that a fatty acid is unsaturated. 
In the absence of double bonds the fatty acid is said to be saturated. Derivatives of 
both linoleic acid and α-linolenic acid have more than one double bond and are 
commonly referred to as polyunsaturated fatty acids, (PUFA). Classical 
nomenclature of PUFA is based on the number of carbon atoms in the fatty acid, the 
number of double bonds and the position of the first double bond (Canalejo et al. 
1996). Derivatives of linoleic acid include n-3 PUFAs, n-3 denoting the first double 
bond is on the third carbon. The n-3 PUFAs, EPA or eicosapentaenoic acid (20:5) 
and DHA or docosahexaenoic acid (22:6) are commonly found in high fat fish and 
marine mammals (Marszalek and Lodish 2005). On the other hand, conjugated 
linoleic acids (CLAs), exist as positional and stereoisomers of conjugated dienoic 
derivatives of linoleic acid, specifically, dienoic octadecadienoate (18:2). The c9,t11 
(cis-9,trans-11) CLA isomer predominantly found in foods derived from ruminants 
such as meat and dairy is used throughout this study (Belury 2002).  
 
Ingestion of PUFA leads to their incorporation into virtually all cells in the body 
(Kew et al. 2004, Fritsche 2006). Recognition of the anti-inflammatory properties of 
PUFA has led to several nutritional studies investigating their health benefits 
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including; protection against the onset and incidence of coronary heart disease 
(Hamer and Steptoe 2006) and diabetes (Suresh and Das 2003). The impact of 
PUFA in immune-mediated disease in humans is also widely reported including; 
rheumatoid arthritis (RA), inflammatory bowel disease (IBD), systemic lupus 
erythematosus (SLE) and asthma (Fritsche 2006, MacLean et al. 2004, Schachter et 
al. 2004and).  
 
Promising results from various animal models investigating the beneficial effects of 
PUFA has encouraged an emerging number of clinical trials and nutritional studies 
in the field. (Leslie et al. 1985) demonstrated very early in the 1980’s that n-3 PUFA 
delayed and reduced incidence of type II collagen induced arthritis in mice. 
Similarly, EPA and DHA have been shown to reduce streptococcal cell wall induced 
arthritis in rats (Volker, FitzGerald and Garg 2000). (Bassaganya-Riera et al. 2004) 
found that feeding animals CLA ameliorated the severity of dextran sodium sulphate 
(DSS) induced colitis by reducing weight loss and lessening disease activity. In 
addition, mounting evidence from in vitro studies report the ability of PUFA to 
dampen production of inflammatory mediators such as cytokines and alter 
infiltration of immune cells such as lymphocytes and macrophages which has 
spurred clinical interest. 
 
Due to the vast number of clinical trials performed results are routinely collated and 
reviewed extensively by many to assess progress in the field (Fritsche 2006, Calder 
2006, Calder 2008). (Fritsche 2006) reviews multiple randomized control trials 
(RCTs) assessing the effects of n-3 PUFA in various disease states. RCTs regarding 
n-3 PUFA efficacy in RA, involve clinical assessment measuring parameters such as 
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pain, swollen joints and disease activity. Here for example several groups report n-3 
PUFA reduced pain over placebo while others also report reduced severity of 
swollen joints in comparison to baseline. Similarly, (MacLean et al. 2004) reviewed 
extensively multiple trials focused on the role of n-3 PUFA in the prevention or 
treatment of diseases including arthritis and asthma. In a qualitative analysis of 
seven studies that assessed the effect of n-3 PUFA on anti-inflammatory drug or 
corticosteriod requirement among arthritis patients, six demonstrated reduced 
requirement for these drugs. Encouraging results have also been reported by others, 
Belluzzi et al. showed that supplementation with 2.7 g of n-3 PUFA preparation 
daily reduced the rate of relapse of patients with Crohns disease in remission 
(Belluzzi et al. 1996). However, following a systematic review of 26 studies 
regarding the beneficial effects of n-3 PUFA in asthma Fritsche and collegues also 
report a clinical outcome comparable to baseline with inconsistency being a major 
issue. 
 
As such, while many trials look promising with regard to the beneficial effects of 
PUFA among immune mediated disease the general consensus in the field is for the 
strengthening of controls. Testing the effects relative to a control substance is of 
paramount importance. Also, many clinical studies cannot account for the 
background diets of their subjects unlike in the majority if not all animal studies 
were the diet is completely controlled therefore including a baseline assessment of 
dietary n-3 and n-6 fatty acid intake should be accounted for. 
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Ultimately researchers endeavour to elucidate the mechanisms through which PUFA 
exert their effects and there are namely three categories under which PUFA exert 
their modulatory actions, none of which are mutually exclusive. They include altered 
membrane composition and function, modified eicosanoid production and 
modifications in gene expression, as reviewed by (Lee and Hwang 2006, Fritsche 
2006, Li et al. 2006, Li et al. 2005, Sampath and Ntambi 2005) and represented in 
figure 1.13.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13.1: Potential mechanisms by which  polyunsaturated fatty acids (PUFA) can 
affect inflammatory cell function. Adapted from (Calder 2004). 
 
 
    Altered PUFA Availability 
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During inflammation, arachidonic acid ((AA), [20:4n-6]) is released from membrane 
phospholipids of immune cells and metabolised to eicosanoids, which have potent 
inflammatory properties. Increased incorporation of PUFA in cell membranes is 
partly at the expense of arachidonic acid and results in decreased production of 
eicosanoid products (Albers et al. 2002, Mantzioris et al. 2000). The cyclooxygenase 
(COX) pathway gives rise to prostaglandins and thromboxanes (TXB) and the 
lipoxygenase (LOX) pathway produces leukotrienes (LTB) (Luster, Alon and von 
Andrian 2005). Alterations in eicosanoid production as a result of altered PUFA 
intake is relatively well understood (Calder 2006, Hwang 2000). Particularly, EPA 
and DHA can act as substrates for COX and LOX enzymes giving rise to less potent 
inflammatory mediators known as resolvins and lipoxins (Serhan 2007). 
 
PUFA can affect gene expression through several mechanisms including, but not 
limited to, changes in calcium levels, membrane composition and indeed eicosanoid 
production (Sampath and Ntambi 2005). Particularly, there is evidence to suggest 
that PUFA exert their effects by altering NFκB activation.  (Weldon et al. 2007) 
demonstrate that EPA and DHA down-regulate NFκBp65 and increase cytosolic 
IκBα levels in a human macrophage cell line. Additionally, we have previously 
demonstrated CLA to suppress NFκBp65 activation in dendritic cells (Loscher et al. 
2005a). Furthermore, cell specific metabolism and fatty-acid regulated transcription 
factors such as peroxisomal proliferator-activated receptors (PPARs) are likely to 
play a role in determining cell responses to altered PUFA compostion (Jump 2002a). 
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PUFA mediated modulation of gene expression and nuclear receptor activation are 
reviewed extensively by (Sampath and Ntambi 2005, Bordoni et al. 2006).  
 
The fatty acid composition of cell membranes influences their fluidity. Increased 
saturated fatty acids and cholesterol increase rigidity, while unsaturated fatty acids 
make membranes more fluid (Brenner 1984, Stubbs and Smith 1984, Bruno, Koeppe 
and Andersen 2007). A change in membrane fluidity modifies membrane function 
and membrane bound receptors, enzymes and proteins. PUFA incorporation was 
reported to enhance the phagocytic activity of murine macrophage (Lokesh and 
Wrann 1984, Calder et al. 1990). In addition, membrane fluidity has been shown to 
upregulate insulin receptors on the membrane and as a result lower insulin resistance 
(Das 2005).  
 
Specifically, much research has focused on PUFA modulation of immune function 
by means of ‘lipid raft’ microdomain alterations (Li et al. 2006, Li et al. 2005, 
Stulnig and Zeyda 2004). Current evidence suggests that translocation of immune 
receptors into lipid rafts regulates immune activation. PUFA treatment has been 
shown to alter lipid raft composition and displace signalling molecules leading to 
impaired signalling (Stulnig et al. 1998). The Src kinase family of protein tyrosine 
kinases and transmembrane adaptor, LAT (linker for activated T cell), play a vital 
role in T cell activation (Bijlmakers 2009). Lck and Fyn two Src kinases and LAT 
are activated following T cell stimulation and are constitutively expressed in rafts. 
(Stulnig et al. 1998and, Stulnig et al. 2001) show that treatment of Jurkat T cells 
with EPA displaced Lck, Fyn and LAT from lipid rafts. This and other studies 
suggest that lipid raft alterations are an underlying inhibitory effect of PUFA on T 
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cell signalling. Furthermore, research in the area of PUFA-mediated raft 
modifications has focused on the immunological synapse. As such, it remains for 
further studies to examine the effects of PUFA on other important immune receptor 
complexes. Taken together the potential mechanisms by which PUFA can affect cell 
function warrants further investigation. 
 
Much research has focused on the modualtory actions of PUFA among immune cell 
types including lymphocytes, dendritic cells and macrophage.Particularly, multiple 
in vitro studies demonstrate the dampening of pro-inflammatory cytokine production 
in PUFA treated cells. CLA has previously been shown to suppress potent 
inflammatory cytokine, IL-12 in murine DC and a caco-2 cell model of human 
intestinal epithelium (Loscher et al. 2005a, Reynolds et al. 2008). Similarly, EPA-
mediated inhibition of IL-12 has been reported in murine dendritic cells (DC) (Wang 
et al. 2007). Of particular interest to the macrophage model employed in the work 
presented here, several studies report suppression of inflammatory cytokines in 
PUFA treated macrophage. (Babcock et al. 2002) demonstrate that EPA can 
suppress TNFα production by murine macrophage. In addition, studies employing 
human macrophage models have reported that EPA and DHA inhibit TNFα, IL-6 
and IL-1β production (Goua et al. 2008, Chu et al. 1999). While cytokine profiling is 
an aspect of macrophage functional status widely investigated in terms of PUFA 
mediated effects, phagocytosis has also been largely examined. Indeed, (Lokesh and 
Wrann 1984, Calder et al. 1990, Mahoney et al. 1977) demonstrated that altering the 
fatty acid composition of murine macrophages in vitro with PUFA made 
macrophage more phagocytically active. However, discrepencies do exist, (Kew et 
al. 2003) report no change in monocyte or neutrophil phagocytic activity in a murine 
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PUFA feeding study. Similarly, EPA and DHA were described as having no effect 
on the ability of alveolar macrophage to phagocytose (D'Ambola et al. 1991).  
 
As a result of several other dispcrepencies in PUFA studies it has become largely 
accepted that inhibition of pro-inflammatory cytokines by PUFA may partly explain 
their overall anti-inflammatory effects. As such, it remains for more complete and 
thorough investigations to be carried out, specifically, looking at the complete 
spectrum representing functional status of macrophage. Indeed, this is infact true for 
all cell types as most recent literature suggests a clear dependency on cell type for 
PUFA exerted effects.  
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AIMS AND OBJECTIVES 
While polyunsaturated fatty acids (PUFA) have been shown to modulate immune 
responses and have therapeutic effects in inflammatory disorders, the specific 
mechanisms of their actions remain unknown. Specifically this work aims to 
elucidate mechanisms regarding the effects of the n-6 derivative, conjugated linoleic 
acid (CLA) and n-3 PUFA, DHA and EPA on macrophages responses to LPS. 
Herein a tailored approach is taken to examine possible mechanisms of PUFA 
mediated modulation in macrophage by looking at their effects on cellular function, 
membrane markers and downstream signalling; as outlined below. 
 
 The effects of PUFA on macrophage function are investigated by 
examining maturation, cytokine and chemokine production, migration 
and phagocytosis. 
 
 The possible mechanisms used by PUFA to elicit their anti-inflammatory 
effects in macrophage are deduced by looking at alterations in NFκB and 
IRF-3 downstream of TLR4.  
 
 The possibility of a PUFA modulated interaction of LPS with the TLR4 
receptor complex is investigated by examining LPS-binding, surface 
marker expression over time, lipid raft localization and endocytosis of the 
receptor complex. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 MATERIALS 
 
TISSUE CULTURE MATERIALS/REAGENTS 
Materials Source 
Tissue culture flasks T-75 cm2 Nunc™ 
6.5mm Transwell® plate (8.0 µm pore) Corning Inc. 
Sterile Petri Dishes Nunc™ 
6, 24, 96-well tissue culture plates Nunc™ 
96 round bottom plates Sarstedt 
Dimethyl sulphoxide (DMSO) Sigma® 
Recombinant IL-2 BD Pharmingen 
GM-CSF R&D Systems® 
Trypan blue (0.4% v/v) Sigma® 
G418 Geneticin Sigma® 
CellTiter 96® Aqueous One Solution Pierce 
RPMI-1640 Invitrogen™ 
Foetal Calf Serum (FCS) Invitrogen™ 
Penicillin Streptomycin Invitrogen™ 
DMEM Invitrogen™ 
LPS (E.Coli serotype R515) Alexis Biochemicals 
Hygrogold Invitrogen™ 
Blasticidin Invitrogen™ 
DPBS Invitrogen™ 
 
TABLE 2.1: All tissue culture materials/reagents and corresponding sources. 
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PROTEIN MANIPULATION  
Materials Source  
Chloroform > 99.99% Sigma® 
Methanol Sigma® 
BCA Protein Assay Pierce 
Triton X-100 Sigma® 
Potassium Chloride (KCl) Sigma® 
Sodium phosphate dibasic (Na2PHO4) Sigma® 
Dithiothreitol (DTT) Sigma® 
Potassium phosphate (KH2PO4) Sigma® 
Glycerol 99.99 % Sigma® 
Trizma Base Sigma® 
Sodium dodecylsulphate (SDS) Sigma® 
Tween® 20  Sigma® 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma® 
Sodium Azide Sigma® 
Ammonium persulphate (APS) Sigma® 
Fuji SuperRX film FujiFilm Ireland Ltd. 
Precision Plus Protein™ Dual Color Standard Bio-Rad 
Propan-2-ol (isopropanol) VWR International Ltd. 
30 % Acrylamide/Bis solution Bio-Rad 
Sodium Orthovanidate Sigma® 
Leupeptin Sigma® 
Aprotinin Sigma® 
Iodoacetamide Sigma® 
Immobilon Western HRP Substrate Millipore 
Re-Blot Plus Solution (10 X) Millipore 
Ponceau S Solution Sigma® 
Phenylmethanesulfonyl fluoride (PMSF) Sigma® 
 
TABLE 2.2: All reagents/materials used for protein purification, quantification, western 
blotting, and lysis buffers. 
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FATTY ACIDS 
Materials Source 
Eicosapentaenoic Acid (EPA) Sigma® 
Docosahexaenoic Acid (DHA) Sigma® 
Conjugated linoleic acid cis-9, trans-11 (CLA) Cayman Chemical 
Lauric Acid (LA) – Dodecanoic acid  Sigma® 
 
TABLE 2.3: All polyunsaturated fatty acids and saturated fat lauric acid with 
corresponding sources. 
 
 
 
 
 
 
ELISAs 
Materials Source 
96-well microtitre plate Nunc™ 
3,3’,5,5’-tetramethyl-benzidine (TMB) Sigma® 
Tween® 20 Sigma® 
Bovine serum albumin (BSA) Sigma® 
DuoSet ELISA kits R&D Systems® 
IL-23 (p19/p40) “Ready-SET-Go!”  ELISA 
kit 
eBioscience 
5x assay diluent and TMB also provided  
 
TABLE 2.4: All ELISA materials/reagents and corresponding sources. 
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 LIPID RAFT ISOLATION  
Materials Source 
Triton® X-100 Sigma® 
MES Sigma® 
Mineral Oil Sigma® 
25G 1″ needle BD Microlance™ 
Dounce Homogeniser set Sigma® 
Sucrose Sigma® 
Iodoacetamide Sigma® 
p-Nitrophenyl phosphate (pNPP) tablets Sigma® 
 
TABLE 2.5: Reagents/materials used for isolation of lipid rafts. 
 
 
 
 
 
WESTERN BLOTTING ANTIBODIES 
Antibody Source 
Anti-CD14 AbCam® 
Anti-Flottilin-1 BD Transduction Laboritories 
Anti-β-actin Sigma® 
Anti-mouse IgG peroxidase Sigma® 
Anti-rabbit IgG peroxidase Sigma® 
 
TABLE 2.6: All antibodies used for western blotting analysis. 
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FLOW CYTOMETRY 
 
 
 
TABLE 2.7: Antibodies used for FACs analysis of cell surface markers; suppliers and 
concentrations used. 
 
 
 
 
FACS MACHINE/PREPARATION 
Materials Source 
FACS Flow BD 
FACSRinse BD 
FACSClean BD 
37% (v/v) paraformaldehyde Sigma® 
 
TABLE 2.8: Materials/reagents used for flow cytometry and FACS preparation. 
 
Antibody Fluorochrome Source Isotype Control 
Concentration/ 
106 cells 
TLR4-MD-2 PE BD RatIgG2a 0.5 µg 
CD14 FITC eBiosciences Rat IgG2a 0.5 µg 
CD204 (SR-A) FITC Acris Antibodies Rat IgG2b 0.5 µg 
CD40 FITC BD Ham IgM 0.5 µg 
CD80 PE BD Ham IgG 0.5 µg 
CD86 FITC BD Rat IgG2a 0.5 µg 
MHCII FITC BD Rat IgG2a 0.5 µg 
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LPS BINDING 
Materials Source 
Free FITC Sigma® 
Biotin-LPS InvivoGen 
Avidin, Alexa Flour® 488 conjugate Invitrogen™ 
Biotin Sigma® 
LPS (E.Coli serotype R515) Alexis Biochemicals 
Biotin-labelling Kit  Pierce 
 
TABLE 2.9:  Materials used for LPS-binding assay by Flow Cytometry. 
 
 
 
DNA MANIPULATION AND LUCIFERASE ASSAYS 
Materials Source 
geneJuice® Transfection Reagent Novagen® 
QIAprep Spin Maxiprep kit QIAgen© 
10 X Passive Lysis buffer Promega 
 
TABLE 2.9: Materials used for manipulation of DNA plasmids in transient transfections. 
 
 
 
CONFOCAL 
Materials Supplier 
Poly-L-lysine 0.1% (w/v) in H2O Sigma® 
Coverslips Sigma® 
Glass slides Sigma® 
 
TABLE 2.10: Materials used for preparation of cell monolayer slides for confocal 
microscopy. 
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BRUSH BORDER MEMBRANE VESICLE PREPARATION 
For brush border membrane vesicle (BBMV) isolation, buffers A and B were pre-
prepared and stored at 4 ºC.  On the day of isolation all materials denoted * and 
protease inhibitor mix, C were freshly prepared and added just before use. 
 
 A 
BUFFER A To Make 500 ml 
10 mM  Immidazole  0.340 g 
5 mM  EDTA  0.730 g 
1 mM  EGTA  0.190 g 
 To Make 25 ml 
0.2 mM DTT*  5 µl of 1M stock 
200 µg/ml Pefabloc* 5 ml of 1 mg/ml stock 
BUFFER A + Protease Inhibitor (PI) Mix  
1 µl PI mix added per ml of BUFFER A 
 
 
 B 
BUFFER B To Make 500 ml 
75 mM KCL 2.790 g 
5 mM MgCl2 0.238 g 
1 mM EGTA 0.190 g 
10 mM Imidazole  0.340 g 
 
To Make 25 ml 
0.2 mM DTT*  5 µl of 1M stock  
BUFFER B + Protease Inhibitor (PI) Mix 
1 µl PI mix added per ml of BUFFER B 
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BRUSH BORDER MEMBRANE VESICLE ANALYSIS 
Materials Source 
CHAPS Sigma® 
Biacore  L1 sensor chip  GE Healthcare 
HEPES Sigma® 
Purified anti-mouse CD66a eBioscience 
Anti-mouse FITC conjugate eBioscience 
Carboxymethyl-dextran (CM-dextran) Sigma® 
Bovine Serum Albumin (BSA) Sigma® 
 
TABLE 2.11: Materials used for BBMV analysis by flow cytomtry and Biacore3000™. 
 
 
C 
Protease Inhibitor (PI) Mix Stock To Make 10  ml 
1 µg/ml pepstatin 1 mg/ml 10 µl 
1  µg/ml α2-macroglobulin (papaine) 1 mg/ml 10 µl 
15  µg/ml benzamidine 2.5 mg/ml 6 µl 
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TABLE 2.12: Buffers used for BBMV analysis on L1 chip using Biacore3000™. 
 
 
Running Buffer pH 7.4 To make 100 ml 
10 mM HEPES 0.238 g 
150 mM NaCl 0.876 g 
3 mM EDTA 0.087 g 
  
Conditioning Buffer To make 100 ml 
20 mM CHAPS 1.229 g 
  
Activation/Regeneration Buffer To make 100 ml 
40 mM CHAPS 2.459 g 
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2.2 METHODS 
 
2.2.1 PREPARATION AND HANDLING OF REAGENTS 
 
2.2.1.1 BUFFERS 
The most commonly used buffers are listed in Table 2.13 and any others are 
described within the text and detailed within the Appendix. EDTA (ethylene 
diamine tetraacetic acid) is used in the isolation of BBMV [see section 2.9.1] to 
chelate magnesium ions thus removing the essential cofactor required by protein 
kinases. Similarly, EGTA (ethylene glycol tetraacetic acid) is also used for BBMV 
isolation however; EGTA has a much higher affinity for calcium than magnesium 
ions. Both EDTA and EGTA are important for making buffers representative of the 
environment within living cells. Various protease inhibitors have been used for 
protein manipulations. Sodium orthovanidate is used to inhibit protein tyrosine 
phosphatases. Iodoacetamide is an alkylating reagent for cysteine and histidine 
residues in proteins and acts as an irreversible enzyme inhibitor. Aprotinin is a 
competitive serine protease inhibitor while leupeptin and phenylmethanesulfonyl 
fluoride (PMSF) inhibit serine and cysteine proteases. The combination of inhibitors 
used ensured that after lysis that proteolysis and protein kinase activities were 
negligible. As a result proteins under investigation were fixed at the levels in vitro at 
the time of cell lysis.  
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TABLE 2.13: Composition of most commonly used buffers. 
  
BUFFER COMPOSTITON 
Membrane Extraction Buffer (MEB) 20 mM MES, 150 Mm NaCl, pH 6.5 
Membrane Fractionation Buffer (MFB) 
20 mM Tris, pH 7.5/10 mM MgCl2/1 mM 
EDTA/250 µM sucrose/200 µM PMSF 
10 X Phosphate Buffered Saline (10 X PBS) 
8 mM Na2HPO4, 1.5 M KH2PO4, 137 Mm 
NaCl, 2.7 mM KCL, pH 7.4 
PBS-Tween (PBS-T) 1 X PBS with 0.05% Tween® 20 
10 X Tris Buffered Saline (10 X TBS) 20 mM Trizma, 150 mM NaCl pH 7.2 – 7.4 
TBS-Tween (TBS-T) 1 X TBS with 0.05% Tween® 20 
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2.2.1.2 FATTY ACIDS 
Fatty acids were dissolved in sterile filtered DMSO to a stock concentration of 100 
mM, and sterile filtered again. Aliquots of 10 µl were kept at -20 °C and were 
thawed once and discarded after use to prevent oxidation. Fatty acids were 
purchased from suppliers and were tested for purity by HPLC prior to purchase. All 
newly purchased fatty acids were further tested for reliability; new stocks of PUFA 
were tested for their known inhibitory effect on pro-inflammatory cytokine 
production. 
 
1. Eicosapentaenoic acid (EPA) 20:5n-3 
 C20H30O2   
 
M.W. 302.45 
 cis-5,8,11,14,17- Eicosapentaenoic acid 
 
2. Docosahexaenoic acid (DHA) 22:6n-3 
 C22H32O2   
 
MW 328.49 
 cis-4,7,10,13,16,19-Docosahexaenoic acid 
 
3. cis-9, trans-11-conjugated linoleic acid (c9, t11-CLA)  
 (c9, t11-CLA)  
 C18H32O2 
 MW 280.5 
 (9Z,11E)-octadeca-9,11-dienoic acid 
 
4. Lauric acid (LA) - SATURATED 
 12:0 CH3(CH2)10COOH 
 MW 200.32 
Dodecanoic acid 
C H 3
O H
O
 87 
2.3 CELL CULTURE 
All tissue culture was carried out using aseptic technique in a class II laminar airflow 
unit (Holten 2010 – ThermoElectron Corporation, OH, USA). Cell cultures were 
maintained in a 37 °C incubator with 5 % CO2 and 95 % humidified air (Model 381- 
Thermo Electron Corporation OH USA). Cells were grown in complete RPMI-1640 
or DMEM medium as indicated. All media compositions and supplements are given 
in the Appendix. FCS was heat inactivated (56 °C for 30 min) to inactivate 
complement and aliquoted for storage at -20 °C. Supplemented medium was stored 
at 4 °C. 
 
 
2.3.1 MURINE MACROPHAGE CELL LINE J774 
The murine macrophage cell line J774A.1 was used extensively in this study and is 
referred to solely as J774 throughout. The J774 cell line was purchased from the 
ECACC. J774A.1 cells were maintained in complete RPMI-1640 [see Appendix] in 
75 cm2 flasks. Cell monolayers were passaged at a confluency of 80 % (every 3 to 4 
days). Cells were detached by gentle tapping and transferred to a 50 ml falcon. Cells 
were spun at 1200 rpm for 5 min and supernatant discarded. Cells were resuspended 
in 10 ml of complete RPMI-1640. Each 75 cm2 flask yielded approx. 20 x 106 cells. 
For subculture, cells were split 1 in 20 into 25 ml complete RPMI-1640 in a fresh 75 
cm2 flask. For experiments cells were counted as described [see section 2.3.4]. 
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2.3.2 HUMAN EMBRYONIC KIDNEY CELL LINES HEK293 
Human embryonic kidney cell line HEK293 and those stably transfected with TLR4, 
(HEK293-TLR4), TLR4, CD14 and MD-2, (HEK293-MTC) were a kind gift from 
Prof. Luke O’Neill, School of Biochemistry, Trinity College Dublin. All HEK293 
cell lines were cultured with appropriately supplemented complete DMEM media 
[see Appendix]. Cells were cultured in 75 cm2
 
flasks as follows; HEK293: complete 
DMEM, HEK293-TLR4: complete DMEM supplemented with 500 µg/ml Geneticin 
(G418) to maintain TLR4 expression and HEK-MTC: complete DMEM 
supplemented with 50 µg/ml Hygrogold and 1 µg/ml Blasticidin to maintain 
expression of TLR4, CD14 and MD-2. Cells were passaged every 3 to 4 days based 
on confluency. For subculture, the media was removed from flasks and cells washed 
twice with 5 ml ice cold sterile PBS (Invitrogen™). Following this cells were 
detached from flasks by incubating for 5 min at 37 °C with 1 ml 1 X Trypsin 
solution (Sigma®). 4 ml of appropriate media was used to resuspend cells and cells 
were spun at 1200 rpm for 5 min. Finally cells were resuspended in media, 
subcultured or counted for experiments. 
 
2.3.3 HUMAN ASTROCYTOMA CELL LINE U373 
In addition, human astrocytoma cell line U373 and those stably expressing CD14 
(U373-CD14) were another kind gift from Prof. Luke O’Neill, School of 
Biochemistry, Trinity College Dublin.  Cells were cultured in 75 cm2
 
flasks as 
follows; U373: complete DMEM, U373:CD14: complete DMEM supplemented 
with 500 µg/ml G418 to maintain CD14  expression. Similarly to section 2.3.2, cells 
were passaged based on confluency, subcultured or counted for experiments.
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2.3.4 CELL ENUMERATION AND VIALBILITY ASSESMENT 
Cell viability was assessed using the trypan blue dye exclusion test. This test is 
based on the ability of viable cells to actively exclude dye as a result of having an 
intact cell membrane.  Dead cells are unable to exclude the dye and appear blue 
when viewed under a microscope.  100 µl of cell suspension was mixed with 150 µl 
PBS and 250 µl of trypan blue solution (0.4% (v/v)).  After ~2 min cells were 
applied to a brightline haemocytometer (Sigma®) and examined under high-power 
magnification (× 40) using an inverted microscope (Olympus CKX31, Olympus 
Corporation, Tokyo, Japan). An average count of four ‘Grids’ was taken [Figure 
2.1]. 
 
A viable cell count was determined using the following formula:  
 
    Cell/ml = N x 5 x 104 
 
Where, N = average cell number counted, 5 = dilution factor, and 104 = constant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.1 Diagrammatic Representation of Haemocytometer used to count cells 
Shaded area  
is one ‘Grid’ 
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2.3.5 PREPARATION OF CELL STOCKS 
Cell stocks were prepared from cultures that were approx. 70 – 80 % confluent. 
Cells were removed from culture as appropriate and resuspended in 1 ml 
cryoprotectant (10 % (v/v) dimethylsulphoxide (DMSO), 40 % (v/v) FCS and 50% 
RPMI) and transferred to labelled and dated cryovials (Nalgene®, Cryoware). 
Cryovials were placed in a Nalgene® Mr. Frosty freezing container. The Mr. Frosty 
container was filled with isopropanol and placed in a – 80 °C freezer. Mr. Frosty 
freezing container provided slow preservation of cells at a rate of 1 °C/min. After 2 h 
vials were transferred to liquid nitrogen for long term storage. 
 
2.3.6 REVIVAL OF FROZEN STOCKS 
Cryovials were carefully removed from liquid nitrogen tank and quickly thawed in a 
37 °C water bath. Thawed cells were transferred to 10 ml RPMI on ice and carefully 
resuspended. Cells were spun at 1200 rpm for 5 min to remove excess DMSO. 
Following this supernatant was discarded and cells resuspended in 10 ml of room 
temp RPMI. Cells were spun again and a third wash carried out using 37 °C RPMI. 
After the final wash cells were resuspended in 1 ml of the appropriate medium and 
transferred to a 75 cm2 flask with appropriately supplemented media [see 
Appendix]. 
 
 
 
 91 
2.3.7 ADDITION OF FATTY ACIDS  
The vehicle control DMSO, and the fatty acids, CLA, and LA, were added to cells at 
a concentration of 50 µM.  The n-3 PUFA, EPA and DHA were added at 25µM. In 
all experiments cell lines were cultured for 7 days in DMSO, CLA, EPA, DHA or 
LA at the indicated concentration.   
2.3.8 STIMULATION WITH LPS 
Cells were activated with 100 ng/ml LPS E.Coli serotype R515 (Alexis 
Biochemicals) and incubated for 24 h, unless otherwise stated before being used in 
the relevant assays. 
 
2.3.9 CYTOTOXICITY ASSAY FOR PUFA DOSE RESPONSE 
The CellTiter 96® AQueous One Solution (Promega) is a colorimetric method for 
determining the number of viable cells in a sample.  It contains an MTS tetrazolium 
compound (Owen’s reagent) which is bioreduced by viable cells into a soluble 
coloured formazan product.  The quantity of formazan product is measured at an 
absorbance reading of 490 nm and is directly proportional to the number of living 
cells in the culture medium. J774 macrophage were cultured for 7 days as described 
[see section 2.3.1]. Fatty acids were added at concentrations of 25, 50, or 100 µM on 
day 1 of the cell culture.  On day 7 cells were counted and plated in a 96-well plate 
with 100 µl per well at 1 x 106 cell/ml left unstimulated for 24 h. After the 24 h, 20 
µl of the CellTiter 96® AQueous One solution was added to each well.  Plates were 
incubated for 2 h at 37 ºC in 5 % CO2 and absorbance read at 490 nm.  The cell 
viability of each sample was calculated by treating the absorbance of the vehicle 
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control, DMSO as 100 % and comparing remaining samples to this and expressing 
results as percentage viability. 
2.4 FLOW CYTOMETRY 
2.4.1 CELL SURFACE MARKER STAINING  
J774 macrophage were cultured with fatty acids for 7 days as described [see section 
2.3.7]. Cells were then plated at a concentration of 1 x 106 cell/ml in a 6-well plate 
(2 ml/well). To observe maturation of macrophage, cells were left unstimulated and 
stimulated with LPS (100 ng/ml) for 24 h. For kinetic analysis cells were stimulated 
with LPS for 0, 2, 4, 6, 12 and 24 h. Following LPS treatment cells were scraped 
using a pasteur pipette and collected in falcon tubes.  An equal volume of FCS was 
added for 15 min to prevent non-specific binding.  Tubes were spun at 1200 rpm for 
5 min and cells resuspended in FACS buffer see Table 2.13. 200 µl of cells were 
added to a 96-well round bottom plate to give approximately 400,000 cell/well.  One 
well per treatment group (i.e., each PUFA treatment +/- LPS) was allocated for each 
antibody group. Additionally, one well was plated for every corresponding isotype 
control group.   
Plates were spun at 2000 rpm for 10 min and supernatant carefully removed from the 
wells.  100 µl of the correct antibody or isotype mixture was added to the 
appropriate wells.  Plates were incubated in the dark at 4 oC for 30 min.  Following 
incubation, plates were spun at 2000 rpm for 10 min at 4ºC.  Cells were washed by 
resuspending in 200 µl FACS buffer twice. Cells were then fixed in 200 µl 4% (v/v) 
formaldehyde/PBS before being transferred to labelled FACS tubes.  Samples were 
acquired immediately or left overnight in the dark at 4 ºC.  30,000 events were  
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acquired per sample using a 4-colour FACSCalibur (fluorescence activated cell 
sorter) Becton Dickinson (BD). Data was analysed using CellQuest™ software to 
generate histograms and fluorescence intensity values of surface marker staining. 
 
 
TABLE 2.13: Antibody groups generally used for macrophage flow cytometry. 
. 
2.4.2 PHAGOCYTOSIS 
J774 macrophage were cultured with fatty acids for 7 days as described [see section 
2.3.7]. 5 x 105 cells were plated onto 6 well plates in a total volume of 2 ml/well and 
left to rest overnight at 37 ºC. On the next day, to investigate phagocytosis 2.5 µl of 
flourescently labelled latex beads were added at a concentration of 1 x 106 beads/µl 
for a period of 0, 2, 4, 6, 12 and 24 h. Following this media was removed and each 
well washed twice with ice cold PBS. Cells were then scraped and transferred to 15 
ml falcons. Cells were spun at 1200 rpm for 5 min and resuspended in 200 µl 4% 
(v/v) paraformaldehyde/PBS. Phagocytosis of latex beads was assessed by flow 
cytometry on BD FACSCalibur™. For the analysis of phagocytosis after stimulation 
cells were treated with 100 ng/ml LPS for 24 h prior to the addition of latex beads. 
Note: latex beads were sourced from Sigma® and were 1 µm in diameter.  
       
Fluorochrome 
Antibody 
Group 1 
Antibody 
Group 2 
Antibody 
Group 3 
Antibody 
Group 4 
  
FITC CD14 CD204 CD40 CD86   
PE  TLR4 CD80    
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2.4.3 CHEMOTAXIS ASSAY 
J774 macrophage were cultured with fatty acids for 7 days as described in [see 
section 2.3.7].  Cells were then plated at a concentration of 1 x 106 cell/ml in a 6-
well plate (3 ml/well) and stimulated with LPS (100 ng/ml) for 24 h.  Following 
incubation, cells were removed from wells using a transfer pipette and counted. 
Transwell® plates were used in accordance with the manufacturer’s instructions; 3 x 
105 cells were added to the insert well in 100 µl of media, and 600 µl of media 
supplemented with or without chemoattractants GM-CSF (10 ng/ml) and IL-2 (10 
BRMP/ml; where 1 BRMP = 40 pg/ml) were added to the bottom chamber.  Plates 
were incubated at 37 ºC for 5 h.  Cells that had migrated to the bottom chamber were 
collected in eppendorf tubes, spun and resuspended in 4% (v/v) formaldehyde/PBS 
before being transferred to FACS tubes.  Migrated cells were counted for 60 seconds 
on a BD FACSCalibur™. 
 
 
 
 
 
 
Figure 2.2: Diagrammatic representation of Chemotaxis Assay Transwell™. Schematic 
taken from Transwell® Permeable Supports Selection and Use Guide, Corning. 
3x105 cells  
GM-CSF 10 ng/ml/IL-2 1BRMP/ml 
Transwell® Insert 
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2.4.4 OPTIMISATION OF LPS BINDING IN HEK293 CELLS 
HEK293 and HEK-MTC cells were cultured in the absence of fatty acids as 
described [see section 2.3.2]. On reaching confluency cell suspensions of 2 x 107 
cells/ml were prepared. 50 µl of cells (1 x 106) were incubated with 50 µl of 5, 10 
or 50 µg/ml LPS-Biotin (Invitrogen™), house LPS-Biotin (using LPS (E.Coli 
serotype R515), Alexis Biochemicals and Biotin-labelling kit, Pierce), free Biotin 
(Sigma®), or InlB-Biotin. Note: Internalin-B, (InlB) is found on the extracellular 
membrane of Lysteria. monocytogenes and known to be a TLR2 ligand. InlB-
Biotin was provided by Dr. Elizabeth Tully of the Applied Biochemistry Group, 
Dublin City University.  Incubation with the various biotinylated molecules was 
carried out overnight at 4 °C. On the following day cells were washed 3 times in 
ice cold PBS and incubated with avidin Alexa Flour® 488 conjugate 
(Invitrogen™) for 15 min on ice. Cells were then washed as before and 
resuspended in 1% (v/v) paraformaldehyde/PBS. Binding of LPS to cells was 
measured on a BD FACS Calibur™.  
2.4.5 LPS BIINDING IN PUFA TREATED HEK293 CELLS 
HEK-MTC cells were cultured with fatty acids for 7 days as described [see 
section 2.3.7]. Based on the optimisation of LPS binding in section 2.4.4, 5 
µg/ml LPS-Biotin was used in this experiment. Internal controls similar to those 
performed in section 2.4.4 were included.  
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2.5 ENZYME LINKED IMMUNOSORBANT ASSAY 
(ELISA) 
The concentration of cytokines IL-1β, IL-6, IL-10, IL-12p40, IL-12p70, IL-17, 
TNF-α and chemokines MIP-1α, MIP-2 and MCP-1 in cell supernatants was 
determined using ELISA Duoset kits from R&D Systems in accordance with the 
manufacturers’ instructions.  A diagrammatic representation of the principles of a 
sandwich ELISA are shown in Figure 2.3 
 
 
 
 
 
 
 
 
   
 
 
 
 
 FIGURE 2.3: Schematic representation of sandwhich ELISA. Schematic taken 
from ELISA Kit Technology Principals on www.epitomics.com. 
 
 
 97 
2.5.1 IL-10, IL-12p40, TNF-α, MCP-1, MIP-1α and MIP-2 ELISA 
96-well Nunc™ microtitre plates were coated with 100 µl of the relevant capture 
antibody diluted to working concentration in PBS see Table 2.13 and incubated 
overnight at room temperature.  After washing plates x 3 with wash buffer 
(PBS/0.05% Tween® 20), wells were blocked with 300 µl of reagent diluent (1% 
w/v BSA/PBS) for at least 1 h at room temperature.  After repeating the washing 
step, 50 µl of reagent diluent and 50 µl of  supernatant or serially diluted 
standards (top standard serially diluted in reagent diluent – see Table 2.13) were 
added to wells in duplicate. Plates were incubated overnight at 4 oC. The 
following day plates were washed x 3 with wash buffer. 100 µl of the relevant 
biotinylated detection antibody, diluted in reagent diluent (1:180 dilution), was 
added to each well and plates were incubated for 2 h at room temperature. Plates 
were washed x 3 with wash buffer and 100 µl of streptavidin-HRP (1:200 
dilution in reagent diluent) was added to each well. Plates were incubated for 20 
min in the dark at room temperature.  Finally, wells were washed x 3 with wash 
buffer and 100µl of TMB was added to each well. Plates were incubated in the 
dark until colour developed. The reaction was stopped by adding 50 µl 2N H2SO4 
per well. Optical densities were read immediately at 450 nm on VERSA Amax 
microplate reader (Molecular devices, CA, USA). Cytokine/chemokine 
concentrations in supernatants were determined from standard curves. 
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2.5.2 IL-1β  
The method above was followed with two deviations: 
Blocking buffer used was 1%BSA/PBS + 0.05% NaN3 and the reagent diluent 
was 0.1% BSA/TBS + 0.05% Tween. 
2.5.3 IL-6 
Samples were diluted 1:10 in reagent diluent and 100µl of diluted samples and 
undiluted standards were added to plates in duplicate.  Concentrations of samples 
were multiplied by the dilution factor once calculated from the standard curve. 
 
2.5.4 IL-23p19 
The IL-23 “Ready-SET-Go!” ELISA kit was purchased from eBioscience and 
IL-23 concentrations determined in supernatants according with the 
manufacturers’ instructions.  96-well plates were coated with 100 µl of IL-23p19 
capture antibody diluted 1:250 in PBS and plates were incubated overnight at 4 
ºC.  After washing x 4 with wash buffer (PBS/0.05 % Tween® 20), wells were 
blocked with 300 µl of assay diluent for 1 h at room temperature.  Assay diluent 
was provided in the kit at a 5 x stock and diluted in distilled water before use.  
After repeating the wash step, 50 µl of assay diluent, and 50 µl of supernatant or 
serially diluted standards (top standard serially diluted in assay diluent – see 
Table 2.13) were added to wells in duplicate, and plates were incubated 
overnight at 4 oC. The following day plates were washed x 4 with wash buffer.  
100 µl of the biotinylated p40 detection antibody, diluted in assay diluent (1:500 
dilution), was added to each well and plates were incubated for 1 h at room 
temperature.  Plates were washed x 4 with wash buffer and 100µl of streptavidin-
HRP (1:250 dilution in assay diluent) was added to each well. Plates were 
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incubated for 20 min at room temperature.  Finally, wells were washed x 4 with 
wash buffer.  100 µl of TMB (eBioscience – supplied with kit) was added to each 
well and plates incubated in the dark. The reaction was stopped by adding 50 µl 
2N H2SO4 per well once the colour had developed.  Optical densities were read 
immediately at 450 nm on VERSA Amax microplate reader (Molecular devices, 
CA, USA). Cytokine concentrations in supernatants were determined from 
standard curve. 
 
Cytokine 
Capture Antibody 
(µg/ml) 
Top Standard 
(pg/ml) 
Detection 
Antibody (ng/ml) 
IL-1β 4.0 1000 400 
IL-6 2.0 1000 200 
IL-10 4.0 2000 500 
IL-12p40 4.0 2000 400 
IL-23p19 
(p19)  
2 
1000 
(p40) 
200 
TNF-α 0.8 2000 75 
Chemokine 
Capture Antibody 
(µg/ml) 
Top Standard 
(pg/ml) 
Detection 
Antibody (ng/ml) 
MCP 0.2 250 50 
MIP-1α 0.4 1000 100 
MIP-2 2.0 500 75 
 
TABLE 2.13: Concentration of standards, capture and detection antibodies used in 
sandwich ELISA assays. 
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2.6 CELL MEMBRANE ANAYLSIS 
2.6.1 MEMBRANE FRACTIONATION OF J774 MACROPHAGE 
J774 macrophage were cultured with fatty acids for 7 days as described [see 
section 2.3.7].  Cells were seeded at 2 x 105 cell/ml in a 6-well plate (3 ml/well) 
and left to rest overnight. Cells were stimulated with LPS (100 ng/ml) for 0, 2, 4 
and 6 h. Following stimulation cells were scraped into 300 µl membrane 
fractionation buffer (MFB) see Table 2.13. Protease inhibitors were added just 
before use as follows: 1 µg/ml aprotinin, 1 µg/ml leupeptin, 100 µM sodium 
orthovanidate and 0.5 M PMSF. Cells were lysed with 50 strokes of a dounce 
homogenizer (Sigma®) and spun in thick wall polycarbonate Beckkman tubes at 
425,000 g for 1 h at 4 °C. The resulting supernatant (i.e., the cytosolic fraction) 
was removed to a fresh tube, and the pellet, (i.e. the membrane fraction) was 
resuspended in 60 µl of 5 X sample buffer [see Appendix]. Protein within the 
cytosolic fraction was concentrated by MeOH/Chloroform precipitation [see 
below section 2.6.2] and resuspended in 60 µl 5 X sample buffer. Equal volumes 
of samples were run on 10 % (v/v) SDS-PAGE gels [see Appendix]. 
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2.6.2 METHANOL (MeOH)/CHLOROFORM PROTEIN EXTRACTION 
The entire protein extraction protocol was performed on ice. 200 µl of the 
relevant protein sample was placed in a sterile 2 ml centrifuge tube. 800 µl of ice 
cold MeOH was added. The sample was vortexed and pulsed for 30 sec in a 
benchtop centrifuge. 200 µl of ice cold chloroform was added in a fume hood, 
vortexed and pulsed for 30 sec. 600 µl of ice cold H20 was added and the sample 
was vortexed and spun at 6000 g for 5 min. At this point the upper phase was 
removed as protein was concentrated at the interphase. 600 µl of ice cold MeOH 
was added and the sample was vortexed and spun at 14000 g for 10 min. The 
supernatant was aspirated off quantitatively and the protein pellet dried under 
nitrogen gas for 20 min. Finally, the protein pellet was resuspended in 60 µl of 5 
X sample loading buffer [see Appendix]. Samples were vortexed vigorously to 
ensure full resuspension of the protein pellet.  
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2.6.3 LIPID RAFT ISOLATION AND OPTIMISATION  
2.6.3.1 MEMBRANE PREPARATION 
J744 macrophage were cultured in fatty acids for 7 days as described [see section 
2.3.7]. 100 x 106 cells are required for sufficient protein levels for lipid raft 
analysis. As such, with an 80 % 75 cm2 flask yielding approx. 20 x 106 cells, 5 x 
75 cm2 flasks were cultured per sample. Cell monolayers were detached by 
gentle tapping and spun out of culture at 1200 rpm for 5 min. Cell pellets were 
washed three times in ice cold sterile PBS (Invitrogen™). Following this cell 
pellets were resuspended in 2 ml membrane extraction buffer (MEB) [see Table 
2.13] containing 5 mM iodoacetamide, 1 mM PMSF, 1ug/ml aprotinin and 1 
ug/ml leupeptin and left on ice for 30 min. For mechanical cell disruption lysates 
were freeze thawed in liquid nitrogen three times. This was followed by 40 
strokes with a dounce homogeniser and passage through a 25G 1" syringe (BD 
Microlance™) ten times. Lysates were spun at 100,000 g for 1 h at 4 ºC. The 
cytolsolic fraction was washed away and the membrane pellet resuspended in 
500 µl MEB containing 0.5 % (v/v) Triton X-100 and stored at – 80 oC before 
application to sucrose density gradient [see section 2.6.3.2]. Note: For the 
optimisation of lipid raft isolation different concentrations of Triton X-100 were 
employed and are indicated in the text.  In addition, for the isolation of lipid raft 
in stimulated cells, J774 were treated with 100 ng/ml LPS for 30 min prior to 
membrane preparation. 
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2.6.3.2 SUCROSE DENSITY GRADIENT 
For the isolation of lipid rafts membrane preparations [see section 2.3.6.1] were 
mixed with an equal volume (500 µl) 90 % (w/v) sucrose/MEB (with protease 
inhibitors as described section 2.3.6.1). This 1 ml sample was transferred to the 
bottom of a beckman polycarbonate tube and overlaid with 5.5 ml 30% (w/v) 
sucrose/MEB (with protease inhibitors) followed by 4.5 ml 5% (w/v) 
sucrose/MEB (with protease inhibitors). Tubes were filled to the top with mineral 
oil (Sigma®) and spun for 18 h at 175,000 g in a TH-641 swinging bucket rotor 
in a Sorvall WX ultracentrifuge. After spinning 1 ml fractions were carefully 
collected form the top of the gradient (designated fraction 1 – 11) and stored at – 
80 oC for further analysis. 
2.6.3.3 ALKALINE PHOSPHATASE ACTIVITY 
The alkaline phosphatase activity of lipid raft fractions was determined using 
SIGMAFAST™ p-nitrophenyl phosphate (pNPP) tablets. pNPP was made 
according to manufacturers’ instructions. 20 µl of each lipid raft fraction was 
added to a 96 well plate. Following this 200 µl of pNPP substrate was added to 
each well and the plate incubated in the dark for 30 min. Following incubation 
the plate was read at 405 nm on a VERSA Amax microplate reader.  
 104 
2.6.3.4 ANALYSIS OF LIPID RAFT FRACTIONS 
The flottilin-1, CD14 and β-actin content of lipid raft fractions was analysed by 
western blot [see section 2.7.3]. Protein from each fraction was precipitated as 
described [see section 2.6.2]. For qualitative comparison of protein, pellets form 
precipitations were resuspended in 60 µl 5 X sample loading buffer and equal 
volumes run on 10 % (v/v) SDS-PAGE gels [see Appendix]. However, for 
quantitative comparison of PUFA lipid raft fractions, protein pellets were 
resuspended in 60 µl MEB (with protein inhibitors) and protein levels normalised 
based on NanoDrop3300 quantification. Samples were normalised to 8 µg in a 
total volume of 50 µl with appropriate vol of 5 X loading buffer and run on a 10 
% (v/v) SDS-PAGE gel. Antibodies used in western analysis are listed in Table 
2.6. 
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2.7 PROTEIN ANALYSIS 
2.7.1 PREPARATION OF SAMPLES FOR GEL ELECTROPHORESIS 
All protein samples were prepared in 5 X sample buffer as described. Before 
loading on gels samples were boiled at 95 oC for 5 min to denature proteins. 
 
2.7.2 DENATURING POLYACRYLAMIDE GEL ELECTROPHORESIS 
(SDS-PAGE) 
Proteins were separated by SDS denaturing polyacrylamide gel electrophoresis 
(SDS- PAGE).  Acrylamide gels (10 %)  [see Appendix] were cast between two 
glass plates and affixed to the electrophoresis unit using spring clamps. Electrode 
running buffer [see Appendix] was added to the upper and lower reservoirs.  
12µl of prepared samples were loaded into the wells and run at 30 mA per gel for 
approximately 45 minutes.  Pre-stained protein molecular weight markers (Bio-
Rad laboratories) ranging from 10 – 250 kDa were added to the first lane in each 
gel. 
 
2.7.3 WESTERN BLOTTING  
Proteins were quantitatively transferred to nitrocellulose membranes using the 
iBlot® Dry Blotting System (Invitrogen™). The iBlot® efficiently and reliably 
blots proteins from polyacrylamide gels in 7 min without the need for additional 
buffers or an external power supply in a self-contained unit. Following transfer, 
the nitrocellulose membrane was removed and processed for immunoblotting. 
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2.7.4 IMMUNODETECTION AND DEVELOPMENT 
Following transfer, non-specific sites on the membrane were blocked with 
freshly prepared blocking buffer,  5 % (w/v) dried skimmed milk/TBS-T [see 
Table 2.13] for 1 h on a slow rocker at room temperature. Membranes were then 
washed x 3 with TBS-T (wash buffer) and incubated with appropriate primary 
antibodies. Incubation details including reagent diluent and the concentration of 
antibodies used are listed in Table 2.14.  Membranes were gently agitated with 
the primary antibodies overnight at 4 ºC.  Following overnight incubation, 
membranes were washed eight times for 2 min in wash buffer. Membranes were 
then incubated with the relevant secondary antibodies (horseradish peroxidase 
(HRP) conjugated secondary antibody) [see Table 2.14] and incubated with 
gentle agitation at room temperature for 1 h. Following incubation with 
secondary antibody, membranes were washed eight times for 2 min with washing 
buffer.  
HRP-labelled antibody complexes were visualised using the enhanced 
chemiluminescence (ECL) method.  Membranes were incubated for 5 minutes in 
3 ml of Immobilon Western HRP Substrate (Millipore).  Excess substrate was 
decanted and the membrane placed between acetate sheets and immediately 
exposed to FujiFilm SuperRX film in a dark room under red light.  The film was 
developed using a film Hyperprocessor (Amersham Pharmacia Biotech).  
Exposure times varied depending on the concentration of protein used and the 
intensity of signals obtained. In general exposure times varied between 15 sec to 
5 min. The density of resultant bands was calculated using the densitometry 
program on the Syngene gel analysis and documentation system (Syngene NJ 
USA). 
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2.7.5 STRIPPING AND RE-PROBING MEMBRANES 
To reprobe membranes, antibody complexes were removed by incubating 
membranes in 10 ml 1 X Re-Blot Plus Solution (made according to 
manufacturers’ instructions) for 15 min with gentle agitation. Following this 
membranes were washed in 5 ml of blocking buffer twice for 5 min to remove 
excess stripping solution. At this point membranes were either re-probed with 
antibodies or stored in TBS-T at 4 °C.   
 
1° ANTIBODY AND DILUTION 2° ANTIBODY AND DILUTION 
CD14 1:5000 
Anti-rabbit IgG 
peroxidase 
1:2000 
FL-1 1:250 
Anti-mouse IgG 
peroxidase 
1:2000 
β-actin 1:10000 
Anti-mouse IgG 
peroxidase 
1:20000 
TABLE 2.14: Dilution of primary and secondary antibodies for western blotting. Both 
1° and 2° antibody dilutions were made in 5 % (w/v) dry skimmed milk/TBS-T. All 1° 
antibody incubations were performed at 4 °C overnight and all 2° antibody incubations 
were performed for 1 h at room temperature. 
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2.8 DNA MANIPULATION 
2.8.1 DNA TRANSFORMATION INTO BACTERIA 
Chemically competent DH5α E. coli cells and ligation DNA were generated by 
Kathy Banahan (Biochemistry, Trinity College Dublin). For transformation cells 
were thawed on ice after which, ligated DNA (5-10 µl) was added, mixed gently 
and incubated for 5 min on ice. The cells were heat shocked in a water bath at 42 
ºC for 2 min and returned to ice for a further 2 min. As ligation DNA contained 
an ampicillin cassette for transformation, cells were plated onto selective LB agar 
plates containing 100 µg/ml ampicillin and grown overnight at 37 ºC.   
 
2.8.2 PURIFICATION OF PLASMID DNA FROM BACTERIA 
To prepare milligram quantities of plasmid DNA an individual quantity of 
plasmid transformed bacteria was inoculated into 4 ml LB broth for 6 h. This 
starter culture was then used to inoculate a 500 ml LB broth supplemented with 
100 µg/ml ampicillin and grown overnight at 37 °C in a shaking incubator. 
Bacterial cells were harvested by centrifugation at 300 rpm for 15 min at 4 °C. 
Milligram quantities of plasmid DNA were purified using a QIAprep Spin 
Maxiprep kit according to manufacturers’ instructions. The DNA was quantified 
using a NanoDrop3300. Stocks were stored at 4 ºC and used for transient 
transfection of HEK293 and U373 cell lines. A 500 ml culture typically yielded 1 
– 3 mg/ml of plasmid DNA. 
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2.8.3 LUCIFERASE ASSAY BY TRANSIENT TRANSFECTION OF 
HEK293/U373 CELLS 
GeneJuice® (Novagene) transfection reagent is a liposomal based transfection 
reagent. The ISRE luciferase plasmid, NFκB luciferase plasmid, Renilla 
luciferase plasmid and empty pcDNA3.1 vector (Invitrogen™) along with 
luciferase assay reagents were kind gifts from Prof. Luke O’Neill, School of 
Biochemistry, Trinity College Dublin.  All transfections were performed in 24-
well tissue culture plates with a total volume of 500 µl/well. Cells were seeded as 
follows; HEK293 and HEK-TLR4 cells at 2 x 105 cell/ml, HEK-MTC cells at 4 x 
105 cell/ml and both U373 and U373-CD14 cells at 8 x 104 cell/ml. Cells were 
incubated overnight and transfected the following morning using geneJuice® 
transfection reagent according to the manufacturers’ instructions. For 
ISRE/NFκB luciferase assays, 75 ng of ISRE/NFκB luciferase plasmid, 30 ng of 
Renilla luciferase, and 115 ng empty pcDNA3.1 vector made up to a total of 220 
ng of DNA were transfected into each well of a 24-well plate.  For both ISRE and 
NFκB luciferase assays cells were left to rest for 24 h after transfection before 
stimulating with 100 ng/ml LPS for 6 h. Following stimulation media was 
aspirated from each well and cells were lysed in 100 µl of 1 X passive lysis 
buffer (Promega, Southampton, UK) for 15 min. Firefly luciferase activity was 
assayed by the addition of 40 µl of luciferase assay mix (20 mM Tricine, 1.07 
mM (MgCO3)4Mg(OH)2·5H2O, 2.67 MgSO4, 0.1 M EDTA, 33.3 mM DTT, 270 
mM coenzyme A, 470 mM luciferin, 530 mM ATP) to 20 µl of the lysed sample. 
In addition, Renilla luciferase was read by the addition of 40 µl of a 1:1000 
dilution of Coelentrazine (Argus Fine Chemicals) in PBS to 20 µl of lysed 
sample. Luminescence was read using a Reporter microplate luminometer 
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(Turner Designs). The Renilla luciferase plasmid was used to normalize for 
transfection efficiency in all experiments. 
2.9 Confocal Microscopy 
HEK-MTC cells were cultured for 7 days in fatty acids as described in section 
2.3.7. Autoclaved glass coverslips were placed in 6 well cell culture grade plates. 
500 µl of poly-L-lysine 0.1% (w/v) in H2O was used to coat slides for 5 min in 
preparation for cell culture. Poly-L-lysine was removed and slides left to dry for 
30 min. Cells were harvested from culture and counted. Cells were plated at 1.25 
x 105 cell/ml (3 ml/well) and left to rest overnight. For the investigation of TLR4 
and EEA1 localisation, TLR4-YFP construct was a kind gift from Douglas 
Gollenbock in the University of Massachusetts Medical School, Worcester, 
Massachusetts, USA and the EEA1-CFP construct was a gift from Terje 
Espeviks at the Norwegian University of Science and Technology, Institute of 
Cancer Research and Molecular Medicine, Trondheim, Norway. Yellow 
fluorescent protein (YFP) and cyan fluorescent protein (CFP) are spectral 
variants of green fluorescent protein (GFP) and make possible the visualisation 
of two or more different proteins. Cells were transfected with TLR4-YFP (0.75 
µg) and EEA1-CFP (0.75 µg) using geneJuice® as described in section 2.8.3. 
Cells were left to rest for 24 h before removing media and supplying 3 ml fresh 
media to cells. On the 4th day cells were stimulated for 7.5 and 15 min with 250 
ng/ml LPS. Following stimulation media was removed and cells washed on ice 
three time with ice cold PBS. Cells were fixed to glass coverslips by incubating 
with 2% (v/v) paraformaldehyde/PBS, pH 7.4 for 15 min at room temperature. 
Slides were washed a further three times in PBS and mounted onto glass slides 
using mounting medium (90% glycerol, 10% PBS) and sealed using varnish. Cell 
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preparations were analysed using an Olympus FluoView™ FV1000 and FV1000 
Viewer Software version 1.7. 
2.10 BRUSH BORDER MEMBRANE VESICLES 
2.10.1 BBMV ISOLATION AND CHARACTERISATION 
Brush border membrane vesicles, (BBMV) were prepared using an established 
method (Ferrary et al. 1999). Briefly, BBMVs were isolated from freshly 
harvested mucosa from the whole small intestine of a BALB/C mouse. The 
mucosa was diluted in 10 ml per mg mucosal tissue weight with Buffer A [see 
section 2.1] and stirred for 1 h at 4 °C. Mechanical cellular disruption was 
performed by 10 strokes in a glass dounce homogeniser (Sigma®). Following this 
the cellular suspension was spun at 1000 g for 10 min at 4 °C. Supernatant was 
discarded and the pellet washed again with 10 ml Buffer A and centrifuged at the 
same setting. Three washes were performed in total. After the final wash, 
BBMVs were isolated using a sucrose density gradient. The pellet was 
resuspended in 10 ml Buffer B [see section 2.1] and mixed with a 40 % (w/v) 
sucrose solution in Buffer B. This sample was overlaid onto an equal volume of a 
65 % (w/v) sucrose solution in Buffer B. The sample was spun at 15000 g for 30 
min at 4 °C. Purified BBMVs were isolated from the 40%:65% interphase of the 
sucrose gradient. BBMVs were characterised by flow cytometry on a BD 
FACSAria™ staining with a monoclonal antibody recognising CD66a, also 
known as ‘CEACAM1’ (carcinoembronic antigen-related cell adhesion molecule 
1). CD66a is constitutively expressed on brush border membranes (Sundberg and 
Obrink 2002, Hansson, Blikstad and Obrink 1989). 
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2.10.2 STUDIES – BBMV IMMOBILISATION 
Analyses were carried out on a Biacore 3000™ instrument using the L1 sensor 
chip. The L1 sensor chip has a surface matrix of carboxylated dextran to which 
lipophilic alkyl residues are covalently attached (Biacore 2003). This facilitates 
stable retention of lipid membranes on the surface at low flow rates. The running 
buffer for all Biacore experiments was detergent free HBS (HBS-DF), pH 7.4 
containing 10 mM HEPES, 150 mM NaCl and 3 mM EDTA [see section 2.1]. 
Running buffer was freshly prepared, filtered (pore size of 0.22 µm) and 
degassed using a vacuum filtration apparatus (Millipore sintered glass filtration 
unit) before use. The L1 sensor chip was activated by injecting activation buffer 
(40 mM CHAPS) over the sensor chip for 3 min at a flowrate of 5 µl/min. A 1 in 
5 or 1 in 10 dilution of purified BBMVs was injected over the activated chip 
surface for 3-5 min at a flowrate of 5 µl/min. In all experiments surface 
regeneration was mediated by a 45 sec pulse of 40 mM CHAPS. 
 
2.10.3 BINDING OF LPS TO IMMOBLISED BBMV 
Following the immobilisation of BBMV onto the L1 chip, LPS (10 µg/ml) was 
passed over the surface at a flowrate of 5 µl/min. LPS binding was reflected by 
the increase in sensorgram signal measured in arbitrary response units (RU).  
 113 
2.10.4 ASSESSMENT OF NON SPECIFIC BINDING 
In order to accurately qualify the LPS binding data it was important to determine 
the degree of interference from non-specific binding (NSB). A structured 
approach was taken to assess any NSB of LPS to the L1 chip. Initially, NSB to 
the unblocked L1 chip (without BBMVs) was determined. Subsequently, a 12 
mg/ml solution of BSA and CM-dextran was incorporated as a surface blocking 
agent.  Additionally, LPS was incubated with CM-dextran BSA before being 
passed over the surface. Finally, a liposome solution was used to pre-block the 
L1 chip following BBMV immobilisation and prior to injecting LPS. Liposome 
solution (30:30:10 % molar ratio DSPC:Cholesterol:DSPE-PEG) see Appendix 
was a kind gift from Paul Foran M.D. of the Applied Biochemistry Group, DCU.  
 
2.11 Statistical Analysis 
One-way analysis of variance (ANOVA) was used to determine significant 
differences between conditions.  When this indicated significance (p<0.05), post-
hoc Student-Newmann-Keul test was used to determine which conditions were 
significantly different from each other. There was no significant difference 
between cells alone and DMSO (vehicle control) treated cells, therefore DMSO 
was used as the reference treatment. An unpaired t-test was performed to assess 
statistical differences between two treatment groups where indicated. 
 
The confocal microscopy and luciferase experiments in chapter 5 
represented by figure 5.9 – 5.10 and figures 5.11 – 5.14, respectively were 
carried out in conjunction with Dr. Sarah Doyle and Dr. Claire Mc Coy in 
the Biochemistry Group in TCD.  
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CHAPTER 3 
 
THE EFFECTS OF PUFA ON 
MACROPHAGE FUNCTION 
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3.1 INTRODUCTION 
There is widespread evidence that polyunsaturated fatty acids (PUFA) are 
beneficial within the immune system [see section 1.11] (Hwang 2000). PUFA 
are found naturally in the diet; n-3 PUFA, EPA and DHA, are commonly found 
in fish oils, and CLA, a derivative of n-6 PUFA, is present in meat and dairy 
products. Incorporation of PUFA within the diet is notably important in the 
prevention of autoimmune disorders such as rheumatoid arthritis, systemic lupus 
erythematosus (SLE) and renal disease (Fernandes et al. 2008).  
 
Increasingly, evidence is pointing towards the benefits of PUFA in the 
prevention and treatment of inflammatory disease. The n-3 fatty acids, EPA and 
DHA have been found to reduce cardiovascular mortality (Hamer and Steptoe 
2006). While CLA is known to specifically reduce early atherosclerosis (Toomey 
et al. 2006). Contemporary treatments of inflammatory disease can have severe 
deleterious effects. As such, research has focused on the development of more 
natural therapeutic agents. While the exact mechanisms through which PUFA 
exert their effects remains elusive, our investigation and that of others have 
endeavoured to pinpoint their modes of action in order to elucidate their true 
therapeutic potential.  
 
Macrophage, (MØ) execute many roles within innate immunity and their 
activation is vital to initial host defence and in directing subsequent immune 
responses [as discussed see section 1.3]. Concurrently, the role of MØ in various 
inflammatory disorders has been well documented including; inflammatory 
bowel disease (Zhang and Mosser 2008), schistosmiasis (Hesse et al. 2001) and 
atherosclerosis (Wilson, Barker and Erwig 2009). As a result, we hypothesized 
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that MØ may be one of the targets of PUFA. In this study we have addressed the 
effect of PUFA on MØ activation in a comparative assessment between EPA and 
DHA and CLA. 
 
There are a number of parameters of MØ activation which PUFA may affect. 
Cellular activation signifies a change in the secretary profile and morphology of 
MØ. Activation signals the release of several pro-inflammatory cytokines 
including IL-1β, TNFα and IL-6 (Mosser 2003, Duffield 2003, Gordon 2003). 
On the other hand, production of anti-inflammatory or regulatory cytokines such 
as IL-10 act as potent deactivators of MØ pro-inflammatory cytokine synthesis 
(Clarke et al. 1998, Brandtzaeg et al. 1996). Differentiation of T cells into 
various subsets is partly determined by the cytokines MØ secrete. IL-10 inhibits 
TH1 responses by reducing the capacity of MØ to produce IL-12, a potent 
inducer of a TH1 phenotype. IL-23, IL-1 and IL-6 are involved in generating 
TH17 cells and IL-10 secreted by regulatory MØ directs TH2 phenotype (Mosser 
2003). Therefore, the effect of PUFA on LPS-induced cytokine release from MØ 
was assessed to evaluate any beneficial changes that may occur. 
 
In tandem, the activation of MØ leads to an upregulation of co-stimulatory 
molecules, pathogen recognition receptors (PRRs) and surface markers including 
CD40, CD80, CD86 and TLRs. Importantly, the expression of these markers is 
vital in providing bi-directional stimulatory signals between MØ and T cells 
(Janeway et al. 2008, Hoebe, Janssen and Beutler 2004). In fact, such signals 
make possible the interaction of MØ and T cells, supporting T cell activation and 
the regulation and activation of MØ. Therefore, changes to several surface 
makers in PUFA-treated MØ in response to LPS were assessed. 
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Activation also triggers the production of various chemokines acting as potent 
chemoattractants for immature DCs, neutrophils, NK cells and activated T cells. 
These include MIP-1α/CCLS, MIP-1β/CCL4 and MCP. Dysregulated expression 
of chemokines and their receptors has been implicated in the development of 
many human diseases including; allergy, psoriasis, atherosclerosis, and malaria 
(Murdoch and Finn 2000). Much effort has been placed on the development of 
therapeutic targets that modulate the activities of chemokines.  As a result we 
have investigated the effect of PUFA on LPS-induced chemokine release from 
MØ to evaluate any advantageous changes. Furthermore, the response of cells to 
chemokines and subsequent recruitment to sites of inflammation remains crucial 
during an immune response. As such, we have also assessed the chemotaxis of 
PUFA-treated MØ in response to LPS. 
 
Phagocytosis is a critical process in the clearance of infection. Throughout the 
body MØ are actively involved in this process. Phagocytosis of microbial 
products triggers the release of pro-inflammatory chemokines and cytokines and 
activates antigen processing and presentation by the enhancement of key surface 
markers MHCII, CD40 and CD80 (Kang et al. 2008). Subversively, it suppresses 
genes encoding molecules involved in bacterial recognition. TLR stimulation 
increases the phagocytic activity of MØ and promotes phagosome maturation, 
allowing sufficient capture and destruction of microbes (Blander and Medz 
2004). As key phagocytes, the rate of phagocytosis by MØ in a PUFA 
environment in response to TLR4 ligand, LPS was also examined. 
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With an ever emergin role for MØ in the pathogenesis of various inflammatory 
disorders the effect of PUFA on these cells is the first focus of our investigations.  
By examining multiple parameters of macrophage function we aim to elucidate a 
collective view of the modulatory effects of PUFA on this cell type. The 
modulatory effect of PUFA on cytokine and chemokine production, surface 
marker expression, phagocytosis and migratory profile of macrophage in 
response to LPS are thoroughly examined.   
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3.2 RESULTS 
 
3.2.1 THE CONCENTRATIONS OF PUFA USED HAVE NO 
SIGNIFICANT  EFFECT ON CELL VIABILITY  
The viability of cells following PUFA treatment was determined using CellTiter 
96® AQueous One Solution (Promega) according to the manufacturer’s 
instructions.  The concentrations of fatty acids selected for use in future 
experiments did not have significant cytotoxic effects on J774 macrophage in 
vitro, i.e. 50 µM DMSO, 25 µM EPA, 25 µM DHA, 50 µM CLA and 50 µM LA 
[Figure 3.1].  
 
3.2.2 PUFA MODULATE IN VITRO LPS-INDUCED CYTOKINE 
 PRODUCTION BY J774 MURINE MACROPHAGE  
J774 macrophage were cultured for 7 days with either DMSO (50 µM, vehicle 
control), EPA (25 µM), DHA (25 µM), CLA (50 µM) or LA (50 µM). The 
resultant fatty acid-treated macrophage were harvested and plated at a 
concentration of 1 x 106 cell/ml before stimulating with 100 ng/ml LPS (E.Coli 
serotype R515).   After 24 hours, supernatants were removed and assessed for 
levels of IL-12p40, IL-23p19, IL-1β, IL-10, TNF-α and IL-6 [Figure 3.2] using 
specific immunoassays. 
 
The production of the pro-inflammatory cytokine IL-12p40 [Figure 3.2] was 
inhibited significantly after culture with EPA (p<0.001). The saturated fatty acid, 
LA and PUFA, CLA and DHA had no effect on LPS induced IL-12p40 
production. In contrast, both CLA (p<0.001) and EPA (p<0.001) suppressed the 
production of pro-inflammatory cytokine, IL-23p19, following LPS stimulation 
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[Figure 3.2]. In addition, CLA was found to enhance IL-1β in response to LPS 
[Figure 3.2].  
 
The production of IL-10, an anti-inflammatory or regulatory cytokine, was 
substantially increased in PUFA-treated macrophage following LPS stimulation 
[Figure 3.2].  CLA (p<0.001) had the most profound effect on IL-10 production 
enhancing secretion significantly both before and after LPS stimulation. EPA 
(P<0.01) also enhanced IL-10 but to a lesser extent. The saturated fatty acid 
control, LA, had no effect on IL-10 production following LPS stimulation. In 
contrast to the other cytokines, which were modulated significantly, levels of 
TNF-α [Figure 3.2] remained relatively unchanged regardless of fatty acid 
treatment. PUFA, EPA (p<0.001) and DHA (p<0.01) significantly reduced IL-6 
[Figure 3.2] production in LPS stimulated macrophage, while CLA showed no 
effect. LA, had no effect on either of the cytokines.  
 
3.2.3 PUFA MODULATE IN VITRO LPS-INDUCED CHEMOKINE 
PRODUCTION BY J774 MURINE MACROPHAGE  
J774 macrophage were cultured for 7 days with either DMSO (50 µM, vehicle 
control), EPA (25 µM), DHA (25 µM), CLA (50 µM) or LA (50 µM). The 
resultant fatty acid-treated macrophage were harvested and plated at a 
concentration of 1 x 106 cell/ml before stimulating with 100 ng/ml LPS (E.Coli 
serotype R515).  After 24 hours, supernatants were removed and assessed for 
levels of MIP-1α, MIP-2 and MCP [Figure 3.3] using specific immunoassays. 
 
The production of pro-inflammatory chemokine, MIP-1α was not significantly 
affected by PUFA-treated macrophage following LPS stimulation [Figure3.3]. 
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Similarly, the saturated fatty acid control, LA had no effect. However, CLA 
significantly suppressed MIP-1α in unstimulated cells (p<0.01) [Figure3.3]. 
 
CLA (p<0.05) and DHA (p<0.01) enhanced MIP-2 following LPS stimulation 
[Figure 3.3], while EPA and LA exhibited no effect. CLA also enhanced MIP-2 
secretion prior to treatment with LPS [Figure 3.3]. Neither PUFA nor LA had 
any effect on the production of MCP-1 following LPS stimulation [Figure 3.3] 
however, similar to MIP-1α  and MIP-2, CLA enhanced secretion of this 
chemokine (p<0.01) in resting macrophage [Figure 3.3]. 
 
3.2.4 PUFA MODULATE CELL SURFACE MARKER EXPRESSION IN 
J774 MACROPHAGE 
J774 macrophage were cultured for 7 days with either DMSO (50 µM, vehicle 
control), EPA (25 µM), DHA (25 µM), CLA (50 µM) or LA (50 µM). The 
resultant fatty acid-treated macrophage were harvested and plated at a 
concentration of 1 x 106 cell/ml before stimulating with 100 ng/ml LPS (E.Coli 
serotype R515).  Control and LPS-stimulated cells were subsequently stained 
with fluorochrome-labelled monoclonal antibodies for numerous cell surface 
markers (i.e., CD40, CD80, CD86, CD204 (SR-A), TLR4-MD-2 and CD14) [See 
Table 2.7].  
 
PUFA modulated the levels of key surface markers in unstimulated and 
stimulated J774 macrophage. Expression of CD40 and CD86 was suppressed by 
all PUFA [Figure 3.4] and [Figure 3.6]. However, the effect of CLA on CD86 
was more marked than with other PUFA treatments. The levels of CD80 
expression in response to LPS were relatively unchanged with PUFA [Figure 
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3.5]. Treatment of macrophage with PUFA resulted in enhanced expression of 
SR-A which was not seen in the saturated, LA control [Figure 3.7]. Furthermore, 
expression of TLR4-MD-2 was markedly suppressed in PUFA-treated groups in 
response to LPS [Figure 3.8]. Again, no effect was observed in LA-treated cells. 
Expression of CD14 was modulated differently among PUFA-treated 
macrophage both before and after stimulation with LPS [Figure 3.9]. CLA 
significantly suppressed CD14 in both resting and stimulated macrophage while 
the n-3 fatty acid, EPA enhanced CD14. Levels of CD14 remained unchanged in 
both DHA- and LA-treated macrophage [Figure 3.9]. 
 
3.2.5 THE RATE OF PHAGOCYTOSIS IN J774 MACROPHAGE 
INCREASES OVER TIME 
Macrophage were cultured until reaching confluency and plated at 2.5 x 105 
cell/well and left to rest overnight. On the next day, 2.5 x 106 fluorescently 
labelled latex beads (Sigma®) were added to each well for 0, 2, 4, 6, 12, 20 and 
24 h. At each time point wells were washed to remove excess beads and cells 
scraped and fixed in 200 µl 4 % (v/v) paraformaldehyde/PBS. The rate of 
phagocytosis over time in macrophage was assessed using a BD FACSCalibur™, 
indicated by [ M2 ], [Figure 3.10A]. To assess the rate of phagocytosis in 
stimulated cells, J774 macrophage were treated with 100 ng/ml LPS 24 h prior to 
the addition of fluorescently labelled latex beads. The rate of phagocytosis also 
increased over time in LPS stimulated macrophage but to a greater extent 
[Figure 3.10B]. 
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3.2.6 PUFA MODULATE THE RATE OF PHAGOCYTOSIS IN 
MACROPAHGE IN VITRO 
J774 macrophage were cultured for 7 days with either DMSO (50 µM, vehicle 
control), EPA (25 µM), DHA (25 µM), CLA (50 µM) or LA (50 µM). To assess 
the rate of phagocytosis in both resting and stimulated cells, PUFA treated cells 
were left treated or untreated with 100ng/ml LPS 24 h prior to the addition of 
fluorescently labelled latex beads. The phagocytosis assay was performed as 
described [see section 3.2.5]. Among unstimulated groups phagocytosis in DHA 
treated cells was enhanced robustly from 4 h onwards comparative to control 
(DMS0). Phagocytosis was enhanced in EPA treated cells at 6 and 24 h [Figure 
3.11]. Graphical representation of phagocytosis in unstimulated PUFA treated 
cells by mean fluorescent intensity values (MFI) of [ M2 ]  is shown in [Figure 
3.13]. [ M2 ]  MFI values are indicative of the rate of phagocytosis as described in 
[Figure 3.10]. 
 
Among PUFA treated cells stimulated with LPS, CLA-treated cells displayed a 
small decrease in phagocytosis at 6 and 12 h [Figure 3.12]. EPA and DHA 
treated cells demonstrated a suppressed ability to phagocytose from 2 h onwards. 
While in LA-treated cells phagocytosis was unchanged comparative to control 
[Figure 3.12]. Graphical representation of phagocytosis in stimulated PUFA-
treated cells by mean fluorescent intensity values (MFI) of [ M2 ]  is shown in 
[Figure 3.13]. [ M2 ]  MFI values are indicative of the rate of phagocytosis as 
described in [Figure 3.10]. 
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3.2.7 CLA ENHANCES J774 CHEMOTAXIS BEFORE AND AFTER 
STIMULATION WITH LPS 
GM-CSF and IL-2 are commonly employed in macrophage chemotaxis studies 
and have also been used here (Stagg et al. 2004, Perri, Annabi and Galipeau 
2007). IL-2 is a ligand for CXCR2, which is robustly expressed on macrophage 
and implicated in the recruitment of macrophage to sites of inflammation 
(Boisvert et al. 1998).  GM-CSF (granulocyte-macrophage colony stimulating 
factor) is a cytokine that induces activation of monocytes and macrophages 
(Hasskamp, Elias and Zapas 2006). The chemotaxis of J774 macrophage 
following LPS activation towards chemokines IL-2 and GM-CSF was 
significantly enhanced by culturing with CLA (p<0.01) and DHA (p<0.01) 
[Figure 3.14].  The presence of EPA or LA had no effect on macrophage 
chemotaxis following LPS stimulation. Only CLA (p>0.05) rendered 
macrophage more responsive to IL-2 and GM-CSF prior to LPS stimulation 
[Figure 3.14].    
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FIGURE 3.1: The concentrations of fatty acids used during the course of in vitro cell 
culture do not significantly affect the viability of J774 macrophage. A dose response 
assay was carried out in macrophage to assess the possible toxicity of increasing 
concentrations of fatty acids. Macrophage were cultured for 7 days with the specified 
concentrations (25, 50 and 100 µM) of either DMSO (vehicle control), EPA, DHA, CLA 
or LA. After 7 days cellular viability was assessed using an MTS assay (CellTiter 96® 
AQueous One Solution (Promega)). Results are expressed as a percentage of untreated 
cells. 
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FIGURE 3.2: Pro-inflammatory (IL-12p40, IL-23p19, IL-1β, TNFα, IL-6) and anti-
inflammatory (IL-10) cytokine production by fatty acid treated-J774 macrophage 
following LPS stimulation. Macrophage were cultured in DMSO (vehicle control), EPA 
(25 µM), DHA (25 µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), 
for 7 days. Subsequently, 1 x 106 cell/ml were stimulated in vitro with LPS (100ng/ml) 
and supernatants recovered after 24 hours.  Levels of pro- and anti-inflammatory 
cytokines were measured using specific immunoassays. 
Results are mean ± SEM of quadruplicate assays and represent three independent 
experiments. 
***P<0.001, **P<0.01, *P<0.05 vs. DMSO vehicle control determined by one-way 
ANOVA test. 
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FIGURE 3.3: MCP production in PUFA-treated macrophage following LPS 
stimulation. Macrophage were cultured in DMSO (vehicle control), EPA (25 µM), DHA 
(25 µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days. 
Subsequently, 1 x 106 cell/ml were stimulated in vitro with LPS (100 ng/ml) and 
supernatants recovered after 24 hours.  Levels of MIP-1α [A] and MIP-2 [B] were 
measured using specific immunoassays. 
Results are mean ± SEM of quadruplicate assays and represent three independent 
experiments.   
***P<0.001, **P<0.01, *P<0.05 vs. DMSO vehicle control determined by one-way 
ANOVA test  
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FIGURE 3.4: PUFA modulate the expression of CD40 on the surface of mature J774 
macrophage. MØ were cultured in DMSO (vehicle control), EPA (25 µM), DHA (25 
µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days, before 
activation with LPS (100 ng/ml). Subsequently, cells were washed and stained with 
antibody specific for CD40 or with an isotype matched control.  Results of flow 
cytometric analysis are shown for unstimulated DMSO-treated MØ (filled histogram), 
stimulated MØ (thin black line) and isotype control (dotted line) [A]. Results are also 
shown for DMSO-treated MØ (shaded histogram) vs. PUFA-treated MØ (black line) for 
unstimulated [Control] vs. stimulated [LPS] cells. Mean Flourescent Intensity (MFI) 
values are also presented for each histogram. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.5: PUFA modulate the expression of CD80 on the surface of mature J774 
macrophage. MØ were cultured in DMSO (vehicle control), EPA (25 µM), DHA (25 
µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days, before 
activation with LPS (100 ng/ml). Subsequently, cells were washed and stained with 
antibody specific for CD80 or with an isotype matched control.  Results of flow 
cytometric analysis and corresponding MFI values are shown for unstimulated DMSO-
treated MØ (filled histogram), stimulated MØ (thin black line) and isotype control 
(dotted line) [A]. Results are also shown for DMSO-treated MØ (shaded histogram) vs. 
PUFA-treated MØ (black line) for unstimulated [Control] vs. stimulated [LPS] cells. 
MFI values for PUFA treated cells are also displayed on all histograms for comparison 
of those of DMSO groups indicated in [A]. Mean Flourescent Intensity (MFI) values are 
also presented for each histogram. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.6: PUFA modulate the expression of CD86 on the surface of mature J774 
macrophage. MØ were cultured in DMSO (vehicle control), EPA (25 µM), DHA (25 
µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days, before 
activation with LPS (100 ng/ml). Subsequently, cells were washed and stained with 
antibody specific for CD86 or with an isotype matched control.  Results of flow 
cytometric analysis are shown for unstimulated DMSO-treated MØ (filled histogram), 
stimulated MØ (thin black line) and isotype control (dotted line) [A]. Results are also 
shown for DMSO-treated MØ (shaded histogram) vs. PUFA-treated MØ (black line) for 
unstimulated [Control] vs. stimulated [LPS] cells. Mean Flourescent Intensity (MFI) 
values are also presented for each histogram. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.7: PUFA modulate the expression of CD204 (SR-A) on the surface of 
mature J774 macrophage. MØ were cultured in DMSO (vehicle control), EPA (25 µM), 
DHA (25 µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 
days, before activation with LPS (100 ng/ml). Subsequently, cells were washed and 
stained with antibody specific for SR-A or with an isotype matched control.  Results of 
flow cytometric analysis are shown for unstimulated DMSO-treated MØ (filled 
histogram), stimulated MØ (thin black line) and isotype control (dotted line) [A]. 
Results are also shown for DMSO-treated MØ (shaded histogram) vs. PUFA-treated 
MØ (black line) for unstimulated [Control] vs. stimulated [LPS] cells. Mean 
Flourescent Intensity (MFI) values are also presented for each histogram. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.8: PUFA modulate the expression of cell surface marker, TLR4-MD-2 on 
the surface of mature J774 macrophage. MØ were cultured in DMSO (vehicle control), 
EPA (25 µM), DHA (25 µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 
µM), for 7 days, before activation with LPS (100 ng/ml). Subsequently, cells were 
washed and stained with antibody specific for TLR4-MD-2 or with an isotype matched 
control.  Results of flow cytometric analysis are shown for unstimulated DMSO-treated 
MØ (filled histogram), stimulated MØ (thin black line) and isotype control (dotted line) 
[A]. Results are also shown for DMSO-treated MØ (shaded histogram) vs. PUFA-
treated MØ (black line) for unstimulated [Control] vs. stimulated [LPS] cells. Mean 
Flourescent Intensity (MFI) values are also presented for each histogram. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.9: PUFA modulate the expression of CD14 on the surface of stimulated and 
unstimulated J774 macrophage. MØ were cultured in DMSO (vehicle control), EPA (25 
µM), DHA (25 µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 
7 days, before activation with LPS (100 ng/ml). Subsequently, cells were washed 
and stained with antibody specific for CD14 or with an isotype matched control.  Results 
of flow cytometric analysis are shown for unstimulated DMSO-treated MØ (filled 
histogram), stimulated MØ (thin black line) and isotype control (dotted line) [A]. 
Results are also shown for DMSO-treated MØ (shaded histogram) vs. PUFA-treated 
MØ (black line) for unstimulated [Control] vs. stimulated [LPS] cells. Mean 
Flourescent Intensity (MFI) values are also presented for each histogram. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.10: The rate of phagocytosis in unstimulated [A] and stimulated, LPS (100 ng/ml) [B] J774 macrophage is enhanced over time. 
Macrophage were plated at 5 x 105 cell/well in a 6-well plate and left to rest overnight. On the next day, 2.5 x 106 fluorescently labelled latex beads 
(1 x 106 beads/µl) (Sigma®) were added to each well at the indicated times. After the completed time course all wells were washed to remove excess 
beads and fixed in 200 µl 4 % (v/v) paraformaldehyde/PBS. The rate of phagocytosis over time in macrophage was assessed using a BD 
FACSCalibur™. Note: In [B], macrophage were stimulated with LPS (100 ng/ml) for 24 h prior to the addition of latex beads. 
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FIGURE 3.11: PUFA modulate the rate of phagocytosis in unstimulated J774 macrophage.  Macrophage were cultured in DMSO (vehicle control), 
EPA (25 µM), DHA (25 µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days. Cells were then plated at 5 x 105 cell/well in 
a 6-well plate and left to rest overnight. On the next day 2.5 x 106 fluorescently labelled latex beads (Sigma®) were added to each well at the 
indicated times. At 0 h all wells were washed to remove excess beads and fixed in 200 µl 4 % (v/v) paraformaldehyde/PBS. The rate of phagocytosis 
over time in macrophage was assessed using a BD FACSCalibur™.  
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FIGURE 3.12: PUFA modulate the rate of phagocytosis in J774 macrophage stimulated with LPS. Macrophage were cultured in DMSO (vehicle 
control), EPA (25 µM), DHA (25 µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days. Cells were then plated at 5 x 105 
cell/well in a 6-well plate and left to rest overnight. On the next day, cells were stimulated for 24 h with LPS, 100 ng/ml. On the third day 2.5 x 106 
fluorescently labelled latex beads (Sigma®) were added to each well at the indicated times. After the completed time course all wells were washed to 
remove excess beads and fixed in 200 µl 4 % (v/v) paraformaldehyde/PBS. The rate of phagocytosis over time in macrophage was assessed using a 
BD FACSCalibur™. 
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Figure 3.13: Graphical representation of mean fluorescent intensity values (MFI) for 
unstimulated [A] and stimulated [B] macrophage phagocytosis assays. MFI values of [ M2 
] have been plotted, indicative of the rate of phagocytosis as shown in figure 3.15. 
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FIGURE 3.14: CLA and DHA enhance the chemotaxis of MØ iN response to LPS. MØ 
were cultured in the presence of fatty acids and stimulated with LPS (100 ng/ml).  3 x 105 
cells were placed in the upper chamber of a Transwell® plate (8.0 µm).  Media containing 
recombinant GMCSF (10 ng/ml) and IL-2 (10 BRMP/ml; were 1 BRMP = 40 pg/ml) was 
added to the lower chamber and plates were incubated for 5 hours at 37 ºC. To determine 
the number of migrated cells, media from the bottom well was collected and events (cells) 
counted for 1 min on a BD FACsCalibur™.   
***P<0.001, **P<0.01, *P<0.05 vs. DMSO vehicle control determined by one-way 
ANOVA test. 
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3.3 DISCUSSION 
 
The findings of this study demonstrate that polyunsaturated fatty acids (PUFA), 
CLA, EPA and DHA have the ability to modulate LPS-induced responses in 
macrophage. Exacerbated macrophage activation results in extensive tissue damage 
associated with autoimmune diseases such as rheumatoid arthritis (RA) (Szekanecz 
and Koch 2007) and with infection, such as schistosmiasis (Hesse et al. 2001). 
Furthermore, several studies strongly suggest that ongoing activation of 
macrophage in inflamed lamina propria mucosa is central to the immunopathology 
of inflammatory bowel disease (IBD) (Papadakis and Targan 2000, Papadakis and 
Targan 1999, Podolsky 2002). Therefore, modulating macrophage responses holds 
great therapeutic potential. Critically, the parameters assessed here have broad 
implications and importance in both macrophage activation in inflammatory 
disease and their involvement in the immune response to infection. Furthermore, 
this comparative study has revealed that exposure to n-3 versus n-6-derived PUFA 
results in distinct functional effects on macrophage.   
 
Results here provide evidence that the n-3 PUFA, EPA robustly inhibits the 
biologically active subunit of potent pro-inflammatory cytokine IL-12, IL-12p40 in 
macrophage. IL-12 is a vital link between innate and adaptive immunity, favouring 
the differentiation of a TH1 phenotype (Trinchieri 2003a). As such, IL-12 is largely 
implicated in autoimmune and TH1 mediated diseases including; multiple sclerosis 
(MS), IBD and RA (La Cava and Sarvetnick 1999, Papadakis and Targan 2000). It 
is also one of many pro-atherogenic cytokines found at sites of atherosclerotic 
lesions (Kleemann, Zadelaar and Kooistra 2008). Targeting this cytokine may hold 
therapeutic potential. EPA-mediated inhibition of IL-12 has been reported in 
murine dendritic cells (DC) (Wang et al. 2007) but not macrophage. Administration 
 140 
of EPA in combination with aspirin has been shown to afford protection against 
sulfonic acid-induced colitis in balb/c mice mediated by a reduction in nitric oxide 
synthase and IL-12 (Arita et al. 2005). DHA, CLA and saturated fatty acid, LA 
showed no effect on LPS induced IL-12 production. However, CLA has previously 
been shown to suppress IL-12 production in murine DC and a caco-2 cell model of 
human intestinal epithelium (Loscher et al. 2005a, Reynolds et al. 2008). IL-12 is a 
potent inducer of IFNγ (Trinchieri 2003a) which directs the induction of classically 
activated macrophage by inactivating feedback inhibitory mechanisms, such as 
those mediated by IL-10 (Mosser and Edwards 2008, Hu, Chakravarty and 
Ivashkiv 2008).  The unchanged response of IL-12 production in CLA and DHA 
treated cells suggests that IL-12 is not a mechanism utilised by these PUFA to 
direct an anti-inflammatory phenotype in macrophage.  
 
IL-23 is a cytokine consisting of the IL-12p40 sub-unit and a unique p19 sub-unit. 
It binds to the IL-23R on CD4+ T cells promoting their development into TH17 
cells, characterised by the production of IL-17 and IL-6 (Langrish et al. 2005, 
Kikly et al. 2006).  IL-23 has emerged as a key player in a number of chronic 
inflammatory diseases including IBD (Neurath 2007) and collagen-induced 
arthritis (Yago et al. 2007). Marked production of IL-12 and IL-23 by DC and 
macrophage are believed to play a critical pathogenic role in psoriasis, a chronic 
immune mediated skin disease (Yawalkar et al. 2009). The n-3 PUFA, EPA and n-
6 derivative, CLA significantly suppressed LPS induced IL-23 production in 
macrophage. This may suggest a possible downstream role for PUFA-treated 
macrophage on TH17 cell development or maintenance. Furthermore, it implies that 
PUFA may also help ameliorate the symptoms and/or onset of diseases such as 
psoriasis. Importantly, the saturated fatty acid, LA significantly enhanced IL-23 
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production post stimulation. This is indicative of the pro-inflammatory effects of 
saturated fats, which have been reported (Lee et al. 2001, Kennedy et al. 2009, 
Milanski et al. 2009). 
 
EPA and DHA slightly suppressed TNFα and IL-1 in macrophage. In addition, 
statistical significance was observed in suppression of LPS-induced IL-6. A 
previous study has demonstrated that EPA can suppress TNFα production by 
murine macrophage (Babcock et al. 2002)(Babcock et al. 2002). Specifically, this 
suppression was reported to be a direct result of EPA altered NFκB activity (Lo et 
al. 1999). In addition, studies employing human macrophage models have reported 
that EPA and DHA inhibit TNFα, IL-6 and IL-1β production (Goua et al. 2008, 
Chu et al. 1999). Exacerbation of LPS recognition results in elevated levels of these 
cytokine in endotoxemia. In line with other studies, our data suggests that daily 
supplementation of n-3 PUFA may help ameliorate chronic inflammation caused 
during sepsis. 
 
In contrast, CLA significantly enhanced LPS-induced IL-1β production, which was 
surprising given that many of its effects are anti-inflammatory and IL-1β is a pro-
inflammatory cytokine. Other studies in our laboratory have also shown CLA to 
enhance IL-1β production by DC, however the implications of this are still not 
clear.  Furthermore, although not statistically significant, CLA slightly enhanced 
IL-6 production pre- and post stimulation. A linear correlation between elevated 
IL-1 and IL-6 levels is associated with increased fibroblast proliferation and 
collagen synthesis associated with wound healing (McDaniel et al. 2008). The high 
levels of IL-1 reported here in CLA-treated cells, may suggest a pathway through 
which CLA promotes a wound healing phenotype in macrophage. However, IL-1 is 
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a potent pro-inflammatory cytokine and the elevated levels reported here raise 
concerns for the use of CLA in treating inflammatory disease. 
 
It is widely accepted that inhibition of pro-inflammatory cytokines by PUFA may 
partly explain their anti-inflammatory effects. Some studies have already assessed 
the efficacy of n-3 PUFA and specifically the n-6 derivative, CLA (cis-9,trans-11) 
on cytokine production in murine macrohages (Babcock et al. 2002, Lo et al. 1999, 
Novak et al. 2003) and indeed human macrophage (Weldon et al. 2007, Chu et al. 
1999, Zhao and Chen 2005). However, what is evident in the present study, in 
conjunction with most recent literature, is a clear dependency on cell type for 
PUFA exerted effects and a distinct difference between the effects of n-3 versus n-
6 PUFA in murine macrophage.  
 
In contrast to the above mentioned cytokines, IL-10 is considered an anti-
inflammatory or regulatory cytokine. IL-10 critically inhibits macrophage and NK 
activity, T cell proliferation and chemotaxis (Conti et al. 2003, Mocellin et al. 
2004). It suppresses the production of inflammatory cytokines such as IL-1, IL-6, 
IL-12, and TNF-α from antigen presenting cells (APC) and also reduces the 
secretion of IL-2 and IFNγ from TH1 cells (Papadakis and Targan 2000). Indeed,  
IL-10 deficiency in mice leads to  overproduction of pro-inflammatory cytokines 
and the development of chronic inflammatory diseases (Conti et al. 2003).  CLA 
significantly enhanced IL-10 production in macrophage pre- and post stimulation 
with LPS. EPA also enhanced LPS induced IL-10 production but to a lesser extent 
than CLA. This presents a possible mechanism used by CLA and EPA to elicit 
their anti-inflammatory effects. Principally, the increase in IL-10 suggests 
subsequent regulatory effects on T helper (TH) cell differentiation as IL-10 inhibits 
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TH1 development (Conti et al. 2003). The effect of PUFA on IL-10 in macrophages 
is previously unreported. Interestingly, it has been shown that CLA enhances LPS 
induced IL-10 production in murine DC (Loscher et al. 2005a). With DC being the 
most potent APC this emphasises the potential of PUFA in directing subsequent 
adaptive immune responses.  
 
Further to the effects of PUFA on cytokine production, cytokines themselves have 
regulatory roles.  IL-10 can alter surface marker expression. It has been shown to 
inhibit the full maturation of DC by down-regulating CD80, CD86 and ICAM-1 
expression (Esther, Hermelijn and Martien 2005). Interaction of surface markers 
CD40, CD80 and CD86 with T cells plays a major role in the activation and 
expansion of all effector and regulatory TH cell subsets (Janeway et al. 2008). 
Furthermore, the interaction of CD40 and CD40 ligand activates APC and 
enhances T cell activation (van Kooten and Banchereau 2000). Overexpression of 
these surface markers has been implicated in the pathology of tissues from patients 
with IBD, RA and MS (Maerten, Liu and Ceuppens 2003, Liu et al. 2001). As 
such, these markers represent important targets for treating inflammatory disorders.  
 
Particularly, blocking T cell co-stimulatory signals is an attractive approach to treat 
autoimmune disease. CD86 enhances severity of arthritis by enhancing IL-17 
production and increasing the accumulation of effector T cells in joints without 
affecting Th1/Th2 development (Odobasic et al. 2008). Monoclonal antibodies to 
CD80 and CD86 have been shown to differentially modulate the activation of TH1 
and TH2 cells (Kuchroo et al. 1995). However, antibodies to CD80 and CD86 are 
known to exacerbate autoimmune disease, in part through enhanced production of 
TNF in macrophages (Khan et al. 2007). Indeed, this study demonstrates both CLA 
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and the n-3 PUFAs, EPA and DHA suppress CD40 and CD86 post stimulation. 
CLA had the most dramatic effect and suppressed CD86 significantly prior to 
stimulation  It is possible this robust suppression of CD86 observed in CLA treated 
macrophage in both resting and LPS stimulated cells may be attributed to the 
significantly enhanced IL-10 production in CLA treated cells. Furthermore, CLA 
suppression of CD86 offers an alternative mode of suppressing T cell activation 
which may be beneficial in the treatment of autoimmune disease.  
 
There is overwhelming evidence for the role of dysregulated and overexpressed 
chemokines in inflammatory disease. This study has assessed the modulatory 
effects of PUFA on potent chemokines MIP-1α, MIP-2 and MCP. MIP-1α has 
strong chemotactic effects on a vast number of leukocytes and high levels of this 
chemokine are common in inflammatory disorders and infection including; 
meningococcal disease (Moller et al. 2005) and rheumatoid arthritis (Kunkel et al. 
1996). Similarly, MCP is implicated in rheumatoid arthritis and other inflammatory 
disorders and is known to heavily recruit ‘lipid-laden’ macrophage in atheroma 
(Kunkel et al. 1996, Ross 1993). MIP-2 plays a major role in the infiltration of 
neutrophils in response to viral infections. Particularly, MIP-2 enhances the 
infiltration of neutrophils in HSV-1 infected cornea were they indirectly cause 
tissue injury (Yan et al. 1998). However, questions remain as to the benefits of 
targeting chemokines in the resolution of disease. It is unclear as to whether ‘anti’ 
chemokine strategies have the ability to reverse established inflammation. 
Furthermore, recruitment and activation of leukocytes by chemokines enhance 
inherent protective responses to invading pathogens. Leukocyte infiltration is of 
paramount importance during innate host defence. The interplay between 
phagocytes and bacteria leads to the clearance of infection. Depleted levels of MIP-
 145 
2 are associated with impaired bacterial clearance of Klebsiella pneumonia (Strieter 
et al. 1996). Similarly, low levels of MCP-1 markedly reduce clearance of 
Cryptococcus neoforms. This highlights the benefits of these chemokines in 
antibacterial and antifungal host defence. Notably, impaired bacterial clearance and 
increased mortality in mouse models of bacterial pneumonia have been reported 
(Strieter et al. 1996). 
 
Effects on chemokines were not dramatic however, CLA significantly enhanced 
expression of MIP-2 pre- and post stimulation, while DHA-enhanced MIP-2 
expression was observed in activated cells. An unexpected role for MIP-2 in the 
control of mucosal lymphocyte migration has also been reported (Ohtsuka et al. 
2001). Additionally, groups report MIP-2 expression is enhanced in the intestinal 
(Ohtsuka et al. 2001) and corneal (Yan et al. 1998) epithelium by IL-1. High levels 
of IL-1 in CLA-treated macrophage reported here may account for the increase in 
MIP-2 observed in CLA-treated macrophage. Similarly, MCP is regulated by IL-1 
and TNF (Adams and Lloyd 1997). As the majority of chemokines are only 
expressed upon cellular stimulation, CLA enhanced IL-1 may partly account for 
the significantly elevated MCP expression pre-stimulation. In contrast to these 
findings, EPA and DHA have previously been reported to suppress MIP-2 and 
MCP in mycotoxin deoxynivalenol (DON) infected murine lymphoid tissues 
(Kinser et al. 2005). MCP suppression was also observed by EPA and DHA in 
LDL receptor null mice and a diabetic mouse model (Wang et al. 2009, Garman et 
al. 2009)  and was beneficial to the resolution of both disease states. However, as 
chemokines assist rapid inflammatory response to pathogens and bacterial 
clearance, the administration of PUFA may have to be tailored to the particular 
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inflammatory state/disease. As such PUFA exerted effects on macrophage function 
warrants further investigation. 
 
Phagocytosis is a fundamental role of all macrophage populations, important in the 
ingestion and clearing of pathogens. Membrane fluidity strongly influences this 
process. As such several studies have investigated the role of PUFA membrane 
incorporation on phagocytosis activity. Here we report a suppressed ability of LPS-
stimulated macrophage to phagocytose as a result of EPA and DHA treatment. 
However, enhanced phagocytic activity among CLA- treated cells was observed at 
several time points following LPS stimulation. Importantly, LA suppressed 
phagocytosis in unstimulated cells and no change was observed in response to LPS 
comparative to control. To the best of our knowledge this is the first report of 
modulated phagocytic activity in CLA-treated cells. Conflicting evidence on the 
effects of n-3 PUFA on phagocytosis have been observed. Feeding studies 
incorporating n-3 PUFA into mouse diets report elevated PUFA content in lipid 
membrane but no significant effect on monocyte or neutrophil phagocytic activity 
(Kew et al. 2003). Similarly, EPA and DHA were described as having no effect on 
the ability of alveolar macrophage to phagocytose (D'Ambola et al. 1991). 
Alternatively, very early studies in the area demonstrated that altering the fatty acid 
composition of murine macrophages in vitro with PUFA made macrophage more 
phagocytically active (Lokesh and Wrann 1984, Calder et al. 1990, Mahoney et al. 
1977). The discrepencies described here may be due to the varied doses used 
among these studies. Phagocytosis remains an important event in bacterial 
clearance and maintaining homeostasis. Results reported here suggest that the n-6 
PUFA derivative, CLA enhanced phagocytosis and therefore may be beneficial in 
innate protection from infection.  
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Further to this we report enhanced chemotaxis of CLA treated macrophage both 
pre- and post stimulation with LPS, demonstrating that the ability to move to the 
site of infection aswell as phagocytosis, is enhanced. IL-6 strongly enhances the 
ability of cells to migrate (Clahsen and Schaper 2008).  The small enhancement in 
IL-6 in CLA-treated cells reported here may be a mechanism utilised by CLA to 
increase chemotaxis and support the recruitment of cells to site of inflammation.  
Little augmentative effect was displayed in EPA- and LA-treated cells. However, 
DHA significantly enhanced chemotaxis in response to LPS.   
 
Several critical parameters of macrophage activation and functional status have 
been assessed in this study. However, it was also important to define any effects on 
the pathogen recognition ability of these cells.  As LPS, which activates TLR4, was 
used throughout this study the effect of PUFA on this receptor as well as associated 
molecule CD14 and SR-A were investigated. Both CLA and n-3 PUFA, EPA and 
DHA robustly suppressed TLR4-MD-2 surface expression following stimulation 
with LPS, while the saturated fatty acid, LA exhibited no effect. To the best of our 
knowledge this is an unreported finding for both CLA and n-3 PUFA. Studies to 
date have focused on the assessment of PUFA-modulation on TLR4 downstream 
signalling events, particularly NFκB and COX-2 gene expression (Lee et al. 2001, 
Lee et al. 2003, Weatherill et al. 2005). Of further significant interest was the 
observed upregulation of SR-A by all PUFA, with no observed change by LA-
treated cells.  Particularly as in vitro studies have demonstrated the ability of SR-A 
to bind LPS suggesting a possible role for SR-A in LPS clearance (Hampton et al. 
1991). Further to our findings regarding TLR4, its co-receptor CD14 was enhanced 
by EPA following stimulation with LPS. In contrast, CLA significantly suppressed 
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CD14 both in resting and LPS stimulated cells. This finding in relation to altered 
CD14 expression was pivotal in the study. It confirmed distinct immunomodulatory 
effects of n-6 derived CLA isomer (cis-9, trans-11) and n-3 PUFA upstream of the 
parameters previously assessed. Therefore, the regulation of TLR4, CD14 and SR-
A by PUFA presented important mechanisms through which fatty acids may exert 
their anti-flammatory effects. This is investigated thoroughly in chapters 4 and 5.  
 
The focus of this study was to assess the immunomodulatory properties of PUFA 
regarding macrophage activation. Our findings highlight for the first time distinct 
effects of n-3 PUFA, EPA and DHA and n-6 derivative CLA in this regard. A lack 
of experimental and clinical studies in the area complicates any implication of their 
beneficial use in prevention and treatment of disease. As such, it remains for 
further studies to be carried out which may make feasible the administration of 
PUFA and the tailoring of such for the treatment of inflammatory disease and 
infection.  
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CHAPTER 4 
 
 
THE EFFECTS OF PUFA ON  
CELL SURFACE MARKERS 
AND BINDING 
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4.1 INTRODUCTION 
 
Intracellular signalling is the ultimate mechanism for the induction of cellular 
activation. However, this is preceded by the activation of receptors at the cell 
membrane following their ligation by various stimuli. By far, the most widely 
recognised and characterised stimuli of the innate immune response is 
lipopolysaccharide (LPS) (Janeway et al. 2008). LPS has been used extensively 
throughout our study and is a potent activator of the pathogen recognition receptor 
(PRR), Toll-like receptor 4 (TLR4) (Poltorak et al. 1998). Thus far we report 
significant downstream effects of PUFA on the activation and inflammatory status 
of macrophage, MØ. In the field of PUFA research to date, reports have focused on 
the downstream signalling effects of PUFA on TLR signalling, specifically in 
relation to NFκB and COX-2 expression (Lee et al. 2001, Lee et al. 2001, Lee and 
Hwang 2006). Significantly, due to the very nature of PUFA and their ability to 
become incorporated within the plasma membrane (Li et al. 2006, Li et al. 2005), 
we postulate that markers at the cell membrane present important targets for 
PUFA-mediated immune effects upstream of signalling. Here, we examine over 
time the effect of PUFA on surface marker expression to further delineate the 
different effects of EPA, DHA and CLA and determine whether these are early 
events.  
 
This is important given that prolonged activation of TLR4 is broadly accepted to 
contribute to the deleterious effects associated with chronic infection, sepsis and 
inflammatory disease (Karima et al. 1999, Salomao et al. 2008, Leon et al. 2008). 
Furthermore, CD14, an associated molecule of the TLR4 receptor complex plays 
an important role in the maximal responsiveness of TLR4 to LPS (Kirkland et al. 
1993, Landmann, Müller and Zimmerli 2000, Miyake 2006b). As such, PUFA-
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mediated effects on CD14 were investigated further by examining the levels of this 
protein in membrane and cytosolic fractions from PUFA-treated macrophage.   
 
The activation of macrophage and other leukocytes by LPS occurs after LPS 
molecules bind to CD14 followed by loading of LPS to TLR4-MD-2. This 
interaction of CD14 and LPS leads to optimal LPS induced signalling (Kim et al. 
2005). Indeed, CD14 mutants display impaired responses to LPS in HEK 293 cells 
(Juan et al. 1995, Stelter et al. 1999, Ohnishi, Muroi and Tanamoto 2001, Muroi, 
Ohnishi and Tanamoto 2002).   Considering the modulatory effects of PUFA on 
CD14 and TLR4-MD-2 expression reported in the previous chapter, we deemed it 
important to examine the effects of PUFA on the ability of LPS to bind to TLR4. 
This chapter describes the optimisation of a protocol to assess the binding of LPS 
to the TLR4 receptor complex by flow cytometry.  
 
By the very nature of their structure PUFA become incorporated into the plasma 
membrane. As such the membrane provides an important point from which they 
may exert their modulatory effects. As such the possibility of a PUFA modulated 
interaction between LPS and the TLR4 receptor complex at the membrane is 
investigated by examining surface marker expression over time, LPS-binding  and  
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 4.2 RESULTS 
 
4.2.1 PUFA MODULATE EXPRESSION OF KEY CELL SURFACE 
MARKERS AT EARLY TIMEPOINTS 
J774 macrophage were cultured for 7 days with either DMSO (50 µM, vehicle 
control), EPA (25 µM), DHA (25 µM), CLA (50 µM), or LA (50 µM). The 
resultant fatty acid-treated macrophage were harvested and plated at a 
concentration of 1 x 106 cell/ml before stimulating with 100 ng/ml LPS (E.Coli 
serotype R515) for 0, 2, 4, 6 and 12 h. Control and LPS-stimulated cells were 
subsequently stained with fluorochrome-labelled monoclonal antibodies for 
numerous cell surface markers (i.e., CD40, CD80, CD86, CD204 (SR-A), TLR4-
MD-2 and CD14) [See Table 2.7].  
 
PUFA modulated the levels of key cell surface markers in unstimulated and 
stimulated J774 macrophage over time. [Figure 4.1] and [Figure 4.2] shows that 
CD40 and CD80 expression was upregulated in cells over time from 0 h to 12 h. 
There was no suppression of CD40 in any of the PUFA-treated groups or the 
saturated fatty acid control, LA, at any of the early time points examined [Figure 
4.1].  However, there was a marked enhancement of CD40 in DHA treated cells at 
4 h.  This indicates that the observed suppression of CD40 in PUFA-treated cells 
reported in Chapter 3 is a late event. In addition, neither the PUFA or LA exerted 
any effect on CD80 expression between 0 and 12 h stimulation with LPS [Figure 
4.2].  
 
Conversely, expression of CD86 was significantly inhibited in CLA-treated cells 
prior to stimulation with LPS and indeed over the complete time course [Figure 
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4.3]. From the previous chapter, we can see that this effect is maintained at 24 h. 
CD86 expression was unaltered in both DHA- and EPA-treated cells with the 
exception of a slight suppression at 2 h in the EPA group. Our previous study 
indicated a suppression of CD86 in EPA treated cells stimulated with LPS for 24 h. 
Furthermore, LA exerted no effect on CD86 expression over the course of LPS 
stimulation. 
 
The effects of PUFA on SR-A expression were not observed over this early time 
course following LPS stimulation [Figure 4.4], indicating that the increase in SR-A 
in PUFA-treated cells reported in Chapter 3 is a late event.  The previous chapter 
also demonstrated a clear decrease in expression of TLR4 in PUFA-treated 
macrophage. In this study we show that these changes are not obvious at the early 
time points examined, however by 12 h, DHA- and EPA-treated cells begin to 
show a small decrease in the expression of this receptor [Figure 4.5]. This 
indicates that the effects of PUFA on TLR4 expression is a late event.    
 
Given our previous data that CLA suppressed CD14 expression in both resting and 
LPS-activated macrophage, we were particularly interested to see if this change 
was indeed an early event. Our data revealed that CLA suppressed CD14 at early 
time points (0 h, 2 h, 12 h)  [Figure 4.6], confirming that these changes are an early 
event.  In contrast, enhancement of CD14 was observed in EPA and DHA treated 
macrophage from 2 h onwards comparative to control, while treatment with 
saturated fatty acid, LA enhanced CD14 expression from 4 h onwards.  
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4.2.2 PUFA DIFFERENTIALLY MODULATE EXPRESSION OF CD14 
AT THE CELL MEMBRANE 
J774 macrophage were cultured in the absence of fatty acids, as described [section 
2.3.1] and plated at a concentration of 1 x 106 cell/ml or 2 x 105 cell/ml in a 6-well 
plate (3 ml/well) and left to rest overnight. Cells were stimulated with LPS (100 
ng/ml) for 0, 2, 4 and 6 h prior to scraping and fractionating membranes from 
cytosolic fractions as described [section 2.6.1]. Levels of CD14 were assessed by 
western blot. Upregulation of CD14 could not be observed following stimulation 
with LPS in the membrane fraction of cells plated at 1 x 106 cell/ml [See 
APPENDIX A]. However, change in the levels of both membrane and cytosolic 
CD14 was clearly evident in cells plated at 2 x 105 cell/ml [See APPENDIX A]. 
As such it was decided that 2 x 105 cell/ml be used in further experiments 
investigating the effect of PUFA-treatment on cytosolic and membrane bound 
levels of CD14. 
 
Further to this J774 macrophage were cultured for 7 days with either DMSO (50 
µM, vehicle control), EPA (25 µM), DHA (25 µM), CLA (50 µM), or LA (50 µM). 
The resultant fatty acid-treated macrophage were harvested and plated at a 
concentration of 2 x 105 cell/ml (3 ml/well) and stimulated with LPS (100 ng/ml) 
for 0, 2, 4 and 6 h. Membrane and cytosolic fractions were generated as described 
[section 2.6.1] and levels of CD14 assessed by western blot and densitometric 
analysis.  
 
LPS stimulation resulted in enhanced expression of CD14 in the membrane 
fractions of DMSO treated cells between 0 and 6 h [Figure 4.8], [Figure 4.9], 
[Figure 4.10] and [Figure 4.11]. This was accompanied by a drop in cytosolic 
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levels of CD14 at 0, 2 and 4 h and subsequent enhancement at 6 h LPS stimulation. 
PUFA-treatments differentially modulated the expression of membrane-bound and 
cytosolic CD14. Membrane CD14 was significantly decreased at 0 h in CLA-
treated cells [Figure 4.8] which agrees with our flow cytometry data. Furthermore, 
levels of CD14 in these cells are reduced after LPS activation compared to the 
DMSO controls. The opposite was observed in the cytosol of these cells with CD14 
being increased after LPS stimulation compared to the DMSO control. Similar to 
the DMSO group, EPA-, DHA- and LA-treated cells displayed enhanced 
expression of membrane bound CD14 over the course of LPS stimulation with no 
significant differences between the groups. However, in contrast to CLA, EPA and 
DHA treated cells displayed significantly higher levels of CD14 at the membrane 
at early time points compared to DMSO (control), [Figure 4.9] and [Figure 4.10], 
respectively. The cytosolic fractions of DHA-treated cells had decreased levels of 
CD14 particularly at 4 h and 6 h following LPS stimulation [Figure 4.9] with EPA-
treated cells showing no clear differences [Figure 4.10]. The levels of CD14 in the 
cytosol of the LA-treated cells were increased at some of the time points examined 
with little change in the membrane CD14 [Figure 4.11]. 
 
4.2.3 OPTIMISATION OF LPS-BINDING IN HEK 293 CELLS 
HEK 293 and HEK MTC cells were incubated with 5, 10 or 50 µg/ml of various 
biotinylated conjugates as described [section 2.4.4]. Binding of conjugates to cells 
was assessed by flow cytometry on a FACSCalibur™. As expected, binding to 
HEK 293 cells was negligible for all conjugates and free biotin [Figure 4.12B]. On 
the other hand binding to HEK-MTC cells was negligible for all conjugates and 
free biotin except Biotin-LPS (Invivogen™) [Figure 4.13B]. Binding was observed 
at 5, 10 and 50 µg/ml Biotin-LPS. The range of conjugates used in the experiment 
 156 
significantly ruled out non specific binding (NSB). Furthermore, NSB in both cell 
lines was further ruled out by incubating cells solely with the streptavidin-FITC 
conjugate, [Figure 4.12A] and [Figure 4.13A].  Substantial binding at low doses 
of Biotin-LPS (5 µg/ml) lead to the use of this concentration of the conjugate being 
used in experiments to assess the effect of PUFA on binding of LPS in this cell 
line.  
 
 
4.2.4 PUFA DO NOT MODULATE THE BINDING OF LPS IN HEK 293 
CELLS 
HEK-MTC cells were cultured for 7 days with either DMSO (50 µM, vehicle 
control), EPA (25 µM), DHA (25 µM), CLA (50 µM), or LA (50 µM). Following 
this HEK 293 and HEK MTC cells were incubated with 5 µg/ml of Biotin-LPS 
(Invivogen™) and assessed for binding by flow cytometry on a FACSCalibur™, as 
described [section 2.4.5]. Internal controls similar to those performed in the 
optimisation experiments were included. As expected, Biotin-LPS (Invivogen™) 
was the only conjugate to bind to the HEK-MTC cells [Figure 4.14A]. 
Furthermore, no significant change in binding was observed in PUFA treated cells 
compared to DMSO (control) [Figure 4.14B].  
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FIGURE 4.1: Effects of PUFA on CD40 expression on J774 macrophage (MØ). 
Macrophage were cultured with DMSO (vehicle control), EPA (25 µM), DHA (25 µM), 
CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days, before 
activation with LPS (100 ng/ml) for 0, 2, 4, 6 and 12 h. Subsequently, cells were 
washed and stained with antibody specific for CD40.  Results of flow cytometric analysis 
are shown for DMSO-treated MØ (filled histogram) and PUFA-treated MØ (thin black 
line). Mean Flourescent Intensity (MFI) values are also presented for DMSO (bold black) 
and PUFA groups (on histogram) over the time course. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 4.2: Effects of PUFA on CD80 expression on J774 macrophage. Macrophage 
were cultured with DMSO (vehicle control), EPA (25 µM), DHA (25 µM), CLA (50 µM), 
– or a saturated fatty acid control, LA (50 µM), for 7 days, before activation with LPS 
(100 ng/ml) for 0, 2, 4, 6 and 12 h. Subsequently, cells were washed and stained with 
antibody specific for CD80.  Results of flow cytometric analysis are shown for DMSO-
treated MØ (filled histogram) and PUFA-treated MØ (thin black line). Mean Flourescent 
Intensity (MFI) values are also presented for DMSO (bold black) and PUFA groups (on 
histogram) over the time course. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 4.3: Effects of PUFA on CD86 expression on J774 macrophage. Macrophage 
were cultured with DMSO (vehicle control), EPA (25 µM), DHA (25 µM), CLA (50 µM), 
– or a saturated fatty acid control, LA (50 µM), for 7 days, before activation with LPS 
(100 ng/ml) for 0, 2, 4, 6 and 12 h. Subsequently, cells were washed and stained with 
antibody specific for CD86.  Results of flow cytometric analysis are shown for DMSO-
treated MØ (filled histogram) and PUFA-treated MØ (thin black line). Mean Flourescent 
Intensity (MFI) values are also presented for DMSO (bold black) and PUFA groups (on 
histogram) over the time course. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 4.4: Effects of PUFA on SR-A (CD204) expression on J774 macrophage. 
Macrophage were cultured with DMSO (vehicle control), EPA (25 µM), DHA (25 µM), 
CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days, before 
activation with LPS (100 ng/ml) for 0, 2, 4, 6 and 12 h. Subsequently, cells were 
washed and stained with antibody specific for SR-A.  Results of flow cytometric analysis 
are shown for DMSO-treated MØ (filled histogram) and PUFA-treated MØ (thin black 
line). Mean Flourescent Intensity (MFI) values are also presented for DMSO (bold black) 
and PUFA groups (on histogram) over the time course. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 4.5: Effects of PUFA on TLR4-MD-2 expression on J774 macrophage (MØ).  
Macrophage were cultured with DMSO (vehicle control), EPA (25 µM), DHA (25 µM), 
CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days, before 
activation with LPS (100 ng/ml) for 0, 2, 4, 6 and 12 h. Subsequently, cells were 
washed and stained with antibody specific for TLR4-MD-2.  Results of flow cytometric 
analysis are shown for DMSO-treated MØ (filled histogram) and PUFA-treated MØ (thin 
black line). Mean Flourescent Intensity (MFI) values are also presented for DMSO (bold 
black) and PUFA groups (on histogram) over the time course. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 4.6: Effects of PUFA CD14 expression on J774 macrophage (MØ). Macrophage 
were cultured with DMSO (vehicle control), EPA (25 µM), DHA (25 µM), CLA (50 µM), 
– or a saturated fatty acid control, LA (50 µM), for 7 days, before activation with LPS 
(100 ng/ml) for 0, 2, 4, 6 and 12 h. Subsequently, cells were washed and stained with 
antibody specific for CD14.  Results of flow cytometric analysis are shown for DMSO-
treated MØ (filled histogram) and PUFA-treated MØ (thin black line). Mean Flourescent 
Intensity (MFI) values are also presented for DMSO (bold black) and PUFA groups (on 
histogram) over the time course. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 4.8: CLA modulated expression of membrane and cytosolic CD14 in 
macrophage. Macrophage were cultured with DMSO (vehicle control) or CLA (50 µM) for 
7 days. Subsequently, cells were plated at 2 x 105 cell/ml, (3 ml/well) and left to rest 
overnight. Cells were then stimulated with LPS (100 ng/ml) over 6 h, as indicated, after 
which cell lysates were harvested and membrane fractionation performed. Total cellular 
levels of β-actin were used as a loading control. Densitometric analysis was conducted on 
immunoblots and graphical representation of CD14 expression in arbitrary units (AU) is 
given for both membrane and cytosolic fractions. Results are shown for two experiments 
and are representative of 3 independent experiments. 
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FIGURE 4.9: DHA modulated expression of membrane and cytosolic CD14 in 
macrophage. Macrophage were cultured with DMSO (vehicle control) or DHA (25 µM) 
for 7 days. Subsequently, cells were plated at 2 x 105 cell/ml, (3 ml/well) and left to rest 
overnight. Cells were then stimulated with LPS (100 ng/ml) over 6 h, as indicated, after 
which cell lysates were harvested and membrane fractionation performed. Total cellular 
levels of β-actin were used as a loading control. Densitometric analysis was conducted on 
immunoblots and graphical representation of CD14 expression in arbitrary units (AU) is 
given for both membrane and cytosolic fractions. Results are shown for two experiments 
and are representative of 3 independent experiments. 
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FIGURE 4.10: EPA modulated expression of membrane and cytosolic CD14 in 
macrophage. Macrophage were cultured with DMSO (vehicle control) or EPA (25 µM) for 
7 days. Subsequently, cells were plated at 2 x 105 cell/ml, (3 ml/well) and left to rest 
overnight. Cells were then stimulated with LPS (100 ng/ml) over 6 h, as indicated, after 
which cell lysates were harvested and membrane fractionation performed. Total cellular 
levels of β-actin were used as a loading control. Densitometric analysis was conducted on 
immunoblots and graphical representation of CD14 expression in arbitrary units (AU) is 
given for both membrane and cytosolic fractions. Results are shown for two experiments 
and are representative of 3 independent experiments. 
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FIGURE 4.11: Effects of LA on expression of membrane and cytosolic CD14 in 
macrophage. Macrophage were cultured with DMSO (vehicle control) or LA (50 µM) for 7 
days. Subsequently, cells were plated at 2 x 105 cell/ml, (3 ml/well) and left to rest 
overnight. Cells were then stimulated with LPS (100 ng/ml) over 6 h, as indicated, after 
which cell lysates were harvested and membrane fractionation performed. Total cellular 
levels of β-actin were used as a loading control. Densitometric analysis was conducted on 
immunoblots and graphical representation of CD14 expression in arbitrary units (AU) is 
given for both membrane and cytosolic fractions. Results are shown for two experiments 
and are representative of 3 independent experiments. 
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FIGURE 4.12: Optimisation of LPS-binding in HEK 293 cells by flow cytometry. 1 x 106 
cells were incubated with 5, 10 or 50 µg/ml of various biotinylated conjugates. Following 
this a streptavidin-FITC probe was used to detect binding of the conjugates by flow 
cytometry [B]. HEK 293 cells were also incubated with strptavidin-FITC alone to rule out 
any non-specific binding [A]. Results of flow cytometric analysis are shown. Profiles are 
shown for a single experiment and are representative of 3 experiments. 
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FIGURE 4.13: Optimisation of LPS-binding in HEK-MTC cells by flow cytometry. 1 x 
106 cells were incubated with 5, 10 or 50 µg/ml of various biotinylated conjugates. 
Following this a streptavidin-FITC probe was used to detect binding of the conjugates by 
flow cytometry [B]. HEK MTC cells were also incubated with streptavidin-FITC alone to 
rule out any non-specific binding [A]. Results of flow cytometric analysis are shown. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 4.14: PUFA do not affect LPS binding to TLR4. Internal controls for binding of 
LPS in HEK-MTC cells are shown (filled histograms) and unstained cells (dotted line) [A]. 
HEK-MTC cells were cultured with DMSO (vehicle control), EPA (25 µM), DHA (25 
µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days. 
Subsequently, cells were incubated with Biotin-LPS conjugate and binding assessed using 
a streptavidin-FITC probe.  Results of flow cytometric analysis are shown for DMSO-
treated MØ (filled histogram) and PUFA-treated MØ (thin black line) [B]. Profiles are 
shown for a single experiment and are representative of 3 experiments. 
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4.3 DISCUSSION 
 
The focus of this study was to investigate the possible mechanisms underlying the 
PUFA-induced effects on the activation status of macrophage reported in chapter 3. 
To this end, PUFA-modulated expression of cell surface markers, particularly 
TLR4 and CD14, represented important targets upstream of signalling events 
through which PUFA may exert their effects. Furthermore, binding of LPS to 
CD14 and subsequent transfer and loading to TLR4-MD-2 initiates cellular 
activation (Kirkland et al. 1993, Miyake 2006a). Therefore, we also set out to 
assess whether the previously observed downstream effects of PUFA treatment, 
such as altered cytokine and chemokine production were linked to any changes in 
this putative binding event. 
 
While it is clear that PUFA affect signalling events which are downstream of 
TLR4, their exact mechanism of action is still unclear and some studies suggest 
that they exert their effects upstream of the signalling events, at the TLR4 complex 
itself (Lee et al. 2003). Studies have shown that a number of molecules affect LPS 
binding. Specifically, the antibacterial peptides, cathelicidins, secreted by 
mammalian cells have been shown to exert protective actions against endotoxin 
shock by blocking the binding of LPS (Nagaoka et al. 2001).  Moreover, when 
preincubated with RAW264.7 cells they bound to the cell surface and inhibited 
binding of FITC-LPS to the cells. In addition, aside from its commonly known 
function as an anticoagulant, heparin has been shown to inhibit LPS binding and 
subsequent cytokine production (Anastase-Ravion et al. 2003a). Therefore, we 
firstly examined the effects of PUFA on LPS binding.  
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To this end, the protocol for these experiments was rigorously optimised.  
Specifically, a HEK 293 cell line stably expressing TLR4, CD14 and MD-2 (HEK- 
MTC) was employed to rule out any alternate binding to additional LPS receptors 
(e.g. SR-A). Our data presented here demonstrates that PUFA do not modulate the 
binding of LPS to the TLR4 receptor complex. In addition, no significant effect on 
LPS binding was observed in saturated fatty acid, LA treated cells. Given that our 
data from the previous chapter showed that PUFA decreased expression of TLR4, 
we were initially surprised to find that the amount of LPS binding to TLR4 was not 
reduced. However, further experiments in this chapter reveal that the effects of 
PUFA on TLR4 are not early events and changes in the expression of this receptor 
were not obvious until 12 h post LPS-stimulation. SR-A is another receptor present 
on macrophages, which has been shown to bind LPS without any subsequent 
downstream signalling (Haworth et al. 1997). Our previous chapter showed that 
PUFA increased SR-A and indicated the possibility that upregulation of SR-A by 
PUFA may be a mechanism whereby LPS can bind to SR-A instead of TLR4, thus 
decreasing the cells response to LPS stimulation. It was therefore important to 
determine whether these changes occurred early. This study demonstrates that 
changes in SR-A expression are not an early event and therefore cannot be 
responsible for the decreased response of macrophage to LPS following treatment 
with PUFA.  
 
This study also revealed that similar to our observation for SR-A and TLR4-MD-2, 
the effects of PUFA on CD40 and CD80 expression are also not early events and 
are likely to be as a result of the overall diminished response of the macrophage to 
LPS stimulation. However, the expression of CD40 was markedly enhanced in 
DHA treated cells after 4 h stimulation. This is previously unreported, nonetheless, 
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studies involving DHA have looked at the effect of this fatty acid on CD40 after 24 
h stimulation and correlate with our observation of suppressed CD40 at this time 
(Chapter 3) (Wang et al. 2007).  
 
This study so far has demonstrates that many of the changes in cell surface receptor 
expression induced by PUFA are not early events and are therefore likely to be as a 
result of the decreased response of the cells to LPS. In direct contrast to the above, 
CLA suppressed CD14 and CD86 prior to and throughout the course of 
stimulation. Conversely, n-3 PUFA, EPA and DHA did not alter CD86 however; 
both n-3 PUFA were seen to enhance CD14 from as early as 4 h stimulation. As 
discussed before, blocking T cell co-stimulatory signals by targeting CD86 is an 
attractive approach to treat autoimmune disease (Odobasic et al. 2008). On the 
other hand, lack of co-stimulatory signals results in the failure of cytotoxic T cell 
activation against tumor specific antigens (Luque, Reyburn and Strominger 2000, 
Suzuki et al. 2003). Furthermore, high levels of CD86 are found in the bone 
marrow and peripheral blood of patients with chronic graft-versus-host disease 
(Arpinati et al. 2008). Our finding in relation to CD86 further emphasises not only 
the differential effects of fatty acids but the importance of tailoring their 
administration in the treatment of individual inflammatory diseases. The 
consequences of suppressed CD86 in macrophages warrants further investigation. 
 
Our finding regarding the alternate effects of CLA and n-3 PUFA on CD14 
expression and the fact that it is an early event is the most significant piece of data 
generated here and was further assessed in the analysis of membrane versus 
cytosolic expression of the protein. There are continuously emerging roles for 
CD14 in the exacerbation of infection and inflammatory disease. Indeed, high 
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levels of CD14 are indicative of intestinal macrophage populations from patients 
suffering with IBD (Kamada et al. 2008).  Signalling through CD14 has been 
shown to play an obligate role in cardiac inflammation occurring after major burn 
injuries (Barber et al. 2008). (Panaro et al. 2008) demonstrate the overexpression of 
CD14 in specific areas of the central nervous system (CNS) within an endotoxin 
induced mouse model of Parkinson's-like disease. Furthermore, Wegener’s 
granulomatosis is partially characterised by the upregulation of CD14 and CD18 on 
monocytes by antineutrophil cytoplasmic auto antibodies (ANCA) (Yard et al. 
2002). The findings presented here demonstrate by flow cytometry and western 
blot that CLA suppresses surface expression of CD14 prior to and during 
stimulation. Taken together with our earlier findings regarding the effects of CLA 
on activation status (Chapter 3) this implies a cellular phenotype less responsive to 
LPS and therefore less likely to produce exacerbated pro-inflammatory signals in 
the presence of immune stimuli. Interestingly, other studies in our laboratory have 
recently shown that CLA reduces the symptoms of endotoxic shock and that this is 
associated with a decreased expression of CD14 on dendritic cells (unpublished 
observation). In this regard, administration of CLA may offer an alternative to anti-
CD14 therapies suggested by many of the groups cited above.  
 
It cannot be concluded from the results presented here whether PUFA-modulated 
expression of CD14 occurs at the transcriptional level. Indeed, suppressed levels of 
CD14 at the membrane in CLA treated cells is accompanied by significantly 
enhanced levels in the cytosol. This is perhaps due to an inability of transcribed 
CD14 to become incorporated into the membrane and is therefore retained in the 
cytosol. This is a novel finding in relation to CLA. Furthermore, after attachment 
of the GPI-anchor, GPI-anchored proteins are transported to the cell surface via the 
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‘canonical’ secretory pathway (Lippincott-Schwartz, Roberts and Hirschberg 
2000). Thus far, fatty acids have not been reported to interfere with this 
translocation event.  
 
In contrast to CLA, n-3 PUFA, EPA- and DHA-treated cells showed enhancement 
of CD14 at early time points at the membrane along with decreased levels in the 
cytosol. In contrast to our findings (De Smedt-Peyrusse et al. 2008) report 
suppressed levels of membrane CD14 and enhanced cytosolic levels following 
DHA treatment in microglial cells. However, while this was indeed prior to 
stimulation, cells were treated exogenously with DHA (30 µmol/L for 24 h). 
Findings presented here significantly emphasize the different modulatory effects of 
CLA and n-3 PUFA, EPA and DHA on LPS receptor CD14 and requires further 
clarification. Studies assessing the effect of PUFA on CD14 mRNA levels may 
help elucidate the mechanisms involved.  
 
Most significantly, in conjunction with our previous findings, PUFA modulated 
effects on CD14 may be a key point upstream of signalling through which PUFA 
exert their anti-inflammatory effects. Moreover, it is vitally important to assess this 
further. Certainly, (Ji et al. 2006) report suppression of CD14 by components of 
Qinggan Huoxue Recipe (QGHXR), however, the effects of these compounds on 
CD14 was not associated with subsequent suppression of NFκB. 
 
While CD14 is required for the maximum responsiveness of the TLR4 receptor 
complex to LPS, is it absolutely required for TLR4 endocytosis and subsequent 
activation of interferon-β via adaptors Trif and TRAM (Jiang et al. 2005, Kagan et 
al. 2008, Godowski 2005). Lipid rafts represent important microdomains within the 
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plasma membrane of cells that constitutively express GPI-anchored proteins. In 
addition, translocation of key signalling receptors including TLR4 and indeed the 
expression of GPI-anchored proteins is enhanced upon stimulation in these 
domains. As a result, in the following chapter, expression of CD14 in lipid raft 
microdomains of PUFA treated macrophage will be examined. Furthermore, the 
effect of PUFA on TLR4 endocytosis and the induction of key inflammatory 
transcription factors NFκB and IRF will also be assessed. 
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CHAPTER 5 
 
THE EFFECTS OF PUFA ON 
THE TLR4 RECEPTOR 
COMPLEX AND 
DOWNSTREAM SIGNALLING 
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5.1 INTRODUCTION 
 
Throughout this work we have endeavoured to elucidate the pivotal mechanisms 
through which fatty acids exert their anti-inflammatory effects. Thus far our 
finding regarding PUFA modulated expression of CD14 has been of great 
significance. Not only do CLA and n-3 PUFA differentially modulate the 
expression of this protein, in particular suppression can be observed at very early 
stages in CLA-treated cells. This finding and the fundamental role of CD14 in 
TLR4 signalling warranted further investigation. As such the rationale for the 
current study has been to concentrate on PUFA-mediated effects in relation to 
TLR4 endocytosis, downstream signalling and indeed targeting of CD14 itself to 
microdomains of the plasma membrane.   
 
With regard to signalling, TLR4 is unique in that it activates both MyD88 
dependant and independent pathways leading to the induction of the transcription 
factors NFκB and IRF3, respectively (Brikos and O'Neill 2008, Akira, Yamamoto 
and Takeda 2003). This facilitates the production of pro-inflammatory cytokines 
via NFκB (O'Neill 2006) and type І interferons via IRF3 (McCoy and O'Neill 
2008). Activation of the MyD88 dependant pathway is mainly an event initiated at 
the plasma membrane. Furthermore, induction of IRF via the MyD88-independent 
pathway is dependant on the endocyotosis of TLR4 an event requiring the presence 
of CD14 (Jiang et al. 2005, Kagan et al. 2008).  
 
In the previous chapter we describe the suppression of membrane-bound CD14 in 
CLA-treated cells both prior to and at very early stages following stimulation with 
LPS. In this chapter we investigate the effect of PUFA-treatment on the activation 
of IRF3, a completely novel area in the field of PUFA research. In conjunction 
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with this we also assess the modulatory effects of PUFA used in our study on 
NFκB, given that it is broadly accepted that PUFA mediate part of their anti-
inflammatory effects through the suppression of NFκB (Sampath and Ntambi 
2005). Furthermore, we postulate that the effect of CLA on CD14 may indeed 
modulate TLR4 signalling by limiting the ability of TLR4 to become endocytosed 
leading to a suppression of IRF.  Importantly, in support of this (Lee et al. 2003) 
demonstrate that the target for PUFA mediated effects may in fact lie upstream at 
the receptor complex itself.  
 
Interestingly, the activation of several signalling complexes has been linked with 
their specific recruitment to microdomains within the plasma membrane known as 
lipid rafts. In particular, this is widely documented regarding immune cell 
signalling (Dykstra et al. 2003, Goebel et al. 2002). Indeed, lipid rafts have been 
widely implicated in T-cell activation (Horejsi et al. 1999). Specifically, the 
recruitment of TLR2 (Soong et al. 2004)(Soong et al. 2004) and TLR4 and 
associated molecule CD14 (Triantafilou et al. 2002) to lipid rafts following 
stimulation with their respective ligands has been demonstrated. As a result, we 
aim here to assess the effect of PUFA on the recruitment of CD14 to lipid raft 
micro-domains following stimulation with LPS.  
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5.2 RESULTS 
 
5.2.1 OPTIMISATION OF LIPID RAFT ISOLATION FROM J774 
MACROPHAGE  
J744 macrophage were cultured and left unstimulated or stimulated with LPS for 
30 min. Following this lipid raft fractions were isolated as described [see section 
2.6.3]. As a means of optimising the isolation procedure various concentrations of 
Triton X-100 were employed and lipid raft fractions assessed by western blot. 
Results demonstrate that 0.2 % (v/v) Triton X-100 was an insufficient amount of 
detergent to successfully solubilize cellular material and leave lipid rafts free to 
float to the interface of the sucrose gradient (Fractions 4 -6) [Figure 5.1]. Indeed 
this is indicated by the lack of alkaline phosphatase activity, indicative of lipid rafts 
and lipid raft marker, flotillin-1, FL-1 localisation within these fractions. 
Furthermore, CD14 and the non-raft marker β-actin were also detected throughout 
fractions 2- 11. 
 
Alternatively, resuspending cellular membranes in 0.5 % (v/v) Triton X-100 
provided sufficient solubilization for partitioning of lipid rafts to the sucrose 
interface [Figure 5.2]. Indeed, high levels of alkaline phsophatase are indicated in 
fractions (4-6) in both unstimulated and stimulated cell samples. Furthermore, 
specific localisation of lipid raft marker, FL-1 and GPI-anchored protein, CD14 can 
also be observed in these fractions. In addition, the non-raft marker, β-actin is only 
localised within the bottom fraction or ‘pellet’. In contrast, employing 1 % (v/v) 
Triton X-100 completely solubilized non-raft and raft material [Figure 5.3]. In a 
case such as this, both raft and non-raft domains coalescence with detergent and 
result in disordered flotation of proteins throughout the gradient (Shogomori and 
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Brown 2003). Certainly, in support of this, CD14, FL-1 and β-actin were all 
detected throughout the gradient. Furthermore, alkaline phosphatase activity is 
completely skewed in both resting and stimulated cells. Therefore, for the 
investigation of lipid rafts from PUFA-treated macrophage 0.5 % (v/v) Triton X-
100 was employed. 
 
5.2.3 ANALYSIS OF LIPID RAFTS FROM PUFA TREATED J774 
MACROPHAGE 
J774 macrophage were cultured for 7 days with either DMSO (50 µM, vehicle 
control), EPA (25 µM), CLA (50 µM), or LA (50 µM) after which approx. 100 x 
106 cells were left unstimulated or stimulated with LPS for 30 min. Following this, 
lipid raft fractions were isolated as described [see section 2.6.3] and assessed by 
western blot. The lipid raft marker, FL-1 was successfully detected at the interface 
of sucrose gradients for DMSO (vehicle control) and PUFA-treated cells [Figure 
5.4 – 5.7]. Importantly, the non-raft marker, β-actin was also detected distinctly 
apart from FL-1 at the bottom of gradients, mainly in cell pellets [Figure 5.4 – 
5.7].  
 
Furthermore, significant alkaline phosphatase activity was present for lipid raft 
fractions (Fraction 4-6) in DMSO treated cells (vehicle control) both before and 
after stimulation [Figure 5.4]. In contrast PUFA-treatment significantly altered 
alkaline phosphatase activity pellets [Figure 5.5– 5.6]. This was particularly 
prominent in CLA-treated cells [Figure 5.5]. Moreover, LA-treated cells also 
displayed randomised effects on alkaline phosphatase activity throughout the 
sucrose gradient [Figure 5.7]. Importantly, stimulation with LPS resulted in an 
increase in CD14 in the lipid rafts in all of the groups examined [Figure 5.4 – 5.7].  
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The method employed here afforded qualitative assessment of raft associated 
proteins. Nonetheless, even with the restriction of qualitative assessment, CD14 
‘appeared’ to be suppressed in lipid raft fractions of CLA treated cells following 
stimulation [Figure 5.5] unlike raft fractions from EPA  treated cells [Figure 5.6]. 
In conjunction with observed effects of CLA on alkaline phosphatase activity this 
warranted further investigation.  
 
5.2.4 QUANTITATIVE ASSESSMENT OF CD14 LEVELS IN LIPID 
RAFT FRACTIONS OF PUFA TREATED J774 MACROPHAGE 
The direct effects of PUFA on the recruitment of CD14 to lipid rafts following 
stimulation with LPS was quantitatively assessed by western blot. Protein levels 
were normalised following quantitative analysis via a NanoDrop3300 [see section 
2.3.6.4]. Levels of CD14 within the lipid raft fractions of LPS-stimulated CLA-
treated cells were significantly lower compared the same fractions from DMSO-
treated cells (vehicle control) [Figure 5.8B and C]. Conversely, EPA-treated cells 
displayed elevated levels of CD14 in lipid raft fractions compared to the DMSO 
group following LPS stimulation [Figure 5.8B and C]. 
 
5.2.5 PUFA SELECTIVELY INHIBIT NFKB AND IRF3 EXPRESSION 
HEK 293 cells and HEK 293 cells stably expressing TLR4-CD14-MD-2 (HEK-
MTC) were cultured for 7 days with either DMSO (50 µM, vehicle control), EPA 
(25 µM), DHA (25 µM), CLA (50 µM), or LA (50 µM). The resultant fatty acid-
treated cells were plated and transiently transfected with either an NFκB or ISRE 
luciferase reporter plasmid as described [see section 2.8.3]. The IFN-stimulated 
response element (ISRE) provides a specific readout for the induction of IRF3. 
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As expected, no induction of NFκB or ISRE was detected in HEK 293 cells 
stimulated with LPS [Figure 5.9A] and [Figure 5.9B], respectively. Analysis by 
means of unpaired t-test demonstrated that CLA significantly (p<0.001) suppressed 
NFκB in comparison to DMSO (vehicle control) in HEK-MTC cells [Figure 
5.9C]. In addition, the n-3 PUFA, DHA (p<0.05) and EPA (p<0.01) also 
suppressed NFκB in HEK-MTC cells but to a lesser extant than CLA [Figure 
5.9C]. The saturated fatty acid, LA, exerted no effect on NFκB or ISRE in HEK-
MTC cells. 
 
CLA (p<0.01) also significantly suppressed the activation of IRF3 compared to the 
DMSO (vehicle control) in stimulated cells, by unpaired t-test [Figure 5.9D]. 
Furthermore, DHA and EPA treatments exerted no effect on IRF3 induction in 
response to LPS [Figure 5.9D].  Similarly, CLA was observed to suppress levels of 
IRF3 in U373 cells, while n-3 PUFA exerted no effect [Figure 5.10A]. 
Significantly, in a U373 cell line stably overexpressing CD14, the inhibitory effect 
of CLA on IRF3 was completely reversed [Figure 5.10B].  
 
5.2.6 EFFECTS OF PUFA ON LPS INDUCED ENDOCYTOSIS OF TLR4 
HEK-MTC cells were cultured for 7 days with either DMSO (50 µM, vehicle 
control), CLA (50 µM), EPA (25 µM) or LA (50 µM). Subsequently, for the 
investigation of LPS-induced endocytosis of TLR4, HEK-MTC cells were 
transiently transfected with TLR4-YFP and EEA1-CFP (early endosomal antigen) 
constructs as described [see sections 2.8.3 – 2.9]. Cells were either stimulated for 
7.5 min, 15 min or left unstimulated and analysed using an Olympus FluoView™ 
FV1000.  
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Results demonstrate that in resting cells treated with DMSO (vehicle control), 
TLR4 is localised on the plasma membrane with few early endosomes present 
[Figure 5.11]. In addition, there is little co-localisation of TLR4 and EEA1. As 
expected, following 7.5 min stimulation with LPS, TLR4 was rapidly endocytosed 
and is almost completely inside the cell. At this point, early endosome formation 
and co-localisation of EEA1 with TLR4 is more prominent. After 15 min of 
stimulation TLR4 has not returned to the plasma membrane however, there is 
significantly less co-localisation of the two molecules and less endosomes present.  
 
In direct comparison to DMSO, PUFA treated cells displayed distinct patterns of 
TLR4 localisation and endocytosis. Indeed, while TLR4 was clearly localised on 
the plasma membrane in resting cells treated with CLA there was significantly 
more early endosome formation and co-localisation of EEA1 with TLR4 compared 
to DMSO [Figure 5.12]. Following stimulation with LPS at 7.5 min early 
endosome formation and EEA1 and TLR4 co-localisation was comparative to 
DMSO treated cells at this time point. However, significantly more TLR4 was 
retained at the plasma membrane. Similarly, at 15 min stimulation early endosome 
formation and EEA1 co-localisation with TLR4 was comparative to that of DMSO 
however; again TLR4 was seen to remain significantly at the membrane.  
 
Conversely, TLR4 was extremely difficult to detect on the plasma membrane of 
resting cells treated with EPA [Figure 5.13]. Co-localisation of EEA1 and TLR4 
was similar to that of resting cells treated with DMSO. Similar to CLA, treatment 
with this PUFA enhanced the number of endosomes in resting cells. Following 7.5 
min stimulation practically all TRL4 was observed to be inside cells and co-
 184 
localised with EEA1. In addition, at 15 min stimulation there is a definite shift of 
TLR4 away from endosomes, however, more co-localisation is observed at this 
time point in EPA treated cells compared to DMSO. Interestingly, virtually no 
TLR4 is evident on the membrane. Cells treated with the saturated fatty acid 
control, LA, displayed patterns of TLR4 endocytosis and early endosome 
formation similar to those of DMSO-treated cells [Figure 5.14]. 
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FIGURE 5.1: Isolation of lipid raft fractions by sucrose density gradient. Membrane 
preparations from unstimulated [CONTROL] and stimulated [LPS] J774 macrophage 
were solubilised in 0.2 % (v/v) Triton X-100 before application on a discontinuous sucrose 
gradient. Following 16 h of centrifugation, 1 ml fractions were harvested from the top 
(Fraction 1) to the bottom (pellet) of the gradient. Fractions were analysed for alkaline 
phosphatase activity (graph), raft marker flotillin-1 (FL-1), non-raft marker β-actin and 
GPI-anchored protein, CD14 (blots). 
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FIGURE 5.2: Isolation of lipid raft fractions by sucrose density gradient. Membrane 
preparations from unstimulated [CONTROL] and stimulated [LPS] J774 macrophage 
were solubilised in 0.5 % (v/v) Triton X-100 before application on a discontinuous sucrose 
gradient. Following 16 h of centrifugation, 1 ml fractions were harvested from the top 
(Fraction 1) to the bottom (pellet) of the gradient. Fractions were analysed for alkaline 
phosphatase activity (graph), raft marker flotillin-1 (FL-1), non-raft marker β-actin and 
GPI-anchored protein, CD14 (blots). 
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FIGURE 5.3 Isolation of lipid raft fractions by sucrose density gradient. Membrane 
preparations from unstimulated [CONTROL] and stimulated [LPS] J774 macrophage 
were solubilised in 1 % (v/v) Triton X-100 before application on a discontinuous sucrose 
gradient. Following 16 h of centrifugation, 1 ml fractions were harvested from the top 
(Fraction 1) to the bottom (pellet) of the gradient. Fractions were analysed for alkaline 
phosphatase activity (graph), raft marker flotillin-1 (FL-1), non-raft marker β-actin and 
GPI-anchored protein, CD14 (blots). 
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FIGURE 5.4: Isolation of lipid raft fractions by sucrose density gradient. J774 
macrophage were treated with DMSO (50 µM) for 7 days. Subsequently, membrane 
preparations from unstimulated [CONTROL] and stimulated [LPS] cells were solubilised 
in 0.5 % (v/v) Triton X-100 before application on a discontinuous sucrose gradient. 
Following 16 h of centrifugation, 1 ml fractions were harvested from the top to the bottom 
(pellet) of the gradient. Fractions were analysed for alkaline phosphatase activity (graph), 
raft marker flotillin-1 (FL-1), non-raft marker β-actin and GPI-anchored protein, CD14 
(blots). 
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FIGURE 5.5: Isolation of lipid raft fractions by sucrose density gradient. J774 
macrophage were treated with CLA (50 µM) for 7 days. Subsequently, membrane 
preparations from unstimulated [CONTROL] and stimulated [LPS] cells were solubilised 
in 0.5 % (v/v) Triton X-100 before application on a discontinuous sucrose gradient. 
Following 16 h of centrifugation, 1 ml fractions were harvested from the top (Fraction 1) 
to the bottom (pellet) of the gradient. Fractions were analysed for alkaline phosphatase 
activity (graph), raft marker flotillin-1 (FL-1), non-raft marker β-actin and GPI-anchored 
protein, CD14 (blots). 
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FIGURE 5.6: Isolation of lipid raft fractions by sucrose density gradient. J774 
macrophage were treated with EPA (25 µM) for 7 days. Subsequently, membrane 
preparations from unstimulated [CONTROL] and stimulated [LPS] cells were solubilised 
in 0.5 % (v/v) Triton X-100 before application on a discontinuous sucrose gradient. 
Following 16 h of centrifugation, 1 ml fractions were harvested from the top (Fraction 1) 
to the bottom (pellet) of the gradient. Fractions were analysed for alkaline phosphatase 
activity (graph), raft marker flotillin-1 (FL-1), non-raft marker β-actin and GPI-anchored 
protein, CD14 (blots). 
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FIGURE 5.7: Isolation of lipid raft fractions by sucrose density gradient. J774 
macrophage were treated with LA (50 µM) for 7 days. Subsequently, membrane 
preparations from unstimulated [CONTROL] and stimulated [LPS] cells were solubilised 
in 0.5 % (v/v) Triton X-100 before application on a discontinuous sucrose gradient. 
Following 16 h of centrifugation, 1 ml fractions were harvested from the top (Fraction 1) 
to the bottom (pellet) of the gradient. Fractions were analysed for alkaline phosphatase 
activity (graph), raft marker flotillin-1 (FL-1), non-raft marker β-actin and GPI-anchored 
protein, CD14 (blots). 
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FIGURE 5.8: Quantitative analysis of CD14 levels in lipid rafts from PUFA-treated cells 
stimulated with LPS. J774 macrophage were treated with DMSO (50 µM), CLA (50 µM) 
or EPA (25 µM) for 7 days and stimulated with LPS (100ng/ml) for 30 min. Qualitative 
detection of CD14 in lipid rafts from PUFA treated cells is shown [A]. Additionally, 
protein levels were equalised and quantitative analysis of CD14 levels in lipid rafts 
(Fractions 5-6) was performed by western blot [B]. Densitometric analysis was conducted 
on the immunoblot and graphical representation of CD14 expression in arbitrary units 
(AU) is given [C]. 
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FIGURE 5.9: The effect of PUFA on the induction of NFκB and ISRE (IRF3 response 
element) was assessed using luciferase reporter assays. HEK 293 [A&B] and HEK-MTC 
cells [C&D] were cultured for 7 days with either DMSO (50 µM, vehicle control), EPA 
(25 µM), DHA (25 µM), CLA (50 µM) or LA (50 µM). Subsequently, cells were 
transiently transfected with either an NFκB or ISRE luciferase reporter plasmid. 
Induction of both transcription factors was assessed following 6 h stimulation with 
LPS (100 ng/ml). 
Statistical analysis was carried out between DMSO and PUFA-treated groups using an 
unpaired t-test. 
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FIGURE 5.10: Over-expression of CD14 reverses the inhibitory effect of CLA on IRF3 
actiavtion. U373 cells [A] and U373-CD14 cells [B] were cultured for 7 days with either 
DMSO (50 µM, vehicle control), EPA (25 µM), DHA (25 µM), CLA (50 µM) or LA (50 
µM). Subsequently, cells were transiently transfected with an ISRE luciferase reporter 
plasmid. Induction of IRF3 was assessed following 6 h stimulation with LPS (100 ng/ml). 
Statistical analysis was carried out between DMSO and PUFA-treated groups using an 
unpaired t-test. 
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FIGURE 5.11: LPS-induced endocytosis of TLR4 in DMSO treated cells. HEK-MTC 
cells were cultured in DMSO (50 µM) for 7 days. Subsequently cells were transiently 
transfected with TLR4-YFP (green) and EEA1-CFP (red) plasmids. Cells were left 
unstimulated or stimulated with LPS (250 ng/ml) for 7.5 and 15 min. Endocytosis of TLR4 
and its localisation relevant to EEA1 was assessed by confocal microscopy. Co-
localisation of TLR4 and EEA1 is shown in the composite image (yellow).  
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FIGURE 5.12: LPS-induced endocytosis of TLR4 in CLA-treated cells. HEK-MTC cells 
were cultured in CLA (50 µM) for 7 days. Subsequently cells were transiently transfected 
with TLR4-YFP (green) and EEA1-CFP (red) plasmids. Cells were left unstimulated or 
stimulated with LPS (250 ng/ml) for 7.5 and 15 min. Endocytosis of TLR4 and its 
localisation relevant to EEA1 was assessed by confocal microscopy.  Co-localisation of 
TLR4 and EEA1 is shown in the composite image (yellow).  
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FIGURE 5.13: LPS-induced endocytosis of TLR4 in EPA-treated cells. HEK-MTC cells 
were cultured in EPA (25 µM) for 7 days. Subsequently cells were transiently transfected 
with TLR4-YFP (green) and EEA1-CFP (red) plasmids. Cells were left unstimulated or 
stimulated with LPS (250 ng/ml) for 7.5 and 15 min. Endocytosis of TLR4 and its 
localisation relevant to EEA1 was assessed by confocal microscopy.  Co-localisation of 
TLR4 and EEA1 is shown in the composite image (yellow).  
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FIGURE 5.14: LPS-induced endocytosis of TLR4 in LA-treated cells. HEK-MTC cells 
were cultured in LA (50 µM) for 7 days. Subsequently cells were transiently transfected 
with TLR4-YFP (green) and EEA1-CFP (red) plasmids. Cells were left unstimulated or 
stimulated with LPS (250 ng/ml) for 7.5 and 15 min. Endocytosis of TLR4 and its 
localisation relevant to EEA1 was assessed by confocal microscopy. Co-localisation of 
TLR4 and EEA1 is shown in the composite image (yellow).  
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FIGURE 5.15: Representative LPS-induced endocytosis of TLR4 in PUFAtreated cells 
after 15 min of stimulation. HEK-MTC cells were cultured in DMSO (vehicle control), 
EPA (25 µM), CLA (50 µM), – or a saturated fatty acid control, LA (50 µM), for 7 days. 
Subsequently cells were transiently transfected with TLR4-YFP (green) and EEA1-CFP 
(red) plasmids. Cells were stimulated with LPS (250 ng/ml) 15 min. Endocytosis of TLR4 
and its localisation relevant to EEA1 was assessed by confocal microscopy. Co-
localisation of TLR4 and EEA1 is shown in the composite image (yellow).  
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5.3 DISCUSSION 
 
Mounting evidence points towards the beneficial effects of PUFA in the prevention 
and treatment of inflammatory disease. This has prompted widespread research in 
relation to PUFA-mediated anti-inflammatory effects with the hope of elucidating 
the exact mechanisms which can in turn be harnessed for therapeutic use. Currently, 
the field has focused its attention on the effects of PUFA on the events downstream 
of receptor activation, specifically those mediated by modified eicosanoid 
production and gene expression, (Calder 2006, Sampath and Ntambi 2005, Schmitz 
and Ecker 2008).  
 
However, thus far our results highlight the direct effects of PUFA on key surface 
markers, particularly CD14. As a result, we hypothesized, that the plasma 
membrane may be a principal target through which the modulatory effects of 
PUFA are mediated. Indeed, it is well established that by their very nature PUFA 
become incorporated into the plasma membrane. Furthermore, a keynote paper 
published by (Lee et al. 2003) and colleagues supports this hypothesis. 
Fundamentally, the group demonstrated that in RAW 264.7 cells, DHA inhibited 
LPS-induced NFκB activation in the presence of key signaling dominant negative 
mutants with the introduction of constitutively activate TLR4 (TLR4-CA). 
Furthermore, DHA failed to inhibit NFκB activation in the presence of dominant 
negatives and introduction of MyD88-CA or AKT-CA constructs. This indicated 
that PUFA may exert their effects at the membrane, at the receptor complex itself.   
 
Given these findings and the overwhelming observations of our study regarding 
PUFA modulated membrane-bound CD14, the targeting of CD14 to key signaling 
domains known as ‘lipid rafts’ became the first focus of this study. Importantly, in 
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order to critically assess the effects of PUFA on CD14 lipid raft recruitment; a lipid 
raft isolation procedure was stringently optimized. Lipid rafts are isolated based on 
the insolubility of raft proteins and lipids in the presence of non-ionic detergents. It 
is crucially important to obtain a detergent concentration that remains low enough 
not to solubilise tightly packed lipid raft domains and yet solubilise the remainder 
of the membrane or ‘disordered domain’. Detergent insolubility is a relatively, 
cheap and widely used method for the isolation of these domains. However, the 
type and concentration of detergent used will vary from cell type and must be 
appropriately tested to insure separation of raft and non-raft proteins (Shogomori 
and Brown 2003, Chamberlain 2004). Indeed, results presented here demonstrate 
that concentrations lower that 0.5 % Triton X-100 were insufficient to solubilise 
non-raft material. Furthermore, concentrations any higher resulted in complete 
disruption of lipid raft ordered domains.  
 
As such, 0.5 % Triton X-100 was successfully used for the isolation of lipid raft 
domains from J774 macrophage. This concentration of detergent afforded complete 
separation of raft marker flotillin-1, FL-1 from non-raft marker, β-actin. In 
addition, alkaline phosphatase activity, indicative of lipid rafts, was notably high in 
fractions in which FL-1 was detected. As expected, being a GPI-anchored protein, 
CD14 could be successfully detected in raft fractions. Notably, alkaline 
phosphatase activity was used in this study as a marker of lipid raft partitioning at 
the interphase of sucrose gradients (Gargalovic and Dory 2003). While activity 
corresponded to FL-1 localisation in untreated cells, PUFA treated cells displayed 
skewed alkaline phosphatase activity specifically when treated with CLA. As such, 
we suggest that PUFA in some way compromise alkaline phosphatase in lipid rafts 
and that its activity should be used solely during optimisation procedures.  
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In keeping with our previous findings, PUFA distinctly modulated recruitment of 
CD14 to lipid raft domains in LPS-stimulated cells. CLA was seen to significantly 
suppress recruitment of CD14 to lipid raft domains following stimulation. 
Furthermore, EPA acutely enhanced levels of CD14 in lipid raft fractions of 
stimulated cells compared to control. These are completely novel findings in 
relation to PUFA and lipid rafts, specifically regarding CLA. 
 
Certainly to date, studies have documented the effect of PUFA, particularly, n-3 
PUFA on membrane composition and report alterations in size and distribution of 
rafts (Li et al. 2005, Chapkin et al. 2008b, Ma et al. 2004). However, studies have 
also generally focused on the effect of PUFA on T cell function via alteration of the 
lipid raft structure and indeed translocation of signalling molecules. Given the 
potent inflammatory potential of T cells this research is no doubt warranted. 
Nevertheless, mechanisms utilised by PUFA regarding T cells and their lipid raft 
status may indeed be extended to other cell types. The effects of PUFA on T cell 
lipid rafts has been extensively reviewed (Yaqoob 2009). For example, it has been 
demonstrated that changes in the fatty acid composition of lipid rafts was 
associated with a decrease in the translocation of protein kinase C, PKC to lipid 
rafts, a key molecule regulating CD4 + T cell activation(Chapkin et al. 2008a)(Fan 
et al. 2004).  
 
To the best of our knowledge no other anti-inflammatory molecules have been 
reported to alter lipid raft composition or function to the extent of PUFA. With 
regard to our finding in relation to CD14, two studies are of particular interest. (De 
Smedt-Peyrusse et al. 2008) report that DHA affects the proteins presentation but 
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not its localisation to lipid rafts. In contrast to this, (Chapkin et al. 2008b) report 
that DHA specifically increases clustering of signalling proteins to lipid raft 
domains. Furthermore, only one study has cited alterations in the partitioning of 
CD14 to lipid rafts by an anti-inflammatory molecule. (Dai, Zhang and Pruett 
2005) demonstrate that ethanol, EtOH suppresses LPS-induced TNFα and CD14 
recruitment to lipid rafts in RAW 264.7 cells. Dai and colleagues suggest that 
EtOH may cause subtle changes in the lipid portion of rafts, causing changes in 
clustering or sequestration of proteins within them. Recently it has been shown that 
GPI-anchored proteins contain two saturated fatty acid chains in their 
phosphatidylinositol, PI moiety which allow them to be incorporated to lipid rafts 
(Maeda et al. 2007). The remodelling of the GPI anchor takes place between the 
ER and Golgi with the unsaturated sn-2 chain being removed and a saturated one 
added. This process is mediated by post GPI-attachment proteins (PGAP2 and 
PGAP3). Furthermore, S-acylation of proteins with heterogenous unsaturated fatty 
acids has been proposed as a mechanism by which cells regulate signalt 
transduction by altering the association of proteins with rafts (Webb, Hermida-
Matsumoto and Resh 2000, Liang et al. 2001). Our findings that CLA reduced the 
incorporation of CD14 into the lipid raft, may suggest that the fatty acid (Webb, 
Hermida-Matsumoto and Resh 2000, Liang et al. 2001)can interfere with these 
processes.  
 
We suggest the membrane action of CLA regarding CD14 recruitment to lipid rafts 
may be a principal mechanism by which this fatty acid suppresses TLR4 signalling. 
Indeed this finding compounded our interest regarding the effects of CLA on TLR4 
downstream signalling. Thus far the field has focused completely on the 
suppressive effects of PUFA on NFκB, however TLR4 signalling is unique in its 
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ability to activate both NFκB and IRF3 via MyD88 dependant and independent 
pathways, respectively (Brikos and O'Neill 2008, Akira and Takeda 2004). We 
have previously demonstrated that CLA can suppress NFκB in dendritic cells 
(Loscher et al. 2005b) and in adipose tissue from mice fed on diets of CLA 
(Moloney et al. 2007). Furthermore, we have also reported the suppressive effects 
of EPA and DHA on NFκB in a human macrophage cell line (Weldon et al. 2007, 
Mullen, Loscher and Roche 2009). The data generated here agree with these 
previous studies and demonstrate that CLA, EPA and DHA all suppress NFκB 
activation. However, interestingly our data also demonstrates a completely novel 
and selective inhibition of IRF3 in PUFA-treated cells. While both n-3 PUFA and 
CLA suppressed levels of NFκB, CLA was the only fatty acid to significantly 
suppress IRF3. Furthermore, we postulated that this was indeed related to the 
suppression of CD14 at the membrane in CLA-treated cells. Particularly as the 
activation of IRF3 downstream of TLR4 requires endocytosis of the TLR4 complex 
and its subsequent association with TRIF and TRAM (Kagan et al. 2008), a process 
that is dependent on CD14 (Shuto et al. 2005). Certainly, in cells over-expressing 
CD14 the inhibitory effect of CLA on IRF3 was completely reversed.  
 
In order to assess whether the suppression of CD14 was associated with reduced 
endocytosis of TLR4, which would explain the decrease in IRF3 activation, we 
used confocal microscopy to examine TLR4 expression at the membrane and in 
early endosomes in cells treated with CLA and EPA. Given that the involvement of 
CD14 in TLR4 endocytosis has only been reported in the last few years (Shuto et 
al. 2005), there is a lack of literature examining the effects of anti-inflammatory 
compounds on these parameters as a potential mechanism. Indeed the only paper 
we found reported a positive correlation between increased CD14 with increased 
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consequences of TLR4 activation. Specifically, (Hua et al. 2007) report that an 
extract of Ganoderma lucidum polysaccharides enhances CD14 expression which 
results in a subsequent increase in pro-inflammatory cytokine production 
downstream of TLR4. In our study we clearly demonstrate retention of TLR4 on 
the plasma membrane following stimulation with LPS in CLA-treated cells 
indicating a decrease in endocytosis of TLR4 compared to the DMSO control. This 
was not the case in EPA-treated cells. Our data has revealed a novel mechanism for 
how CLA exerts its anti-inflammatory effects in macrophage. Furthermore, to our 
knowledge this is the first report of an anti-inflammatory compound exerting its 
effects via a CD14-dependent suppression of TLR4 endocytosis. A schematic 
illustrating our proposed model for PUFA-mediated effects on TLR4 signalling is 
presented in figure 5.15. 
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FIGURE 5.15: Illustration of our proposed model of PUFA-mediated effects on TLR4 
signalling. Both CLA and n-3 PUFA, EPA and DHA suppress NFκB. CLA selectively 
inhibits signalling through adaptors TRAM and TRIF suppressing IRF3 by means of 
inhibiting recruitment of membrane bound CD14 to the TLR4 complex in lipid rafts. 
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6.1 GENERAL DISCUSSION 
 
Inflammation is the body’s natural response to infection or injury in most 
circumstances. However, when it becomes dysregulated this can lead to extensive 
tissue damage, uncontrolled infection and chronic disease. Ironically, inflammation 
is also vital in order to promote resolution (Serhan et al. 2007) and considerable 
efforts are placed on elucidating mechanisms by which anti-inflammatory 
pathways may be enhanced to promote this process. Furthermore, contemporary 
treatments of inflammatory disease can have severe deleterious effects and research 
now focuses on the development of more natural therapeutic agents. Interestingly, 
evidence continues to point towards the benefits of PUFA in the prevention and 
treatment of inflammatory disease (MacLean et al. 2004, Schachter et al. 2004). 
This study has uncovered a number of PUFA-mediated effects on macrophage in 
vitro that suggest possible pathways used by these molecules to elicit their 
immunomodulatory actions. Furthermore, a novel mechanism implicating CLA in 
the modulation of CD14 within lipid rafts was elucidated and may represent the 
ultimate mechanism through which this fatty acid exerts its anti-inflammatory 
effects. 
 
Macrophage, MØ are highly sophisticated phagocytes and one of the many 
leukocytes recruited to sites of inflammation in order to neutralise and eliminate 
potentially harmful stimuli (Beutler 2004, Mosser 2003). It is not surprising that 
exacerbated MØ responses play a role in various inflammatory disorders including; 
inflammatory bowel disease (Zhang and Mosser 2008), schistosmiasis (Hesse et al. 
2001) and atherosclerosis (Wilson, Barker and Erwig 2009). In this study we have 
found a modulatory role for PUFA regarding the functional status of macrophage 
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with potential implications for inflammatory disease and immune responses to 
infection.  
 
Throughout this study we have found distinct effects of CLA and n-3 PUFA on 
macrophage. This has led us to equally distinct conclusions with regard to their 
possible roles in modulating an immune response. We found that macrophage 
exposed to CLA in vitro produced significantly more IL-10 in response to LPS. 
This anti-inflammatory cytokine has a potent regulatory and immunosuppressive 
role. Administration of IL-10 to patients with Crohn’s disease has been reported to 
reduce bowel inflammation (Mocellin et al. 2004). Furthermore, differentiation of 
T cells into various subsets is partly determined by IL-10 and it has been shown to 
inhibit TH1 responses. Indeed, work in our lab has demonstrated that enhanced IL-
10 production in CLA-treated DC results in diminished T helper cell cytokine 
production (unpublished observation). Our finding in relation to enhanced IL-10 in 
CLA-treated MØ was the first of our results to suggest the potential use of CLA in 
the treatment of inflammatory disease. In support of this, our study also 
demonstrates that CLA-treated MØ display suppressed levels of IL-23 following 
stimulation. The involvement of this cytokine in promoting TH17 development is 
well established. Furthermore, IL-23 is implicated as a major causative agent of 
inflammatory pathology in IBD (Kikly et al. 2006), EAE (Langrish et al. 2005) and 
collagen-induced arthritis (Yago et al. 2007). In addition, CLA treatment resulted 
in significant inhibition of surface CD86.  This co-stimulatory molecule enhances 
severity of arthritis by enhancing IL-17 production and increasing the accumulation 
of effector T cells in joints (Odobasic et al. 2008). Conventional CD86 antibody 
therapies have been shown to exacerbate autoimmune disease. We suggest CLA 
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may provide an alternative mode of suppressing T cell activation which may be 
beneficial in the treatment of these diseases.  
 
One of the results we obtained with regard to cytokine production was very 
surprising. The fact that CLA enhanced the production of IL-1β by macrophage 
was unexpected and raises concerns regarding the administration of CLA during 
inflammatory diseases in which IL-1β is known to play a key role. This increase in 
IL-1β by CLA is a recurrent observation in our laboratory in both macrophage and 
dendritic cell studies and something we cannot explain at this time. We suggest that 
while CLA may in fact be extremely beneficial in the prevention/treatment of 
inflammatory disease its administration may have to be tailored for the treatment of 
specific disease states.  
 
With regard to the more extensively studied n-3 PUFA, DHA and EPA, our study 
demonstrates multiple anti-inflammatory effects of these fatty acids in macrophage. 
Specifically, EPA markedly suppressed levels of the potent pro-inflammatory 
cytokine IL-12 in response to LPS. IL-12 favours the induction of a TH1 phenotype 
(Trinchieri 2003a) and as such IL-12 is largely implicated in autoimmune and TH1 
mediated diseases including; multiple sclerosis (MS), IBD and RA (La Cava and 
Sarvetnick 1999, Papadakis and Targan 2000). EPA-mediated inhibition of IL-12 
has been reported in murine dendritic cells (DC) (Wang et al. 2007) but not 
macrophage and this finding may indicate its therapeutic potential. In addition 
EPA-treated macrophage displayed significantly suppressed levels of IL-23. The 
inflammatory actions of this cytokine are implicated in the pathogenesis of 
inflammatory diseases such as IBD, EAE and arthritis (as discussed). Furthermore, 
blocking T cell co-stimulatory signals is an attractive approach for the treatment of 
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autoimmune disease. Indeed, we found that EPA and DHA suppress CD40 
expression in macrophage following stimulation. Collectively, our study suggests 
that the n-3 PUFA modify cytokine production and surface marker expression in 
macrophage. This may lead to altered(Neurath et al. 1998) antigen presentation 
and/or co-stimulation with the possibility of modulating the expansion and 
cytokine production profile of T cells. We postulate that these critical events are 
mechanisms through which n-3 PUFA prove beneficial in inflammatory disease. 
 
Certainly, many studies involving n-3 PUFA indicate their consumption can benefit 
persons with various inflammatory diseases including; cardiovascular disease and 
rheumatoid arthritis (MacLean et al. 2004, Mantzioris et al. 2000). Unfortunately, 
few have examined their role in macrophage and those that have are commonly 
found to be contradictory. Most recent literature also indicates a clear discrepancy 
between PUFA-induced effects in different cells types. To this end in order to be 
used beneficially in inflammatory disease, it remains for more powerful and 
controlled studies to be carried out. Importantly, (Neurath et al. 1998) suggest that 
targeting NFκB may be a novel molecular approach for the treatment of IBD, 
particularly because over-expression of NFκB by macrophages is common among 
IBD patients. We found that CLA and indeed the n-3 PUFA, DHA and EPA 
suppressed activation of NFκB. As such this represents another potential beneficial 
effect of PUFA in an inflammatory disease situation.  
 
Further to this, we have found the immunomodulatory actions of CLA and n-3 
PUFA in macrophage may afford protective effects during infection. In this regard, 
the enhanced levels of IL-10 and IL-1 production in CLA treated cell may be very 
useful during and after injury and infection. IL-10 is notably involved in the 
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resolution stages of infection (Serhan et al. 2007)(Serhan et al. 2007, Serhan 2007) 
while IL-1 commonly promotes wound healing actions in macrophage populations 
(Mosser and Edwards 2008). CLA treatment also enhanced the ability of 
macrophage to phagocytose, an important event in bacterial clearance and 
homeostasis. Furthermore, we found CLA also significantly enhance chemotaxis 
and MIP-2 production. The infiltration of leukocytes to the site of infection is 
crucial in mounting an immune response. Furthermore, depleted levels of MIP-2 
have been broadly implicated in impaired bacterial clearance (Strieter et al. 1996). 
Therefore, not only do our findings implicate a therapeutic role for CLA in 
inflammatory disease, it also suggests that CLA may be beneficial in innate 
protection from infection.  
 
On the other hand, we found alternative effects mediated by n-3 PUFA that may 
prove beneficial to or hamper innate responses during infection.  DHA and EPA 
significantly suppressed levels of IL-6 in response to LPS stimulation. Certainly, 
studies employing human macrophage models have reported that EPA and DHA 
inhibit TNFα, IL-6 and IL-1β production (Goua et al. 2008, Chu et al. 1999). 
Elevated levels of these cytokines are characteristic of LPS-induced endotoxemia. 
In line with other studies, our data suggests that daily supplementation of n-3 
PUFA may help ameliorate chronic inflammation caused during sepsis. 
Furthermore, DHA markedly enhanced expression of MIP-2 an important 
chemokine in the process of bacterial clearance (as discussed). However, we also 
found that EPA and DHA suppressed the rate of phagocytosis in macrophage. This 
suggests that n-3 PUFA may delay bacterial clearance by impeding the ability of 
macrophage to phagocytose. This conflicts with previous studies employing n-3 
PUFA treatments in macrophage (Calder et al. 1990, Kew et al. 2003, D'Ambola et 
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al. 1991). Certainly, such discrepancies are common in the literature. It is believed 
to be due variations in dose and cell lines used and presents an arguable challenge 
in PUFA research. 
 
In conclusion, there are conflicting reports as to whether PUFA collectively or 
individually have the ability to enhance or diminish immune functions. 
Furthermore, it is notable that PUFA have differential effects on immune function, 
as reviewed extensively by (Fritsche 2006, Calder 2006, Yaqoob 2009). 
Importantly however, it its broadly accepted that the ratio between n-3 and n-6 
fatty acids is significant in determining cell function, whole body physiology and 
human health (Simopoulos 2002, Burdge and Calder 2006, Simopoulos 2008). 
Certainly a lower ratio of n-6/n 3 fatty acids is more desirable in reducing the risk 
of many of the chronic diseases of high prevalence in Western societies. There is 
need not only to examine the effect of dose on immune and inflammatory 
responses, but also to separate the effects of individual PUFA and their 
combination with others in different ratios. These investigations will promote an 
understanding of the mechanisms employed by PUFA to exert their effects. Our 
data certainly suggest that CLA and the n-3 PUFA, DHA and EPA may have 
immunomodulatory effects and could be useful in inflammatory situations. The 
compelling evidence in the literature regarding the many immunomodulatory 
effects of PUFA is certainly difficult to explain and warrants further investigation. 
 
A lack of experimental and clinical studies in the area complicates any implication 
of their beneficial use in prevention and treatment of disease. Indeed, many clinical 
studies cannot account for the background diets of their subjects. In the majority if 
not all animal studies, the diet is completely controlled.  Furthermore, many 
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diseases are the result of genetic predispositions. Quite possibly the dose of PUFA 
administered may depend on the degree of severity of disease on a case by case 
basis. In realistic terms it is foreseeable that PUFA may not be administered for the 
complete prevention or treatment of a disease or infection. But the evident anti-
inflammatory benefits of PUFA suggest that they may help ameliorate symptoms 
and certainly assist in their resolution. 
 
The secondary focus of this work was to define a mechanism through which PUFA 
may exert anti-inflammatory effects with particular interest to CLA. Previous 
investigations in the field have paid particular attention to downstream signalling 
components, and suggest these as pinnacle targets through which PUFA exert their 
effects. Indeed DHA and EPA have been shown to increase phosphorylation of p38 
and epidermal growth factor receptor, EGFR, a beneficial effect considering 
sustained activation of the EGFR and p38 MAPK has been associated with 
apoptosis in human breast cancer cells (Schley, Brindley and Field 2007). 
Furthermore, several groups have demonstrated the anti-inflammatory effects of 
PUFA via the involvement of PI3K/Akt (Wan et al. 2007, Weaver et al. 2009). In 
addition, numerous studies report PUFA mediated suppression of transcription 
factors particularly NFκB (Sampath and Ntambi 2005) and activation of 
peroxisome proliferator activated receptors, PPARs (Jump 2002b).  
 
However, an important observation was made by (Lee et al. 2003) and colleagues. 
Based on their work, with various downstream dominant negative mutants and 
constitutively active molecules, they suggest that PUFA may exert their effects 
upstream at the membrane, or even at the TLR4 receptor complex itself. Notably, 
PUFA-modulated effects are mediated via modifying eicoanoid production. 
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However, PUFA perform this modulation primarily by competing with arachidonic 
acid at the ‘membrane’ leading to the decreased production of the inflammatory 
eicosanoid products (Albers et al. 2002, Mantzioris et al. 2000). Certainly in early 
chapters we found the modulation of CD14 in resting cells treated with CLA to be 
a pivotal finding. This GPI-anchored protein resides in the membrane and acts as 
an associated molecule of TLR4 (Wright et al. 1990), as such it plays a 
fundamental role in TLR4 signalling (Shuto et al. 2005, Juan et al. 1995).  
We also found that CLA suppressed surface expression of CD14 at very early 
stages of stimulation with LPS. This suppression of CD14 at the membrane in 
CLA-treated cells was accompanied by enhanced levels within the cytosol. Further 
to this our study focused on clarifying if modulation of CD14 by CLA involved 
altered targeting of the protein to lipid raft microdomains in the plasma membrane. 
Indeed we found this to be the case. CD14 was markedly suppressed in lipid raft 
fractions isolated from stimulated macrophage treated with CLA. With the 
exception of disrupted raft association of CD14 in EtOH treated cells (Dai, Zhang 
and Pruett 2005), this is the only example of an anti-inflammatory molecule 
modulating CD14 in this way. In addition, we also assessed the consequences of 
this effect on signalling pathways downstream of TLR4 and its possible effects on 
the ability of TLR4 to become endocytosed.  
 
We found direct downstream implications for the activation of NFκB and IRF3, 
with CLA treatment suppressing the induction of both transcription factors. 
However, an exact mechanism was elucidated regarding the suppression of IRF3. 
Indeed, CD14 is a requirement for LPS induced endocytosis of TLR4 and 
subsequent activation of IRF3 (Kagan et al. 2008, Shuto et al. 2005). We found the 
inhibitory effect of CLA on IRF3 was reversed by the over-expression of CD14 in 
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U373 cells. Furthermore, we found that the ability of TLR4 to become endocytosed 
upon activation was diminished significantly in CLA-treated cells. As such, our 
study revealed a novel mechanism for CLA-induced anti-inflammatory effects. 
Furthermore, to our knowledge this is the first report of an anti-inflammatory 
compound exerting its effects via a CD14-dependent suppression of TLR4 
endocytosis. While it was clear that EPA and DHA did not suppress CD14, this 
study did not extend to determining their exact effects at the cell membrane. 
However we did report that these fatty acids suppressed expression of TLR4, 
therefore rendering the macrophage less responsive to LPS. Furthermore, our 
observation that all of the PUFA we examined enhanced the expression of SR-A is 
an interestingly observation, given that this receptor is known to bind LPS, and 
warrants further investigation. These changes in receptor expression at the 
membrane may explain some of the anti-inflammatory effects of these fatty acids. 
 
We postulate that with emerging roles for CD14 in the exacerbation of infection 
and inflammatory disease our finding regarding CLA will have direct implications 
for the possible use of this fatty acid as a treatment. High levels of CD14 are 
indicative of intestinal macrophage populations from patients suffering with IBD 
(Kamada et al. 2008).  Signalling through CD14 has been shown to play an 
obligate role in cardiac inflammation occurring after major burn injuries (Barber et 
al. 2008). The over-expression of CD14 in specific areas of the central nervous 
system (CNS) within an endotoxin induced mouse model of Parkinson's-like 
disease has also been demonstrated (Panaro et al. 2008). Furthermore, diseases 
such as Wegener’s granulomatosis are partially characterised by the up-regulation 
of CD14 on monocytes (Yard et al. 2002). In this regard, we suggest the possibility 
that administration of CLA may offer an alternative to conventional CD14 antibody 
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therapies for inflammatory disease. Importantly, production of IFN-β (downstream 
of IRF3 activation) is essential for induction of endotoxic shock and the activation 
of a full immune response (Pechine et al. 2007).  Since CLA can suppress IRF3, 
our data suggests that CLA may be useful in endotoxic shock. Interestingly a recent 
study in our laboratory has revealed that feeding mice with CLA protects them 
from endotoxic shock (Loscher et al., unpublished).  
 
This work has uncovered a completely novel mechanism regarding the anti-
inflammatory effects exerted by CLA.  Furthermore, this is highly relevant to 
research within our field of nutritional immunology. It was over thirty years ago 
that investigations first examined and tried to elucidate the possible anti-
inflammatory potential of fatty acids (Palmblad and Gyllenhammar 1988). At that 
time it was a well held belief that fatty acid-induced changes in the cell membrane 
were responsible for subsequent changes observed in membrane-dependent 
functions including; phagocytosis and cell signalling events. All were thought to be 
a direct result of alterations in membrane composition and fluidity (Peck 1994). 
However, this theory rapidly lost favour as; ‘it failed to explain why n-6 and n-3 
PUFAs have contradictory actions on the immune system’ (Fritsche 2006, 
Palmblad and Gyllenhammar 1988). Currently, this theory has re-emerged with the 
recent discovery of discrete lipid domains or ‘lipid rafts’ in the plasma membrane. 
We believe that the work in our study reinforces this renewed interest. 
Furthermore, we postulate this will be a critical focus within the field of 
nutritionally based immunological research and prove fundamental in efforts to 
elucidate the multiple mechanisms used by PUFA to elicit their anti-inflammatory 
effects.  
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7.1 FUTURE PERSPECTIVES 
Within chapter 4 a study to assess the binding of LPS to the TLR4 receptor 
complex by flow cytometry is described. Various other groups have conducted 
studies with the premise of elucidating the exact nature of LPS binding in vitro, 
particularly emplying neutrophils and monocytes (Anastase-Ravion et al. 2003b, 
Kitchens et al. 2000). While several knockout mice models have revealed 
unexpected features of LPS action in vivo (Fenton and Golenbock 1998), to the 
best of our knowledge there are no reports citing the examination of LPS binding 
events in an artificial environment outside the living organism (i.e. ex vivo). 
Consequently, we describe herein as a future perspective to the work conducted on 
LPS binding in chapter 4, the development of an ex vivo model to assess LPS 
binding to brush border membrane from the small intestine of BALB/C mice. In 
order to do this, the Biacore3000™ surface plasmon resonance (SPR) system was 
employed, providing a highly sensitive platform for looking at real time binding 
events. The results of this work are presented in appendix C and discussed below. 
 
 
Brush border membrane vesicles (BBMVs) are gaining recognition as an 
alternative tool to investigate active transport interactions as they contain 
phospholipids, hydrolytic enzymes, carrier proteins (Baroni et al. 2006, Balon, 
Riebesehl and Muller 1999, Kramer et al. 1994) and lipid rafts (Danielsen and 
Hansen 2003) that are responsible for many biologic interactions and binding 
events. BBMV surfaces have been useful for the estimation of binding events, 
particularly of orally administered drugs as they possess structural and functional 
similarity to real intestinal membranes (Kim et al. 2004, Cho et al. 2004). They are 
of particular interest as over activated and/or dysregulated function of toll-like 
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receptors including TLR3, TLR4 and TLR5 are largely implicated in many 
diseases of the gut (Lodes et al. 2004, Cario and Podolsky 2000). However, the 
exact expression of TLRs and indeed interaction with their respective ligands in 
BBMVs has not been investigated.  
 
The possibility of using the Biacore 3000™ SPR-based biosensor to monitor ex vivo 
real-time binding of LPS to BBMVs was investigated. Using the L1 chip it was 
possible to successfully capture significant levels of BBMVs. A pilot experiment 
suggested significant LPS binding to the immobilised BBMVs. However, follow-
up experiments indicated that there was substantial NSB of LPS to the L1 chip 
surface itself. A series of scouting experiments was then undertaken to determine 
the most appropriate strategy to counteract the NSB. A high concentration solution 
(12 mg/ml) CM-dextran and BSA blocking buffer was passed across the surface. In 
addition, the LPS was diluted in this same blocking buffer. BSA is a commonly 
employed blocking protein and the CM-dextran mimicked the actual surface matrix 
of the L1 chip and thus, it was postulated that any LPS with non-specific affinity to 
the CM-detxtran surface would be effectively blocked by the high concentration of 
CM-dextran in the blocking buffer. However, this strategy alone did not fully 
eliminate the NSB contribution. (Anderluh et al. 2005) previously reported that 
blocking with lipids was an effective approach to reduce NSB. We found that a 
combination of CM-dextran/BSA blocking buffer and pre-blocking the L1 chip 
surface with a concentrated liposome solution was effective in eliminating NSB.  
 
Unfortunately, when the blocking steps were incorporated no binding of LPS was 
discernable. One possible reason for this is that the CM-dextran/BSA and liposome 
blocking agents also effectively coated and blocked the BBMV surface. This could 
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be overcome by employing an alternative blocking strategy.  It is also possible that 
the integrity of the BBMVs is somehow compromised when immobilised. This 
could be due to aggregation and degradation either on chip or during prolonged 
storage in buffer. It is also important to note that the expression of TLRs on 
BBMVs has not yet been characterised, therefore other ligands, apart from the 
TLR4 ligand used here, will be used during further optimisation. Although at 
present it will not supplant cellular-based assays, it is confidently predicted that 
with further optimisation and amendment this model platform will provide a novel 
strategy for investigating the interactions of other toll ligands in a simple and rapid 
real-time ex vivo assay format. 
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APPENDIX A 
 
CELL CULTURE MEDIA 
 
COMPLETE RPMI 1640     500 ml 
5% Heat inactivated Foetal Calf Serum (FCS)  25ml 
Penicillin/streptomycin/L-glutamine Culture Cocktail 10 ml 
(Gives a final concentration of 2 mM L-glutamine,  
100 µg/ml penicillin and 100 U/ml streptomycin) 
 
COMPLETE DMEM      500 ml 
5% Heat inactivated Foetal Calf Serum (FCS)  25ml 
Penicillin/streptomycin/L-glutamine Culture Cocktail 10 ml 
(Gives a final concentration of 2 mM L-glutamine,  
100 µg/ml penicillin and 100 U/ml streptomycin) 
 
 
10X PHOSPHATE BUFFERED SALINE (PBS) 
Na2HPO4.2H2O (8 mM)    23.2 g 
KH2PO4 (1.5 mM)     4 g 
NaCl (137 mM)     160 g 
KCl (2.7 mM)      4 g 
Make up to 2 L pH to 7.4  
 
10 X TRIS BUFFERED SALINE (TBS) pH 7.6 
NaCl       48.4 g 
Trizma Base      160 g    
  
Dissolve in 2 L dH2O pH to 7.6 
 
2N H2SO4 
H2SO4 (36 N)      11.1 ml 
dH2O       88.9 ml 
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FACS BUFFER  
2%FCS 
0.05% NaN3 
PBS 
 
 
5X SAMPLE BUFFER 
125 mM Tris       6.25 ml 1M Tris HCl pH 6.8 
10 % Glycerol      5 ml 
2 % Sodium dodecyl sulphate (SDS)   10 ml (10 % (w/v) SDS) 
0.05 % (w/v) Bromophenol Blue   0.01 g 
dH2O       28.75 ml 
 
 0.25 M Dithiothreitol (DTT)*   250 µl 1 M DTT S 
* Added to 1 ml 5X Sample Buffer just before use 
 
SEPARATING GEL (10 % (v/v)) 
33% w/v Bisacrylamide (30% stock) 
1.5M Tris-HCl pH8.8 
1% w/v SDS 
0.5% w/v Ammonium persulpate 
dH2O 
0.1% v/v TEMED 
 
STACKING GEL 
6.5% v/v Acrylamide/Bisacrylamide (30% stock) 
0.5M Tris-HCl pH6.8 
1% w/v SDS 
0.5% w/v Ammonium persulphate 
dH2O 
0.1% v/v TEMED 
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ELECTRODE RUNNING BUFFER 
25mM Tris base 
200mM Glycine 
17mM SDS 
 
LIPOSOMES 
Liposomes: 30:30:10 % molar ratio DSPC:Cholesterol:DSPE-PEG 
 
DSPC: Sigma®; DSPE-PEG: Avanti Polar Lipids Inc.,; Cholesterol: Sigma®. 
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APPENDIX B 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8.1: Membrane and cytosolic expression of CD14 in J774 macrophage. Cells 
were plated at 1 x 106 cell/ml, (3 ml/well) [A] or 2 x 105 cell/ml, (3 ml/well) [B] and left to 
rest overnight. On the following day cells were stimulated with LPS (100 ng/ml) over 6 h, 
as indicated. After the completed time course cell lysates were harvested and membrane 
fractionation performed. Total cellular levels of β-actin were used as loading control.  
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APPENDIX C 
 
BRUSH BORDER MEMBRANE CHARACTERISATION 
Brush border membrane vesicles (BBMV) were isolated as described [section 
2.10.1] and characterised with a monoclonal antibody against CD66a which is 
constitutively expressed on BBMV. Following incubation with CD66a antibody 
BBMV were stained with an anti-mouse FITC conjugate and analysed by flow 
cytometry on a BD FACSAria™.  CD66a bound significantly to BBMV 
preparations [Figure 8.2]. In addition binding of solely the anti-mouse FITC 
conjugate to BBMV was negligible. 
 
ESTABLISHING AN EX VIVO MODEL TO INVESTIGATE LPS BINDING  
In an attempt to establish an ex vivo model for the investigation of binding of LPS, 
BBMV were immobilised on the surface of an L1 chip using a Biarcore3000™, as 
described [section 2.10.2]. BBMV were successfully immobilised on the surface 
with a final level of 2166 response units (RU) of covalently attached BBMV 
achieved [Figure 8.2A]. Subsequently, LPS (10 µg/ml) was passed over the surface 
resulting in a binding event to the significance of 216 RU [Figure 8.2A and B]. 
Following this, any non-specific binding (NSB) of LPS to the surface of the L1 
chip was assessed [section 2.10.4]. LPS bound significantly to the surface of a 
blank flowcell [Figure 8.3A]. In addition, blocking the flowcell with CM-dextran 
BSA and preincubation of LPS with the same resulted in binding of LPS to the 
surface of the flowcell by approx. 100 RU [Figure 8.3B]. Furthermore, full 
analysis of a BBMV-functionalised, liposome and CM-dextran BSA blocked chip 
resulted in complete elimination of LPS to the surface [Figure 8.4]. This suggests 
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that the previously observed LPS binding event to immobilised BBMVs was non-
specific [Figure 8.2A]. 
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FIGURE 8.2: Flow cytometric analysis of BBMV isolated from the small intestine of 
BALB/C mice [A]. Unstained BBMV are represented by the grey histogram. Non-specific 
binding of the anti-FITC conjugate used in characterisation was assessed (black 
histogram). Specific binding of CD66a to BBMV is displayed (green histogram). Mean 
fluorescence intensity values are also represented above [B].  
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FIGURE 8.3: Binding sensorgram demonstrating capture of BBMV and subsequent 
binding of LPS in HBS-DF buffer [A]. After passing BBMVs over the surface of the L1 
chip a final level of 2166 RUs of covalently attached BBMVs was achieved. Subsequently, 
LPS (10 µg/ml) was passed over the surface leading to a binding event to the significance 
of 216 RU change. Binding of LPS is highlighted in [B]. The surface of the L1 chip was 
regenerated by injecting 40 mM CHAPS. 
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FIGURE 8.4: Testing for binding of LPS on a blank L1 chip surface [A]. Injection of LPS 
(10 µg/ml) over the blank flowcell resulted in binding response of 161 RU. Non-specific 
binding (NSB) was recognised as a significant problem and in an attempt to overcome this, 
blocking agent CM-dextran BSA was passed over the surface prior to injecting LPS diluted 
in blocking buffer [B]. However, LPS still bound significantly to the surface. 
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FIGURE 8.5: Full analysis of BBMV-functionalised and liposome-blocked chip. 
Following immobilisation of BBMV to the L1 chip surface, non-specific sites were 
blocked using a liposome solution followed by CM-dextran BSA. Blocking procedures 
efficiently abrogated NSB, however there was also a concomitant abrogation of LPS 
binding to captured BBMVs. 
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